EP3429600B1 - New immunobiological products - Google Patents
New immunobiological products Download PDFInfo
- Publication number
- EP3429600B1 EP3429600B1 EP17711627.4A EP17711627A EP3429600B1 EP 3429600 B1 EP3429600 B1 EP 3429600B1 EP 17711627 A EP17711627 A EP 17711627A EP 3429600 B1 EP3429600 B1 EP 3429600B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- chitosan
- acid
- dsm
- liters
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001900 immune effect Effects 0.000 title description 5
- 229920001661 Chitosan Polymers 0.000 claims description 337
- 239000000203 mixture Substances 0.000 claims description 173
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 144
- 238000000034 method Methods 0.000 claims description 129
- 229960005486 vaccine Drugs 0.000 claims description 125
- 239000000416 hydrocolloid Substances 0.000 claims description 114
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 104
- 150000001875 compounds Chemical class 0.000 claims description 93
- 208000004396 mastitis Diseases 0.000 claims description 84
- 229940005605 valeric acid Drugs 0.000 claims description 73
- 239000000463 material Substances 0.000 claims description 68
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 61
- 201000010099 disease Diseases 0.000 claims description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 56
- 241000222122 Candida albicans Species 0.000 claims description 54
- 239000007864 aqueous solution Substances 0.000 claims description 53
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 52
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 48
- 241000893980 Microsporum canis Species 0.000 claims description 48
- 229940095731 candida albicans Drugs 0.000 claims description 48
- 230000000890 antigenic effect Effects 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 43
- 208000006413 Digital Dermatitis Diseases 0.000 claims description 42
- 208000023867 digital dermatitis in cattle Diseases 0.000 claims description 42
- 241000893966 Trichophyton verrucosum Species 0.000 claims description 38
- 241000233866 Fungi Species 0.000 claims description 36
- 208000010668 atopic eczema Diseases 0.000 claims description 33
- 208000002474 Tinea Diseases 0.000 claims description 32
- 239000002253 acid Substances 0.000 claims description 32
- 241001045770 Trichophyton mentagrophytes Species 0.000 claims description 31
- 229940055035 trichophyton verrucosum Drugs 0.000 claims description 30
- 241000223229 Trichophyton rubrum Species 0.000 claims description 29
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 28
- 201000010153 skin papilloma Diseases 0.000 claims description 28
- 230000006196 deacetylation Effects 0.000 claims description 27
- 238000003381 deacetylation reaction Methods 0.000 claims description 27
- 206010020751 Hypersensitivity Diseases 0.000 claims description 26
- 230000000172 allergic effect Effects 0.000 claims description 25
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 23
- 239000011707 mineral Substances 0.000 claims description 23
- 230000007815 allergy Effects 0.000 claims description 21
- 208000004145 Endometritis Diseases 0.000 claims description 20
- 208000017520 skin disease Diseases 0.000 claims description 20
- 206010007882 Cellulitis Diseases 0.000 claims description 18
- 201000004624 Dermatitis Diseases 0.000 claims description 18
- 206010015150 Erythema Diseases 0.000 claims description 18
- 231100000321 erythema Toxicity 0.000 claims description 18
- 208000000260 Warts Diseases 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 16
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 16
- 229940097043 glucuronic acid Drugs 0.000 claims description 16
- 208000030175 lameness Diseases 0.000 claims description 16
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 claims description 16
- 241000223238 Trichophyton Species 0.000 claims description 15
- 230000001965 increasing effect Effects 0.000 claims description 15
- 230000003902 lesion Effects 0.000 claims description 15
- 244000005700 microbiome Species 0.000 claims description 15
- 206010012442 Dermatitis contact Diseases 0.000 claims description 14
- 206010012504 Dermatophytosis Diseases 0.000 claims description 14
- 241001460074 Microsporum distortum Species 0.000 claims description 14
- 208000011623 Obstructive Lung disease Diseases 0.000 claims description 14
- 239000003242 anti bacterial agent Substances 0.000 claims description 14
- 229940088710 antibiotic agent Drugs 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- 230000001154 acute effect Effects 0.000 claims description 13
- 150000007524 organic acids Chemical class 0.000 claims description 12
- 206010039083 rhinitis Diseases 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 11
- 210000000078 claw Anatomy 0.000 claims description 11
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- 206010010741 Conjunctivitis Diseases 0.000 claims description 10
- 206010017533 Fungal infection Diseases 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 8
- 206010067409 Trichophytosis Diseases 0.000 claims description 8
- 201000010105 allergic rhinitis Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 7
- 241000893976 Nannizzia gypsea Species 0.000 claims description 7
- 241000893962 Trichophyton equinum Species 0.000 claims description 7
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 7
- 208000010247 contact dermatitis Diseases 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 6
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 6
- 241001480037 Microsporum Species 0.000 claims description 6
- 230000021736 acetylation Effects 0.000 claims description 6
- 238000006640 acetylation reaction Methods 0.000 claims description 6
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 6
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 6
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 208000024386 fungal infectious disease Diseases 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 4
- 238000003975 animal breeding Methods 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 description 198
- 239000000725 suspension Substances 0.000 description 153
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 142
- 239000000047 product Substances 0.000 description 137
- 239000000243 solution Substances 0.000 description 134
- 208000024891 symptom Diseases 0.000 description 113
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 99
- 238000003756 stirring Methods 0.000 description 89
- 239000003153 chemical reaction reagent Substances 0.000 description 88
- 150000004676 glycans Chemical class 0.000 description 87
- 229920001282 polysaccharide Polymers 0.000 description 87
- 239000005017 polysaccharide Substances 0.000 description 87
- 238000011282 treatment Methods 0.000 description 79
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 69
- 241001480043 Arthrodermataceae Species 0.000 description 66
- 230000037304 dermatophytes Effects 0.000 description 66
- 238000002360 preparation method Methods 0.000 description 64
- 239000008227 sterile water for injection Substances 0.000 description 60
- 229920001817 Agar Polymers 0.000 description 57
- 239000008272 agar Substances 0.000 description 57
- 239000012467 final product Substances 0.000 description 54
- 241000283690 Bos taurus Species 0.000 description 53
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 52
- 239000000427 antigen Substances 0.000 description 52
- 108091007433 antigens Proteins 0.000 description 52
- 102000036639 antigens Human genes 0.000 description 52
- 239000012535 impurity Substances 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 51
- 239000000499 gel Substances 0.000 description 50
- 229910001868 water Inorganic materials 0.000 description 50
- 239000000126 substance Substances 0.000 description 49
- 238000002347 injection Methods 0.000 description 48
- 239000007924 injection Substances 0.000 description 48
- 230000002538 fungal effect Effects 0.000 description 47
- 241000700198 Cavia Species 0.000 description 44
- 206010039509 Scab Diseases 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 238000001514 detection method Methods 0.000 description 42
- 210000003491 skin Anatomy 0.000 description 42
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 39
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 206010042674 Swelling Diseases 0.000 description 36
- 230000008961 swelling Effects 0.000 description 36
- 238000011084 recovery Methods 0.000 description 35
- 238000002255 vaccination Methods 0.000 description 35
- 229960000583 acetic acid Drugs 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 33
- 239000013543 active substance Substances 0.000 description 32
- 239000012620 biological material Substances 0.000 description 32
- 238000007918 intramuscular administration Methods 0.000 description 32
- 208000002193 Pain Diseases 0.000 description 30
- 230000036407 pain Effects 0.000 description 30
- 239000007927 intramuscular injection Substances 0.000 description 29
- 238000010255 intramuscular injection Methods 0.000 description 29
- 238000004519 manufacturing process Methods 0.000 description 29
- 238000000926 separation method Methods 0.000 description 29
- 229960004279 formaldehyde Drugs 0.000 description 28
- 238000001556 precipitation Methods 0.000 description 28
- 239000006228 supernatant Substances 0.000 description 28
- 208000015181 infectious disease Diseases 0.000 description 27
- 229960002242 chlorocresol Drugs 0.000 description 26
- 239000002245 particle Substances 0.000 description 26
- 239000012071 phase Substances 0.000 description 26
- 239000007790 solid phase Substances 0.000 description 26
- 238000005119 centrifugation Methods 0.000 description 25
- 238000001914 filtration Methods 0.000 description 25
- 239000002244 precipitate Substances 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 24
- 239000006285 cell suspension Substances 0.000 description 24
- 239000002609 medium Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 230000036039 immunity Effects 0.000 description 23
- 235000013336 milk Nutrition 0.000 description 23
- 239000008267 milk Substances 0.000 description 23
- 210000004080 milk Anatomy 0.000 description 23
- 238000010790 dilution Methods 0.000 description 22
- 239000012895 dilution Substances 0.000 description 22
- 206010020565 Hyperaemia Diseases 0.000 description 21
- 238000002649 immunization Methods 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 239000004480 active ingredient Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 230000004048 modification Effects 0.000 description 20
- 238000012986 modification Methods 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000008215 water for injection Substances 0.000 description 20
- 238000005259 measurement Methods 0.000 description 19
- 239000002028 Biomass Substances 0.000 description 17
- 230000004071 biological effect Effects 0.000 description 17
- 238000001035 drying Methods 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 230000004054 inflammatory process Effects 0.000 description 17
- 238000011321 prophylaxis Methods 0.000 description 17
- 238000001228 spectrum Methods 0.000 description 17
- 239000008360 visualisation reagent Substances 0.000 description 17
- 241000282472 Canis lupus familiaris Species 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 16
- 206010047924 Wheezing Diseases 0.000 description 16
- 229910052751 metal Inorganic materials 0.000 description 16
- 239000002184 metal Substances 0.000 description 16
- 210000004400 mucous membrane Anatomy 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 16
- 241000282326 Felis catus Species 0.000 description 15
- 239000007791 liquid phase Substances 0.000 description 15
- 230000002269 spontaneous effect Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 230000001338 necrotic effect Effects 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 239000002994 raw material Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- CTIHYOZNWNAKHD-UHFFFAOYSA-N 4-methoxybenzaldehyde;sulfuric acid Chemical compound OS(O)(=O)=O.COC1=CC=C(C=O)C=C1 CTIHYOZNWNAKHD-UHFFFAOYSA-N 0.000 description 12
- 206010030113 Oedema Diseases 0.000 description 12
- 206010040844 Skin exfoliation Diseases 0.000 description 12
- 230000002378 acidificating effect Effects 0.000 description 12
- 230000035618 desquamation Effects 0.000 description 12
- 230000003779 hair growth Effects 0.000 description 12
- 150000002497 iodine compounds Chemical group 0.000 description 12
- 230000000877 morphologic effect Effects 0.000 description 12
- 235000015097 nutrients Nutrition 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 12
- 230000001018 virulence Effects 0.000 description 12
- 241000282817 Bovidae Species 0.000 description 11
- 241000282887 Suidae Species 0.000 description 11
- 230000009851 immunogenic response Effects 0.000 description 11
- 238000003307 slaughter Methods 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- 229920002101 Chitin Polymers 0.000 description 10
- 241000283086 Equidae Species 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000010998 test method Methods 0.000 description 10
- 229940033663 thimerosal Drugs 0.000 description 10
- 206010014025 Ear swelling Diseases 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 239000000084 colloidal system Substances 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 238000001647 drug administration Methods 0.000 description 9
- 239000011630 iodine Substances 0.000 description 9
- 229910052740 iodine Inorganic materials 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 8
- 229920002498 Beta-glucan Polymers 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 8
- 206010018691 Granuloma Diseases 0.000 description 8
- 230000003187 abdominal effect Effects 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical group N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000007928 intraperitoneal injection Substances 0.000 description 8
- 230000001665 lethal effect Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000033458 reproduction Effects 0.000 description 8
- 239000012085 test solution Substances 0.000 description 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 7
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 7
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000012445 acidic reagent Substances 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 7
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 7
- 210000000795 conjunctiva Anatomy 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 210000001508 eye Anatomy 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000028709 inflammatory response Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000004611 spectroscopical analysis Methods 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000030090 Acute Disease Diseases 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 6
- 206010024769 Local reaction Diseases 0.000 description 6
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 231100000360 alopecia Toxicity 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 239000002956 ash Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 238000002559 palpation Methods 0.000 description 6
- 239000012286 potassium permanganate Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000031888 Mycoses Diseases 0.000 description 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 229950006780 n-acetylglucosamine Drugs 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229960004906 thiomersal Drugs 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 4
- 244000132059 Carica parviflora Species 0.000 description 4
- 235000014653 Carica parviflora Nutrition 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 241000605909 Fusobacterium Species 0.000 description 4
- 102000002068 Glycopeptides Human genes 0.000 description 4
- 108010015899 Glycopeptides Proteins 0.000 description 4
- 239000012480 LAL reagent Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 208000030961 allergic reaction Diseases 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 230000034303 cell budding Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 235000011837 pasties Nutrition 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 206010052613 Allergic bronchitis Diseases 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 208000030373 chronic endometritis Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 210000000003 hoof Anatomy 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 108010059345 keratinase Proteins 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- 239000011505 plaster Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- NLQMSBJFLQPLIJ-UHFFFAOYSA-N (3-methyloxetan-3-yl)methanol Chemical compound OCC1(C)COC1 NLQMSBJFLQPLIJ-UHFFFAOYSA-N 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 241001331781 Aspergillus brasiliensis Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 241000605721 Dichelobacter nodosus Species 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- LJTJIFJOYZJWSL-KEWYIRBNSA-N N-[(3R,4R,5S,6R)-2-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1(N)O LJTJIFJOYZJWSL-KEWYIRBNSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000589886 Treponema Species 0.000 description 2
- 241000589892 Treponema denticola Species 0.000 description 2
- 241000589910 Treponema phagedenis Species 0.000 description 2
- 241000984746 Treponema vincentii Species 0.000 description 2
- 241000893982 Trichophyton simii Species 0.000 description 2
- 241000186064 Trueperella pyogenes Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000000576 arachnoid Anatomy 0.000 description 2
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000000937 inactivator Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 150000008040 ionic compounds Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- NAPPWIFDUAHTRY-XYDRQXHOSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 NAPPWIFDUAHTRY-XYDRQXHOSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YCHXNMPJFFEIJG-UHFFFAOYSA-N 3-methyloxiran-2-one Chemical compound CC1OC1=O YCHXNMPJFFEIJG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283726 Bison Species 0.000 description 1
- 235000006506 Brasenia schreberi Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000123346 Chrysosporium Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 241000283899 Gazella Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 241000709704 Human poliovirus 2 Species 0.000 description 1
- 241000709727 Human poliovirus 3 Species 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 241000264375 Nannizzia nana Species 0.000 description 1
- 241000275031 Nica Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001502413 Ovibos Species 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000021129 Postpartum disease Diseases 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000109463 Rosa x alba Species 0.000 description 1
- 235000005073 Rosa x alba Nutrition 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 241000283968 Syncerus caffer Species 0.000 description 1
- 241001459572 Trichophyton interdigitale Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003377 anti-microbal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000001647 gastrula Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002302 glucosamines Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000000796 hypoacidity effect Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008308 lipophilic cream Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012206 semi-quantitative assay Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
Definitions
- the invention relates to a method comprising the step of incubating chitosan in an aqueous solution of an organic carboxylic acid or a salt thereof, a modified chitosan obtainable by the method of the present invention, a hydro colloid, a compound of formula [X]n, a composition comprising the modified chitosan, the hydro colloid or compound according to the present invention, the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in human and/or veterinary medicine and the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in a method of treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis , interdigit
- Mastitis of cattle is distributed worldwide and causes extensive economic damage in agriculture. The damage caused by mastitis is caused in particular by a reduced milk yield and reduced milk quality. Mastitis causes hypogalactia and agalactia in animals. The loss of parts of secretory epithelial cells results in regeneration of connective tissue and to atrophy of the affected part of the udder.
- Endometritis is the inflammation of a mucous membrane of the uterus, which is followed by a more or less significant change of the endometria and an increased activity of the healthy or regenerated uterine glands. The uteritis is most frequently followed by reproduction of polymorphic microflora. Chronic endometritis is a very widespread gynecological disease: it is registered at 12-40% of infertile cows.
- mastitis The most common form of mastitis is the hidden (subclinical) mastitis.
- the hidden mastitis of cows is followed by a softly proceeding inflammatory process with only few or no clinical signs of mastitis.
- Treatment of animals with this form of mastitis is complicated. This form is very common on large dairy units and is usually only diagnosed during monthly performed examinations for the hidden form of mastitis of the milking herd. About 15% of the lactating cows are affected by the latent mastitis during machine milking. The reasons of the hidden mastitis developing are manifold.
- An objective indicator for a healthy cow udder is the quantity of the contained somatic cells in the milk.
- Somatic cells in cow milk are presented by leukocytes and epithelium of mammary glands.
- Epithelial cells are dominated in the milk secretion from a healthy cow.
- the epithelial cells are formed in udder tissues during the process of natural aging and regeneration of tissues.
- mastitis the migration of leukocytes increases in the inflammation area that finally leads to an acute increase of somatic cells in the milk.
- 1ml milk from clinically healthy cows contains 200 - 250 thousand somatic cells. During mastitis their quantity increases up to 900 thousand and more.
- the milk from cows affected with the hidden form of mastitis has hypoacidity since there is comprises an increased content of chlorides, albumin and globulins.
- the quantity of cell elements increases several times, especially the quantity of leukocytes.
- the content of solids casein, lactose, calcium and phosphorus
- milk from cows affected with the hidden form of mastitis is combined with milk of healthy cows the overall quality of the milk is reduced. It cannot be used for cheese preparation and sour milk products and has an extreme adverse effect on human health.
- antibiotics sulfanilamide preparations or mixtures thereof are used for treating the various forms of mastitis and endometritis. Also extracts of plants comprising essential oils with antimicrobic effect are used. In recent years enzyme preparations and immunobiological products comprising probiotics and interferon were used.
- antibiotics there is a need to check preliminary the activators from the affected quarter of an udder on sensitivity to antibiotics.
- milk and products of slaughter from the treated animals can't be used within several days or week.
- the preparation is very effective but milk and products of slaughter from the treated animals can't be used within several days.
- the solutions contain at least 1000 units of recombinant bovine interferon which is packed in 10g injectors.
- the solutions are used intracisternally twice a day with an interval of 8-14 hours for 3 days or until complete recovery. Recovery time is 4-12 days.
- the advantages of this method is the absence any limits for the use of milk and meat from treated animals, it doesn't lead to resistance of pathogenic organisms and it has no locally-irritating and resorptive-toxic properties.
- the disadvantages of this method are the necessity of repeated application of the preparation and the presence of protein components that can provoke allergic reactions.
- DD ID and IP
- DD infectious hoof and claw diseases
- DD infectious hoof and claw diseases
- the incidence depends amongst other on weather, season of year, grazing periods, and housing system.
- DD usually leads to lameness and to a significant decrease in body weight, loss of fertility and decrease of milk production.
- the incidence can be between 5% and 30%.
- IP accounts only for up to 15% of the claw diseases.
- DD etiological factors of DD, ID and IP are the same microorganisms, such as Dichelobacter nodosus, Fusobacterium necroforun and Fusobacterium, spp which first destroy the epidermis and allow the spirochetes from Treponema spp such as T. phagedenis, T. vincentii, and T. denticola to gain entrance into deeper tissues for developing the clinical sings of DD.
- Treponema spp such as T. phagedenis, T. vincentii, and T. denticola
- bacterial species isolated from pathological material from tissues affected with DD, ID and IP are Campylobacter spp, Staphylococcus aureus, Escherichia coli, Arcanobacterium pyogenes, and Prevotella spp. Also, it was suggested that a virus plays an important role in the pathogenesis of the diseases.
- the typical treatment strategy for DD, ID and IP is the application of antibiotics, antibacterial preparations and topical applications pads with antibiotics, antiseptics and astringent solutions. All known vaccines often fail to elicit a sufficient immune response and to protect the animals against interdigital dermatitis and interdigital phlegmone. There are no effective vaccines against digital dermatitis.
- the antigenic material disclosed in WO 97/07232 comprises polysaccharides and/or glycopeptides obtained from keratinophilic fungi and yeasts.
- the antigenic preparations can be used as pharmaceutical compositions as well as vaccines for the treatment of animals and humans, especially for the treatment of allergies and for modulating the immune response. They can be of immunological as well as of pharmacological utility.
- Kuen Y L et al. discloses chitosan derivatives wherein chitosan was acylated to various degrees with acetic, propionic, n-butyric, n-valeric and n-hexanoic reagents. Biocompatibility of said derivatives was tested e.g. in combination with enzymes.
- Kuen Y L et al. discloses that the degree of deacetylation of chitosan should be kept less than 50% for prevention of gelation.
- CN 102 727 887 A discloses an immunological adjuvant in a mouse allergic asthma model comprising preparation of an acetylated chitosan-derivative prepared by using a chitosan-acetic acid solution neutralized by NaOH. OVA is used as a model antigen.
- Seferian P G et al. (Vaccine, Elsevier Ltd, GB, vol. 19, no. 6, 8 November 2000, pages 661-668 ) describes a chitosan antigen mixture wherein the antigen was mixed with a sterile 2% solution in 2% acetic acid solution followed by neutralization with NaOH thereby forming a fine gelatinous precipitate that was used for vaccination.
- Huadong Wang et al. (BMC Infectious Diseases, vol. 14, no. 1, 11 April 2014, page 195 ) discloses the preparation of a murine cytomegalovirus vaccine comprising preparing an antigen solution mixed with a chitosan adjuvant 0.2%(w/v) diluted in a 25 mM sodium acetate solution (pH 5.0).
- the chitosan was prepared by: adding 0.04 g chitosan to 20 ml of a 0.1 M solution of glacial acetic acid [concentration 0.2%(w/v)], mixing it for about an hour to dissolve it and adjusting its pH with NaOH.
- WO 2013/033400 describes in detail the preparation of a murine cytomegalovirus vaccine comprising preparing an antigen solution mixed with a Chitosan adjuvant 0.2% (w/v) diluted in a 25 mM sodium acetate solution (pH 5.0).
- the chitosan was prepared by: adding 0.04 g chitosan to 20 ml of a 0.1 M solution of glacial acetic acid [concentration 0.2% (w/v)], mixing it for about an hour to dissolve it, adjusting its pH with NaOH.
- the object of the present invention is the provision of a more effective immunobiological product/preparation. It is also an object of the present invention to provide a new agent for use in veterinary and/or human medicine. Another object of the present invention is the provision of new agents for treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis , interdigital phlegmon, trichophytosis, microsporosis, mycosis of skin, allergies, as well as diseases complicated by allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic ec
- chitosan refers to a copolymer of 2-amino-2-deoxy-D-Glucopyranose and 2-acetamido-2-deoxy-D-glucopyranose, where the degree of deacetylation is more than 50%, preferably more than 60%, 70%, 80% or 90%.
- Chitosan may be chemically derived from chitin which is a poly-1,4- ⁇ -N-acetyl- D-glucosamine, more particularly a N-acetyl-1,4- ⁇ -D-glucopyranosamine by deacetylation.
- Typical chitosan preparations have varying molecular weights depending on the method of manufacture.
- mastitis refers an inflammation of breast and udder tissue. It preferably comprises latent mastitis and/or acute mastitis. Latent mastitis may also be called hidden mastitis and/or subclinical mastitis. Preferably, latent mastitis can be diagnosed by a well-known method in the art with 2% solution of mastidin. Acute mastitis may also be fibrinous, catarrhal, purulent-catarrhal, hemorrhagic mastitis with visual typical clinical symptoms of disease.
- endometritis refers to an inflammation of the endometrium. More preferably, it refers to an inflammation of a mucous membrane of the uterus, which may be followed by a more or less significant change of the endometria and an increased activity of the healthy or regenerated uterine glands. Preferably, it comprises chronic endometritis, subacute, acute and subclinical (hidden) endometritis. The nature of inflammation is divided into catarrhal, catarrhal-purulent, purulent, fibrinous and hidden. Endometritis may also be called uteritis. Uteritis is most frequently followed by reproduction of polymorphic microflora.
- trichophytosis refers to a disease due to an infection with fungi from genera Trichophyton. Cattle is usually infected by Trichophyton verrucosum while humans, dogs, cats, horses, fur-bearing and other animals are usually infected by T. mentagrophytes. Humans can also be infected by T. rubrum. It may also be called Trichophyton disease.
- microsporosis or “Microsporum canis disease” as used herein refer to a disease due to an infection with genera Microsporum, more preferably with Microsporum canis. Typically cats, dogs, horses and other animals are infected by this disease. It is especially common in pigs, which are mostly infected by Microsporum nanum.
- warts refers in general to a small, rough growth resembling a cauliflower or to a solid blister. Normally, warts are caused by a viral infection.
- warts refers to Common warts, in particular verrucae volgares and paronychial warts.
- hoof- and claw disease refers in particular to infectious hoof- and claw diseases in bovidae and/or pigs. Said diseases are in particular caused by bacteria, fungi and/or viruses. In particular the term “hoof- and claw diseases” refers to digital dermatitis, interdigital dermatitis and interdigital phlegmone.
- phrases refers in particular to cloven-hoofed, ruminant mammals including includes bison, African buffalo, water buffalo, antelopes, gazelles, sheep, goats, muskoxen, and cattle.
- lameness refers in particular to lameness as a result of an infection and damage to tissue.
- lameness refers to lameness due to hoof and claw diseases, more particularly due to digital dermatitis (DD), interdigital dermatitis (ID) and interdigital phlegmone (IP).
- DD digital dermatitis
- ID interdigital dermatitis
- IP interdigital phlegmone
- composition comprising chitosan modified by an organic carboxylic acid or a salt thereof stimulates the immune response and can be used in a method of treating and/or preventing a number of different diseases.
- active agents if already known active agents are administered in combination with a modified chitosan of the present invention, said active agents can be used in an up to 50 times less dose.
- the present invention relates to a method for preparing chitosan modified by an organic carboxylic acid, or a salt thereof, a hydro colloid, a compound and a composition all as defined in the claims.
- the present invention relates to the hydro colloid, the compound or the composition as defined in the claims for use as defined in the claims.
- the modified chitosan is a clear gel with an absent or faint smell of acetic acid.
- the modified chitosan prepared by the method of the present invention has preferably a molecular weight or an average molecular weight of about 50 Da to about 700kDa, in particular of about 15 kDa to about 500 kDa, more particular of about 15kDa to about 150kDa, or of about 80 kDa to about 200 kDa, of about 150 kDa to about 300 kDa, of about 100 kDa to about 250 kDa or of about 300 kDa to about 700 kDa.
- the mass content of ashes of the modified chitosan according to the present invention is preferably about 0.2 to 2%, more preferably about 0.8 to about 1.2% and most preferably 0.22%.
- the modified chitosan according to the present invention may also be called chitosan derivative or chitosan variant.
- the modified chitosan has reactive amino groups in an amount of about 100 to about 500 per 100 kDa of chitosan.
- the modified chitosan prepared by the method according to the present invention has a degree of deacetylation of 62% to 98%, more preferably of 80 to 95 %, more preferably of about 89% to about 93 %, or of about 89% to about 98%, of about 93% to about 98%, of about 93% to 95% or of about 95% to 98%.
- the modified chitosan, chitosan derivative or chitosan variant prepared by the method according to the present invention is preferably a compound of formula [X]n, in which n represents an integer of about 1 to about 5000, in particular an integer of about 300 to about 4000, and X has the following formula (1): , wherein 2 to 38% of the X residues constituting said compound are modified by acetylation and wherein all or part of the X residues constituting said compound are modified by an organic carboxylic acid or a salt thereof.
- the present invention also refers to a compound of formula [X]n, in which n represents an integer of 1 to 5000, in particular an integer of 300 to 4000, and X has the following formula (1): , wherein 2% to 38%, more preferably 5% to 20% of the X residues constituting said compound are modified by acetylation and wherein all or part of the X residues constituting said compound are modified by an organic carboxylic acid or a salt thereof.
- the formula X refers to a deacetylated 2-amino-2-deoxy-D-glucose unit and a D-glucosamine unit, respectively, which is the monomer of 100% deacetylated chitosan. Accordingly, the formula X may also refer to the formula represented in the square brackets of the following formula (2) representing the structural formula of a chitosan with a degree of deacetylation of 100%:
- n represents an integer of about 1 to about 5000. Within that limit n is preferably at least about 10, about 50, about 80, about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900 or about 1000 and/or at most about 4000, about 3000, about 2500, about 2000 or about 1500. In further preferred embodiments of the present invention n represents an integer of about 50 to about 2500, in particular of about 50 to about 1000, or of about 300 to about 1500, of about 1000 to about 2000, of about 400 to about 1700, of about 50 to about 1700 or of about 1000 to about 5000.
- 5% to about 35 %, more preferably about 5% to about 20%, more preferably about 7% to about 11% or about 2% to about 7%, about 5% to about 7% or about 2% to about 5% of the X residues constituting the compound as defined above are modified by acetylation, which means that they are acetylated.
- a modification by acetylation refers to the introduction of an acetyl functional group into the residue according to formula (1) which results in a N-acetyl-D-glucosamine-residue.
- the organic carboxylic acid has a pKs of about 2 to about 5, more preferably of about 2.3 to about 4.9. More preferably, the organic carboxylic acid, or a salt thereof is selected form the group consisting of valeric acid, valeric acid chloride, para-aminobenzoic acid, glucuronic acid, and lactic acid.
- the modification with the organic carboxylic acid or a salt thereof is preferably obtainable by the contact or a reaction with said organic carboxylic acid or a salt thereof or an aqueous solution comprising said organic carboxylic acid or a salt thereof.
- the modification takes place by the contact with an aqueous solution comprising about 0.2 M to about 22.5 M of said organic carboxylic acid or a salt thereof, or in an aqueous solution comprising about 1 mM to about 100 mM of the organic carboxylic acid or a salt thereof, more preferably about 1 mM to about 10 mM.
- the modified chitosan, chitosan derivative or chitosan variant prepared by the method according to the present invention is preferably a Polyamino-sugar colloid, preferably a hydro colloid.
- the modified chitosan, chitosan derivative or chitosan variant is a Chitosan-Glucuronic acid-Hydro-Colloid or Chitosan-p-Aminobenzoic acid-Hydro-Colloid or Chitosan-Valeric acid-Hydro-Colloid.
- the Chitosan-Glucuronic acid-Hydro-Colloid has preferably the chemical formula: (C 6 H 11 O 4 N) x (C 8 H 13 O 5 N y (C 6 H 10 O 7 ) z (H 2 O) m. .
- the Chitosan-Glucuronic acid-Hydro-Colloid has the following molecular weight: x ⁇ (161)+y ⁇ (203)+z ⁇ (194.14)+m ⁇ (18).
- the Chitosan-p-Aminobenzoic acid-Hydro-Colloid has the chemical formula: (C 6 H 11 O 4 N) x (C 8 H 13 O 5 N) y (C 7 H 7 O 2 N) z (H 2 O) m.
- the Chitosan-p-Aminobenzoic acid-Hydro-Colloid has the following molecular weight: x ⁇ (161)+y ⁇ (203)+z ⁇ (137.14)+m ⁇ (18).
- Chitosan-Valeric acid-Hydro-Colloid has the chemical formula: (C 6 H 11 O 4 N) x (C 8 H 13 O 5 N) y (C 5 H 10 O 2 ) z (HCl) z (H 2 O) m.
- Chitosan-Valeric acid-Hydro-Colloid has the following molecular weight: x ⁇ (161)+y ⁇ (203)+z ⁇ (102)+z ⁇ (36.5)+m ⁇ (18).
- the present invention also refers to a hydro colloid comprising:
- the chitosan of the hydro colloid is a compound of formula [X]n, in which n represents an integer of about 1 to about 5000, in particular an integer of about 300 to about 4000, and X has the following formula (1): , wherein about 2% to about 38%, more preferably about 5% to about 20% of the X residues constituting said compound are modified by acetylation and wherein all or part of the X residues constituting said compound are modified by an organic carboxylic acid or a salt thereof as defined below.
- the remaining percentage of the hydro colloid according to the present invention is provided by the dispersion media, preferably water or water and hydrogenchloride (HCl).
- the dispersion media preferably water or water and hydrogenchloride (HCl).
- the hydro colloid according to the present invention is used as a dilution, preferably in a dilution of 0 to 10 times.
- the modified chitosan, chitosan derivative or chitosan variant prepared by the method according to the present invention is preferably a natural white to yellowish viscous liquid.
- the modified chitosan, chitosan derivative or chitosan variant has typical odor of the carboxylic acid, preferably the typical odor of valeric acid.
- the modified chitosan, chitosan derivative or chitosan variant contains preferably about 0.2 % pentanoly chloride, or 0.2% Glucuronic acid, or 0.2% p-Aminobenzoic acid.
- the modified chitosan, chitosan derivative or chitosan variant contains preferably 1% chitosan residue from drying chitosans.
- the modified chitosan, chitosan derivative or chitosan variant has preferably about 10 to about 1000 mOsmol, preferably about 10 to about 200 mOsmol, most preferably about 100 mOsmol.
- the modified chitosan prepared by the method according to the present invention is preferably further modified by a mineral acid.
- Said modification may result from the contact or a reaction with said mineral acid or an aqueous solution comprising said mineral acid.
- Said mineral acid is preferably HCl or H 2 SO 4 .
- the modification takes place by incubating the modified chitosan in an aqueous solution comprising about 0.05 M to about 1 M of said mineral acid, preferably HCl or H 2 SO 4 .
- the present invention also refers to a composition comprising a modified chitosan, chitosan derivative or chitosan variant or a hydro colloid according to the present invention.
- the composition comprising said modified chitosan is a clear gel with an absent or faint smell of acetic acid which is soluble in water and in 1% solution of acetic acid.
- the composition has preferably a molecular weight or an average molecular weight of about 50 Da to about 700kDa, in particular of about 15 kDa to about 500 kDa, more particular of about 15 kDa to about 150kDa, or of about 80 kDa to about 200 kDa, of about 150 kDa to about 300 kDa, of about 100 kDa to about 250 kDa or of about 300 kDa to about 700 kDa.
- the mass content of ashes of the composition according to the present invention is 0.1 to 2%, preferably about 0.8 to about 1.2%, more preferably about 0.22%.
- the modified chitosan of said composition has reactive amino groups in an amount of about 100 to about 500 per 100 kDa of chitosan.
- the modified chitosan of the composition according to the present invention has preferably a degree of deacetylation of about 65% to about 98%, more preferably of about 80% to about 95 %, more preferably of about 89% to about 93 %, or of about 89% to about 98%, of about 93% to about 98%, of about 93% to about 95% or of about 95% to about 98%.
- the composition comprises additionally a mineral acid.
- Said mineral acid supports the solubility of the modified chitosan and/or may further modify the chitosan.
- Said mineral acid is preferably HCl or H 2 SO 4 .
- the aqueous solution comprises preferably 0.05 M to about 1 M mineral acid, preferably HCL or H 2 SO 4 .
- the present invention also relates to a method for preparing a modified chitosan, chitosan variant or chitosan derivative comprising the step of:
- the chitosan is firstly dissolved under acidic aqueous conditions and subsequently precipitated by increasing the pH value to a pH value of about 8.0 to about 8.5 before it is incubated in the aqueous solution of the organic carboxylic acid or the salt thereof as described above.
- the present disclosure also relates to a modified chitosan obtainable by a method comprising
- the present invention also relates to a method comprising the steps of:
- the organic carboxylic acid or a salt thereof of step (a) has preferably a pKs of about 2 to about 5, more preferably of about 2.3 to about 4.9.
- Said organic carboxylic acid is valeric acid, lactic acid, para -aminobenzoic acid or glucuronic acid or a salt thereof, in particular chloride of valeric acid.
- Said carboxylic organic acid or a salt thereof is preferably used in a concentration of about 0.2 M to about 22.5 M.
- step (a) The incubation of chitosan and the recovered chitosan of step (iii), respectively, and the aqueous solution of the organic carboxylic acid or a salt thereof as outlined in step (a) results in the solution of the chitosan, the modification of the chitosan and/or the formation of a gel.
- the pH value of the aqueous solution in step (a) is about 5 to about 6 or about 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9 or 6.0.
- the modification of the chitosan takes place in an aqueous solution comprising about 1 mM to about 100 mM of the organic carboxylic acid or a salt thereof, more preferably about 1 mM to about 10 mM.
- step (a) is performed until the chitosan is modified and dissolved. It is preferably performed by mixing chitosan with an aqueous solution of the organic carboxylic acid or a salt thereof or by suspending chitosan under aqueous conditions and adding the organic carboxylic acid to the suspension. It is preferably performed under stirring for about 1 to about 72 hours, more preferably for about 24 to about 48 hours. Step (a) may comprise the addition of a further acid or may be performed in the presence of a further acid. Said further acid is preferably a mineral acid, an organic acid or a salt of said mineral acid or organic acid.
- the mineral acid is HCl or H 2 SO 4 and the organic acid is glutamic acid, para -aminobenzoic acid or lactic acid.
- the mineral or organic acid is preferably added or present in an amount to adjust the pH value of the mixture of step (a) to a pH value of about 5 to about 6 or about 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9 or 6.0.
- the addition of a further acid may support the dissolution and/or the modification of the chitosan e.g. by decreasing the time which is necessary to dissolve the modified chitosan.
- the concentration of chitosan in step (a), or if the method comprises a step (i) for step (i), is preferably about 1g to about 20 g chitosan per liter, more preferably about 5g to about 15 g chitosan per liter, most preferably about 8 to about 10 g chitosan per liter.
- the chitosan used for step (a), or if the method comprises a step (i) for step (i), may be commercially available chitosan or chitosan isolated from any natural source comprising chitosan such as biomass comprising chitosan.
- chitin may be used which is deacetylated to obtain chitosan prior to step (a), or if the method comprises a step (i) prior to step (i).
- Said chitin may be commercially available or it may be isolated from a natural source comprising chitin such as biomass comprising chitin.
- the biomass for chitin and/or chitosan isolation is preferably biomass of fungi, insects and/or crustaceans.
- the deacetylation of chitin can be performed by known methods in the art as e.g. by using sodium hydroxide (NaOH) in excess as a reagent and water as a solvent or by enzymatic methods.
- NaOH sodium hydroxide
- the isolation of chitosan and/or chitin from natural sources can also be performed by known methods in the art and by the methods described in the Examples of the present invention.
- the chitosan used for step (a), or if the method comprises a step (i) for step (i), has a degree of deacetylation of 62% to 95%, more preferably of 80% to 94 %, more preferably of about 89% to about 93 % or of about 93% to about 98%, of about 93% to 95%, of about 95% to about 98%, or of at least 70%, 80%, 90% or 95%, or a degree of deacetylation of about 80% to about 95%, even more preferably of about 90% to about 95%, most preferably about 77% to about 80%.
- the chitosan used for step (a), or if the method comprises a step (i) for step (i), has preferably a viscosity of about 50 to 400 MPas, more preferably about 70 to about 150 MPas or about 151 to about 350 MPas.
- the chitosan used for step (a), or if the method comprises a step (i) for step (i), has preferably a molecular weight or an average molecular weight of about 50 Da to about 700kDa, in particular of about 15 kDa to about 500 kDa, more particular of about 15 kDa to about 150kDa, or of about 80 kDa to about 200 kDa, of about 150 kDa to about 300 kDa, of about 100 kDa to about 250 kDa or of about 300 kDa to about 700 kDa.
- the chitosan Before the chitosan is used in step (a), or if the method comprises a step (i) in step (i), the chitosan may be sterilized by autoclaving. Said sterilization may result in that the modified chitosan according to the present invention is less toxic, better tolerated by any subject and/or results in less unintended side-effects.
- step (i) is performed by the use of an aqueous solution of an weak acid, preferably by an organic acid or a salt thereof, more preferably by acetic acid, valeric acid, lactic acid, para- aminobenzoic acid or glucuronic acid or a salt thereof, in particular chloride of valeric acid.
- the acid is preferably used in a concentration of about 0.8% to about 2%.
- Step (i) is preferably performed under stirring. The stirring may be performed for about 2 hour to about 24 hours.
- step (i) is performed until a gel or gel suspension is obtained. Unsolved particles may be removed, e.g. by filtration. For example, a metal grid with a cell of 200 ⁇ m to 300 ⁇ m may be used for such a filtration.
- Step (ii) is preferably performed by increasing the pH value of the gel or gel suspension obtained in step (i) until a precipitate is formed. It is preferably performed under stirring. It is preferably performed by treating chitosan under aqueous alkaline conditions, more preferably under aqueous alkaline conditions comprising about 0.1 to about 25.0% alkali. In a preferred embodiment the alkali is NaOH. Preferably, said step is performed at a temperature of about 4°C to about 55°C. Preferably, the treatment is performed for about 20 min to about 2 hours, more preferably for about 30 min to about 70 min, but it may also take up to about 24 h.
- the pH value is increased by adding the alkali to the gel or gel suspension of step (i).
- the pH value is increased to obtain a pH of about 8.0 to about 8.5.
- Step (ii) may result in a further deacetylation of the chitosan. It may also result in that the modified chitosan according to the present invention is less toxic, better tolerated by any subject and/or results in less unintended side-effects.
- Step (iii) is preferably performed by centrifuging the mixture or suspension obtained in step (ii).
- the centrifugation is preferably performed at about 4000 to about 6000 revolution/min, more preferably at about 5000 revolution/min.
- the centrifugation is preferably performed for up to 60 minutes.
- the modified chitosan of the present invention may comprise additional steps.
- the product obtained in step (ii) may be homogenized.
- the step of homogenization is performed in a closed sterile homogenizer.
- the product obtained in step (a) may be dialyzed.
- the dialysis is preferably performed in a closed system to remove free ions of salts and low molecular weight compounds.
- the dialysis is performed by cross filtration for about 1 to about 6 hours or by membrane filtration against distillate water for about 24 to about 48 hours.
- the methods by which the modified chitosan of the present invention is obtainable and the methods of the present invention may comprise a further step of preparing the final product.
- the preparation of the final product may comprise the dilution of the obtained product.
- the product is diluted by the addition of water, more preferably of sterile water for injection.
- the product may also be diluted in any other suitable aqueous solution.
- the preparation of the final product may comprise the addition of one or more further compounds, such as diluents, preservatives, antibiotics, further active substances and/or antigenic material from microorganism and/or enzymes. Suitable preservatives are for example chlorocresol, thiomersal and formalin.
- Suitable antibiotics are for example neomycin, penicillin, gentamycin, cloxacillin, cephapirin and cephalosporin.
- the final product may be sterilized.
- the sterilization is performed by heating, preferably for about 40 to 50 minutes at a temperature of about 65°C to about 80°C.
- said sterilization is repeated one, two, three, four or five times.
- the final product has a concentration of about 0.02g to about 2g modified chitosan per liter, more preferably of about 0.04 to about 1g modified chitosan per liter.
- the methods of the present invention comprise the steps as described in the claims.
- the methods may comprise the following steps:
- the order of the steps as outlined above corresponds to the order as listed above.
- the order of single steps may be varied as long as the same effects are achieved.
- diluents such as water may be added in various stages of the method as described above.
- the steps are preferably performed at room temperature and/or in a range of about 10°C to about 40°C, more preferably in a range of about 20°C to about 30°C.
- the present invention refers to a composition comprising a modified chitosan, chitosan derivative or chitosan variant or a hydro colloid according to the present invention.
- composition of the present invention may comprise further active substances.
- composition of the present invention may additionally comprise a chemotherapeutic preparation, in particular if it is used for the treatment of mastitis.
- composition of the present invention may additionally comprise antigenic material from microorganism and/or enzymes, in particular antigenic material of keratinophilic fungi and/or keratinophilic yeast-like fungi and/or yeasts.
- the antigenic material of keratinophilic fungi or yeasts may be derived from any parts of keratinophilic fungi or yeasts comprising antigens such as from the mycelium, artrospores, dermatophyte microconidia, yeast blastospores or others.
- the antigens are preferably polysaccharides and/or glycopeptides.
- the antigenic material of keratinophilic fungi or yeasts is selected from the group consisting of: homogenised inactivated dermatophyte microconidia, homogenised inactivated yeast blastospores, antigenic material of yeast blastospores and antigenic material of dermatophyte microconidia.
- composition of the present invention may additionally comprise homogenised inactivated dermatophyte microconidia and/or homogenised inactivated yeast blastospores and/or antigenic material of yeast blastospores and/or dermatophyte microconidia.
- the antigenic material of keratinophilic yeasts in particular the yeast blastospores, belong preferably to the genus Candida and more preferably to the species Candida albicans.
- the dermatophyte microconidia belong to the species Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton equinum, Trichophyton sarkisovii, Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Microsporum gypseum and/or Chrisporium tropicum.
- the species Microsporum canis can be Microsporum canis var. obesum and/or Microsporum canis var. distortum.
- the yeast blastospores and the dermatophyte microconidia are obtained from strains of the above mentioned species which has been obtained by directed selection based on spore production and/or attenuation. It is highly preferred to use a strain which grow faster in nutrient medium, produces more microconidia and blastospores, respectively, has a lower virulence and/or no adverse reactions after its intramuscular application in comparison to any epizootic strain from which it is derived.
- strains examples include the strains Trichophyton mentagrophytes DSM - 7279, Trichophyton verrucosum DSM - 28406, Trichophyton rubrum DSM - 9469, Trichophyton rubrum DSM - 9470, Trichophyton rubrum DSM - 9471, Trichophyton rubrum DSM - 9472, Candida albicans DSM - 9456, Candida albicans DSM - 9457, Candida albicans DSM - 9458, and Candida albicans DSM - 9459, Chrisporium tropicum DSM-28405 and Microsporum canis BINO 483.
- the yeast blastospores and the dermatophyte microconidia are obtained from strains Trichophyton mentagrophytes DSM - 7279, Trichophyton verrucosum DSM - 28406, Trichophyton rubrum DSM - 9469, Trichophyton rubrum DSM - 9470, Trichophyton rubrum DSM - 9471, Trichophyton rubrum DSM - 9472, Candida albicans DSM - 9456, Candida albicans DSM - 9457, Candida albicans DSM - 9458, Candida albicans DSM - 9459, Chrisporium tropicum DSM-28405 and Microsporum canis BINO 483.
- the strains Trichophyton rubrum DSM - 9469, Trichophyton rubrum DSM - 9470, Trichophyton rubrum DSM - 9471, Trichophyton rubrum DSM - 9472, Candida albicans DSM - 9456, Candida albicans DSM - 9457, Candida albicans DSM - 9458, and Candida albicans DSM - 9459 have been deposited according to the Budapest Treaty at the "Deutsche Sammlung von Mikroorganismen und Zellkulturen” (DSM), Mascheroder Weg 1B, W-38124 Braunschweig, Germany (which current name and address is "Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH” (DMSZ), InhoffenstraBe 7B, 38124 Braunschweig, GERMANY) on 05 October 1994 by the Basotherm GmbH, Eichendorffweg 5, 88396 Biberach an der Riss.
- the strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9469.
- the strain was obtained by directed selection based on spore production and attenuation of the epizootic strain No. 533, which was identified on a skin of man in 1985.
- the strain was identified using the "Rebell-Taplin" key ( Rebell, G., Taplin, D.: Dermatophytes, their recognition and identification, 3rd Print, University of Miami Press. Coral Gables, Florida, USA, 1978 ).
- the biological properties of the strain are described in Table A.
- Strain No. DSM-9469 differs from the epidemic strain in its faster growth in nutrient medium, an enormous production of microconidia and lower virulence.
- the strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9470.
- the strain was obtained by directed selection based on spore production and attenuation of the epizootic strain No. 535, which was identified on a skin of man in 1990.
- the strain was identified using the "Rebell-Taplin" key ( Rebell, G., Taplin, D.: Dermatophytes, their recognition and identification, 3rd Print, University of Miami Press. Coral Gables, Florida, USA, 1978 ).
- the biological properties of the strain are described in Table B.
- Strain No. DSM-9470 differs from the epidemic strain in its faster growth in nutrient medium, an enormous production of microconidia and lower virulence. TABLE B Properties and characteristics of the strains Strain No.
- DSM-9470 Epidemic Strain No. 535 Description of the culture Mature 15-day colony on agar Sabouraud: white velvety-fluffy in centre, folded, margin of colony regular, under surface colourless or rose, diameter of colony 25 - 30 mm 20-day colony on agar Sabouraud: white, fluffy, margin of colony regular, under surface yellow, 20 mm in diameter Morphological characteristics Mature 15-day culture with septate branching hyphae 1 - 3 ⁇ m wide, round oval puriform microconidia measuring 2 - 3 x 3 - 7 ⁇ m.
- the strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9471.
- the strain was obtained by directed selection based on spore production and attenuation of the epizootic strain No. 620, which was identified on a nail of man in 1989.
- the strain was identified using the "Rebell-Taplin" key ( Rebell, G., Taplin, D.: Dermatophytes, their recognition and identification, 3rd Print, University of Miami Press. Coral Gables, Florida, USA, 1978 ).
- the biological properties of the strain are described in Table C.
- Strain No. DSM-9471 differs from the epidemic strain in its faster growth in nutrient medium, an enormous production of microconidia and lower virulence.
- the strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9472.
- the strain was obtained by directed selection based on spore production and attenuation of the epizootic strain No. 754, which was identified on a nail of man in 1990.
- the strain was identified using the "Rebell-Taplin" key ( Rebell, G., Taplin, D.: Dermatophytes, their recognition and identification, 3rd Print, University of Miami Press. Coral Gables, Florida, USA, 1978 ).
- the biological properties of the strain are described in Table D. Strain No. DSM-9472 differs from the epidemic strain in its faster growth in nutrient medium, an enormous production of microconidia and lower virulence.
- the strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9456.
- the strain was obtained by directed selection based on stabilization of cultural-morphological characteristics and attenuation of epidemic strain No. 008-L, which was identified on man in 1990.
- the strain was identified using the Lodder's key ( Lodder,J: The yeast: A Taxonomic Study. North-Holland Publ. Co., Amsterdam - London (1970 ).
- the biological properties of the strain are described in Table E.
- Strain No. DSM-9456 differs from the epidemic strain in its faster growth in nutrient medium, stabile biological properties, an enormous production of biomass and lower virulence. TABLE E Properties and characteristics of the strains Strain No.
- the strain is weakly virulent. 30 days after intraperitoneal injection of a dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 50% of animals are formed. Lethal effect was not observed.
- the strain is weakly virulent. 30 days after intraperitoneal injection of a dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 80 -100% of animals are formed. Lethal effect in 50 - 70% was observed.
- the strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9457.
- the strain was obtained by directed selection based on stabilization of cultural-morphological characteristics and attenuation of epidemic strain No. 012, which was identified on man in 1992.
- the strain was identified using the Lodder's key ( Lodder,J: The yeast: A Taxonomic Study. North-Holland Publ. Co., Amsterdam - London (1970 ).
- the biological properties of the strain are described in Table F.
- Strain No. DSM-9457 differs from the epidemic strain in its faster growth in nutrient medium, stabile biological properties, an enormous production of biomass and lower virulence. TABLE F Properties and characteristics of the strains Strain No. DSM-9457 Epidemic Strain No.
- the strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9458.
- the strain was obtained by directed selection based on stabilization of cultural-morphological characteristics and attenuation of epidemic strain No. 047, which was identified on man in 1989.
- the strain was identified using the Lodder's key ( Lodder,J: The yeast: A Taxonomic Study. North-Holland Publ. Co., Amsterdam - London (1970 ).
- the biological properties of the strain are described in Table G.
- Strain No. DSM-9458 differs from the epidemic strain in its faster growth in nutrient medium, stabile biological properties, an enormous production of biomass and lower virulence. TABLE G Properties and characteristics of the strains Strain No.
- DSM-9458 Epidemic Strain No. 047 Description of the culture 10-day single-spore colony on agar Sabouraud: cream smooth and pasty glistening, elevated, margin of colony regular, diameter of colony 16 - 18 mm 10-day single-spore colony on agar Sabouraud: cream soft and smooth with feathery offshots at the edges, diameter of colony 10 - 15 mm Morphological characteristics 10-day culture with spherical oval blastospores measuring 3.6 - 6 x 6 - 11 ⁇ m, chlamidospores 12 -15 ⁇ m wide, pseudohyphae 4 - 8 ⁇ m wide, hyphae 1.5 - 3 ⁇ m wide 10-day single-spore culture on agar Sabouraud with spherical oval budding blastospores measuring 3 - 5 x 5 - 8 ⁇ m, chlamidospores 10 - 15 ⁇ m diameter, pseudohyphae 5 - 8 ⁇ m wide,
- the strain is weakly virulent. 30 days after intraperitoneal injection of a dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 50 - 100% of animals are formed. Lethal effect in 50% were observed.
- the strain is weakly virulent. 30 days after intraperitoneal injection by dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 80 -100% of animals are formed. Lethal effect in 70 - 100 % were observed.
- the strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9459.
- the strain was obtained by directed selection based on stabilization of cultural-morphological characteristics and attenuation of epidemic strain No. 158, which was identified on man in 1990.
- the strain was identified using the Lodder's key ( Lodder,J: The yeast: A Taxonomic Study. North-Holland Publ. Co., Amsterdam - London (1970 ).
- the biological properties of the strain are described in Table H.
- Strain No. DSM-9459 differs from the epidemic strain in its faster growth in nutrient medium, stable biological properties, an enormous production of biomass and lower virulence. TABLE H Properties and characteristics of the strains Strain No. DSM-9459 Epidemic Strain No.
- the strain is weakly virulent. 30 days after intraperitoneal injection by dose of 10 -100 million fungal cells to white mice, granuloma in abdominal organs of 40% of animals are formed. Lethal effect was not observed.
- the strain is weakly virulent. 30 days after intraperitoneal injection by dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 50% of animals are formed. Lethal effect in 20 - 50% was observed.
- the strain Trichophyton verrucosum BINO 348 was deposited by the Binomed GmbH (EinsteinstraBe 59, 89077 Ulm) according to the Budapest Treaty at the - Leibniz-Institut DSMZ - Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, InhoffenstraBe 7B, 38124 Braunschweig, Germany under Serial No. DSM-28406 on 12 February 2014. The depositor has authorized the applicants to refer to the deposited biological material in the application and has given his unreserved and irrevocable consent to the deposited material being made available to the public in accordance with Rule 31 EPC. The strain was obtained by directed selection based on spore production and attenuation of epizootic strain Nr. 348, which was isolated from cattle in 1997.
- the strain was identified using the Rebell-Taplin key ( Rebell,G.,Taplin, D.: Dermatophytes, their recognition and identification, 1978 ) and according to Kashkin, P.N. et.al. (opredelitel patogennykh, toksigenykh vrednykh dlya cheloveka gribov, 1979).
- the biological properties of the strain are described in Table J.
- Strain BINO 348-DSM 28406 differs from the epizootic strain in its faster growth in nutrient medium, the enormous production of microconidia, lower virulence and the absence of any adverse reactions after intramuscular application of antigens. Table J Properties and characteristics of the strains Strain No.
- DSM-28406 Epidemic Strain No. 348 Description of the culture 20-day colony on Malt Extract Agar: white or light-yellow, velvety, furrowed, diameter of colony 15 - 20 mm 25-30-day colony in Malt Extract Agar: light-yellow crearn, velvety, folded, undersurface colorless, diameter of colony 10-12 mm Morphological characteristics Mature 20-day culture with numerous oval, pyriform microconidia measuring 1,5 -3 x 3 - 5 ⁇ m.
- the strain is weakly virulent. 9 -10 days after application of a dose of 500 -600 thousand cells of fungal material per cm 2 on scarified skin of guinea pigs, scales are formed. Spontaneous recovery after 15 - 20 days. The strain is virulent. 9-10 days after application of a dose of 500-600 thousand cells of fungal material per cm 2 on scarified skin of guinea pigs, thin necrotic scabs are formed.
- the strain Chrisporium tropicum BINO 122 was deposited by the Binomed GmbH (EinsteinstraBe 59, 89077 Ulm) according to the Budapest Treaty at the - Leibniz-Institut DSMZ - Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, InhoffenstraBe 7B, 38124 Braunschweig, Germany under Serial No. DSM-28405 on 12 February 2014. The depositor has authorized the applicants to refer to the deposited biological material in the application and has given his unreserved and irrevocable consent to the deposited material being made available to the public in accordance with Rule 31 EPC. The strain was obtained by directed selection based on spore production of field strain Nr.122, which was isolated from the soil in 1993.
- the strain was identified using the Rebell-Taplin key ( Rebell,G.,Taplin, D.:Dermatophytes, their recognition and identification, 1978 ) and according to Carmichael, J.N. Chrysosporium and some other aleuriosporic hyphomycetes. - Can.J.Bot., 1962, 40, 1137-1173 .
- the biological properties of the strain are described in Table K.
- Strain BINO 122-DSM 28405 is differ from the field strain in its faster growth in nutrient medium, the enormous production of conidia, weak virulence and the production of enzymes. Table K Properties and characteristics of the strains Strain No. DSM-28405 Field Strain No.
- the strain is weakly virulent. 9 -10 days after application of a dose of 500 -600 thousand cells of fungal material per cm 2 on scarified skin of guinea pigs, hyperemia and scales are formed. Spontaneous recovery after 13 - 15 days.
- the strain is weakly virulent. 9 - 10 days after application of a dose of 500 -600 thousand cells of fungal material per cm 2 on scarified skin of guinea pigs, hyperemia and scales are formed. Spontaneous recovery after 13 - 15 days.
- Reaction response Result of cutaneous application of filtrate of culture quick epithelium regeneration Result of cutaneous application of filtrate of culture: epithelium regeneration Biological properties - enzymatic activity; - enzymatic activity; - immunogenic activity against dermatophytosis; - immunogenic activity against dermatophytosis; - immunocorrection in allergy; - immunocorrection in allergy; - increased regeneration of the skin - regeneration of the skin
- the strain Microsporum canis BINO 483 was deposited by the Binomed GmbH (EinsteinstraBe 59, 89077 Ulm) according to the Budapest Treaty at the - Leibniz-Institut DSMZ - Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, InhoffenstraBe 7B, 38124 Braunschweig, Germany under under Serial No. DSM-32271 on 25 February 2016. The depositor has authorized the applicants to refer to the deposited biological material in the application and has given his unreserved and irrevocable consent to the deposited material being made available to the public in accordance with Rule 31 EPC. The strain was obtained by directed selection based on spore production and attenuation of epizootic strain Nr. 483, which was isolated from cat in 1990.
- the strain was identified using the Rebell-Taplin key ( Rebell,G.,Taplin, D.: Dermatophytes, their recognition and identification, 1978 ) and according to Kashkin, P.N. et.al. (opredelitel patogennykh, toksigenykh vrednykh dlya cheloveka gribov, 1979).
- the biological properties of the strain are described in Table L.
- vaccine strain 483 differs from the epizootic strain in its faster growth in nutrient medium, the enormous production of microconidia, lower virulence and the absence of any adverse reactions after intramuscular application of antigens. Table L Properties and characteristics of the strains Vaccine Strain No.
- BINO 483 Epidemic Strain No. 483 Description of the culture 10-15-day colony on Malt Extract Agar: white, fluffy, convex, narrow growing margin, arachnoid, undersurface yellowish, diameter of colony 35 - 40 mm 15-day colony in Malt Extract Agar: greyish-beige, arachnoid, powdery in centre, growing margin fringed, undersurface brown, diameter of colony 25-30 mm Morphological characteristics Mature 15-day culture with septate branching hyphae 1 to 4 ⁇ m wide, numerous oval, pyriform, cylindrical microconidia measuring 1 ⁇ m to 3 ⁇ m x 3 ⁇ m to 7 ⁇ m, few fusiform macroconidia with 3 to 10 septates measuring 10 ⁇ m to 20 ⁇ m x 40 ⁇ m to 70 ⁇ m Mature 15-day culture with branching hyphae 2 to 6 ⁇ m wide, few pyriform, cylindrical microconidia measuring 1 ⁇ m to 3 ⁇ m x 3 ⁇ m to 7 ⁇
- the composition of the present invention comprises homogenised inactivated dermatophyte microconidia of one microconidia or a mixture of microconidia of two, three, four, five, six, seven, eight, nine or ten of the above listed strains of dermatophytes.
- the composition comprises a mixture of homogenised inactivated dermatophyte microconidia of one, two, three, four, five, six, seven, eight, nine or ten of the above listed dermatophytes and homogenised inactivated yeast blastospores of one, two, three, or four of the above listed yeasts.
- composition comprises homogenised inactivated dermatophyte microconidia of one or a mixture of two, three, or four of the above listed yeasts.
- compositions may additionally comprise antigenic material of dermatophyte microconidia and/or antigenic material of yeast blastospores.
- the composition comprises antigenic material of one dermatophyte microconidia or a mixture of antigenic material of dermatophyte microconidia of two, three, four, five, six, seven, eight, nine or ten of the above listed strains of dermatophyte.
- the composition comprises a mixture of antigenic material of dermatophyte microconidia of one, two, three, four, five, six, seven, eight, nine or ten of the above listed dermatophytes and antigenic material of yeast blastospores of one, two, three, or four of the above listed yeasts.
- the composition comprises antigenic material of yeast blastospores of one or a mixture of two, three, or four of the above listed yeasts.
- the compositions may additionally comprise homogenised inactivated dermatophyte microconidia of one, two, three, four, five, six, seven, eight, nine or ten of the above listed dermatophytes and/or homogenised inactivated yeast blastospores of one, two, three, or four of the above listed yeasts.
- the composition for use of the present invention comprises a mixture of homogenised inactivated dermatophyte microconidia of Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton equinum, Trichophyton sarkisovii, Microsporum canis, Microsporum canis var.obesum, Microsporum canis var. distortum and Microsporum gypseum.
- the vaccine Polivac-TM (manufacturer: "Vetbiochim” LLC, Moscow; Distributor: “Prostore” LLC, Moscow) is in accordance with this embodiment and can be comprised in a composition of the present invention.
- Polivac-TM is a vaccine designed for animals such as cats, dogs, horses and others.
- the composition of the present invention comprises a mixture of homogenised inactivated dermatophyte microconidia of Trichophyton mentagrophytes, Trichophyton verrucosum and Trichophyton sarkisovii.
- the vaccine Polivac-T (manufacturer: “Vetbiochim” LLC, Moscow; Distributor: “Prostore” LLC, Moscow) is in accordance with this embodiment and can be comprised in the composition of the present invention. Polivac-T is a vaccine specifically designed for cattle.
- composition of the present invention comprises dermatophyte microconidia of only one strain or yeast blastospores of only one strain said dermatophyte microconidia or yeast blastospores can be prepared as follows:
- composition of the present invention comprises a mixture of dermatophyte microconidia and/or yeast blastospores said mixture can be prepared as follows:
- the growing of the dermatophytes of the above described preparation processes is preferably done on agar and wort in culture flasks.
- the culture is performed for about 15 to about 30 days.
- the cultivation is performed at a temperature of about 26°C to about 28°C.
- the growing of the yeasts of the above described preparation processes is preferably done on malt extract-agar or agar Sabouraud in culture flasks.
- the culture is performed for about 4 to about 7 days.
- the cultivation is performed at a temperature of about 28 to about 37°C.
- the dermatophytes and yeasts are homogenized to obtain a fine suspension.
- the homogenization is performed in deionized water, in an aqueous solution comprising about 0.1 to 0.3% fermented hydrolysed muscle protein or about 0.1 to 1 % soy or pork peptone in combination with about 5 to 6% glucose and about 0.1 to 1 % yeast extract, or in an aqueous solution comprising 0.1-0.9% (w/v) modified chitosan according to the present invention.
- Suitable volumes for homogenization are about 100 to 500 ml.
- the concentration of microconidia and blastospores, respectively is adjusted to about 30 to about 90 million microconidia and blastospores, respectively, per ml or to about 250 to about 500 thousand, more preferably about 250 to about 400 thousand microconidia and blastospores, respectively, per ml.
- the suspension may optionally be additional adjusted to about 40, 50 or 60 million of microconidia and blastopores, respectively, per ml or to about 250 to about 500 thousand, more preferably to about 250 to about 400 thousand microconidia and blastospores, respectively, per ml with distilled water, physiological salt solution as e.g. sodium chloride or another suitable solution.
- the single suspensions are preferably adjusted to the same amount of microconidia and blastospores, respectively, per ml and equal volumes of each culture in suspension are mixed in a single container.
- the inactivation is preferably performed by using thiomersal, formaldehyde and/or 2-propiolactone.
- the agents for inactivating can be added directly to the cell suspension.
- Preferred is an inactivation by adding thiomersal in a ratio of about 1:11000 to about 1:2500 (w/v).
- the mixture is preferably incubated.
- the incubation can be performed for about 1 to 30 days at a temperature of about 20°C to about 37°C.
- the microconidia of the compositions of the present invention are in a swollen condition and/or have germ tubes. More preferably, at least 50% of the blastospores and/or microconidia are in a swollen condition and/or have germ tubes.
- the swollen condition and/or the germ tubes of dermatophytes can e.g. be obtained by a second incubation step. Said second incubation step is preferably performed after the homogenization and before inactivation as described above.
- the microconidia suspension is placed in a separate vessel containing the same medium of the first incubation step.
- the second cultivation step is preferably performed for about 10 to about 48 hours.
- the second cultivation step is preferably performed at a temperature of about 28°C.
- the second cultivation step is continued until at least 50% of the microconidia display a swollen or germinating condition and no more than about 7 to 10% of the cells display a second mycelial branch.
- the diameter of swollen and germinated microconidia is increased by about 1.2 or more compared to regular microconidia.
- the antigenic material of yeast blastospores and/or dermatophyte microconidia preferably comprises polysaccharides and/or glycopeptides isolated from keratinophilic fungi or yeasts.
- said antigenic material can be antigenic nonsoluble material (ANMP), antigenic soluble material (ASMP) or antigenic exogenous material (AEMP).
- the keratinophilic fungi are preferably of the species Trichophyton or Microsporum, more preferably Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton equinum, Trichophyton sarkisovii, Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum gypseum, Microsporum canis and Chrisporium tropicum, and the keratinophilic yeasts are preferably of the species Candida, more preferably Candida albicans.
- antigenic material derived from Trichophyton mentagrophytes DSM - 7279, Trichophyton verrucosum DSM - 28406, Trichophyton rubrum DSM - 9469, Trichophyton rubrum DSM - 9470, Trichophyton rubrum DSM - 9471, Trichophyton rubrum DSM - 9472, Chrisporium tropicum DSM-28405, Candida albicans DSM - 9456, Candida albicans DSM - 9457, Candida albicans DSM - 9458, and Candida albicans DSM - 9459.
- the antigenic material is, for example, obtainable by the method disclosed in WO 97/07232 .
- the fungal cells belonging to the group of keratinophilic fungi or yeasts are treated under aqueous alkaline conditions, the solid and liquid phases of the preparation are separated, and after separation the solid phase is treated with mineral or organic acid.
- the treatment under aqueous alkaline conditions is preferably performed with about 0.1 to 5 % (w/v) KOH or NaOH at about 20°C to 150°C for up to 30h.
- the solid phase is preferably treated with 0.2 to 1.5 M organic acid or 0.05 to 1 M mineral acid and washed with an aqueous solution. More specifically, the keratinophilic fungi or yeasts are preferably cultivated on Agar plates.
- One preferred medium is for example malt extract agar from Oxoid. Other media that will ensure growth of keratinophilic fungi or yeast may be used as well.
- the resulting fungal biomass was lifted off and treated with the aqueous solution of alkali.
- the solid and liquid phases of the preparation are separated, for example by centrifugation, filtration or sedimentation.
- the separation is performed by centrifugation, e.g. at 3500g, which allows good separation of the fungal cell debris.
- Both the treatment under aqueous alkaline conditions and the separation step may be repeated several times. After alkaline treatment, the resulting supernatant is treated under the acidic aqueous conditions as outlined above.
- HCl or acetic acid can be used.
- the treatment with acid is preferably performed for about 0.5 to about 3 hours.
- the temperature is preferably in the range of about 70 to about 100°C.
- the aqueous solution for washing is preferably distilled water.
- the washing is repeated about five times.
- the solid phase is lifted off and homogenized in water for injection or in an aqueous solution of 0.1-0.9% solution of the modified chitosan, chitosan variant or chitosan derivative according to the present invention.
- the homogenization is preferably performed in a volume of about 100 to about 500 ml.
- the concentration of particles is then preferably adjusted to about 30 to 90 million particles per ml.
- the preparation comprising the antigenic material can be lyophilised and stored under dry conditions.
- ASMP can generally be obtained as follows: Fungal cells of keratinophilic fungi or yeasts are treated under aqueous alkaline conditions, the solid and liquid phases of the preparation are separated, after separation the supernatant is treated with mineral or organic acid, and after separation ASMP is precipitated from the supernatant. More particularly, keratinophilic fungi or yeasts are cultivated on Agar plates, for example as described in EP 0564620 . One preferred medium is for example malt extract agar from Oxoid. Other media that will ensure growth of keratinophilic fungi or yeast may be used as well. The resulting fungal biomass was lifted off and treated with an aqueous solution of alkali.
- Preferred aqueous alkaline solutions are NaOH or KOH at preferred concentrations of 0.1-5% (w/v).
- Alkaline treatment is preferably performed at about 20 -150°C for up to 30h.
- the solid and liquid phases of the preparation are separated, for example, by centrifugation, filtration or sedimentation.
- the separation is achieved by centrifugation, which ensures good separation of the fungal cell debris, for example, at forces of about 3500g.
- the treatment under aqueous alkaline conditions, as well as the separation step may be repeated several times. After the alkaline treatment and separation, the resulting supernatant is treated under acidic aqueous conditions, e.g.
- 0.2-1.5M organic acid or 0.05-1M mineral acid preferably HCl or acetic acid can be used, preferably at pH values of about pH 2.5 to pH 4.5.
- the treatment under aqueous acidic conditions is for about 2 to 4 hours at temperatures of about 4 to 8°C, where after separation of the solid and liquid layers took place.
- the treatment under aqueous acidic conditions, as well as the separation step may be repeated several times, preferably under conditions as above indicated.
- the supernatant from the separation step was subjected to a precipitation step.
- the precipitation was performed by adding a suitable organic solvent, e.g. an alcohol such as a lower alkanol, for example methanol or ethanol.
- a ratio of one volume supernatant to 2-5 volumes of alcohol will result in a good precipitation of the antigenic material.
- Other nonalcoholic precipitation procedures known to the person skilled in the art may be used as well, for example, ammonium sulphate or other salt precipitation.
- the solid phase is then subject to a further separation step, preferably under conditions as described above.
- the resulting solid phase is recovered and, if desired, dissolved in an aqueous solution, preferably in distilled water, typically in a volume of about 25 to 100 ml.
- the ASMP preparation can be lyophilized and stored for prolonged time periods under dry conditions.
- AEMP can generally be obtained as follows: fungal cells of keratinophilic fungi or yeasts are cultivated in liquid medium, the solid phase and liquid phases of the preparation are separated, and after separation AEMP is precipitated from the supernatant. More particularly, keratinophilic fungi or yeasts may be incubated in aqueous solution or cultivated in liquid medium. As well as the keratinophilic fungi may be incubated in aqueous solution with keratin. The cultivation may be for up to about 240 to 250 hours. The volume of the solution or culture is here defined as primary volume (PV). Distilled water can be used as well as media described in EP 0564620 .
- PV primary volume
- the fungal cells are separated, for example, by centrifugation, filtration or sedimentation, preferably by centrifugation under conditions as described above.
- the resulting supernatant is then lyophilized and subsequently dissolved in aqueous solution, preferably in water.
- the volume of water is about 0.1 to 0.2 volumes of the primary volume (PV).
- the resulting solution or the resulting supernatant obtained after separation is then subject to a precipitation step.
- the precipitation was performed by adding a suitable organic solvent, e.g. an alcohol such as a lower alkanol, for example methanol or ethanol.
- a ratio of one volume supernatant to about 1 to 5 volumes of alcohol will result in a good precipitation of the antigenic material.
- Other nonalcoholic precipitation procedures known to the person skilled in the art may be used as well, for example ammonium sulphate or other salt precipitation.
- the resulting precipitate is recovered and, if desired, dissolved in an aqueous solvent, preferably in distilled water. Preferably, about 0.5 to 50mg of the precipitate are dissolved in 1 ml aqueous solvent.
- the AEMP solution can be lyophilized and stored for prolonged time periods under dry conditions, preferably at about 2 to 10°C.
- composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention inactivated dermatophyte microconidia of Trichophyton mentagrophytes, in particular of Trichophyton mentagrophytes DSM - 7279.
- composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention inactivated dermatophyte microconidia of Trichophyton verrucosum, in particular of Trichophyton verrucosum DSM - 28406.
- composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention inactivated yeast blastospores of Candida albicans, in particular of Candida albicans DSM - 9456.
- composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention ASMP of Candida albicans, in particular of Candida albicans DSM - 9456.
- composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention ANMP of Candida albicans, in particular of Candida albicans DSM - 9456.
- the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention a mixture of homogenised inactivated dermatophyte microconidia of Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton equinum, Trichophyton sarkisovii, Microsporum canis, Microsporum canis var.obesum, Microsporum canis var. distortum and Microsporum gypseum and optionally ASMP of Candida albicans, in particular of Candida albicans DSM - 9456. More preferably, the composition of the present invention comprises the vaccine Polivac-TM and optionally ASMP of Candida albicans, in particular of Candida albicans DSM - 9456.
- composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention AEMP of Chrisporium tropicum, in particular of Chrisporium tropicum DSM - 28405, or of Microsporum canis BINO 483.
- the concentration of inactivated dermatophyte microconidia and/or yeast blastospores in the composition of the present invention is preferably about 30 to about 90, more preferably about 45 to about 80 million microconidia and blastospores, respectively, per ml or about 250 to about 500 thousand, more preferably about 250 to about 300 thousand microconidia and blastospores, respectively, per ml.
- the concentration of ASMP in the composition of the present invention is preferably about 50 to about 500 ⁇ g/ml, more preferably about 100 to about 400 ⁇ g/ml.
- the concentration of ANMP in the composition of the present invention is preferably about 30 to about 90, more preferably about 40 to about 80 million per ml.
- the concentration of Polivac-TM in the composition of the present invention is preferably about 40 million per ml to about 50 million per ml, more preferably about 40 million per ml to about 45 million per ml.
- the concentration of AEMP in the composition of the present invention is preferably 0.5 to about 2 U/ml, more preferably about 1 to about 1.2 U/ml.
- composition of the present invention is preferably a pharmaceutical composition which comprises a pharmaceutical acceptable diluent, excipient and/or carrier.
- present invention also refers to a pharmaceutical composition comprising a modified chitosan or the hydro colloid according to the present invention and a pharmaceutical acceptable diluent, excipient and/or carrier.
- the concentration of the modified chitosan or the hydro colloid in the compositions or pharmaceutical compositions of the present invention is preferably about 0.1% to about 2.0% (w/v), more preferably about 0.1% to about 1.4% (w/v), more preferably about 0.1% to about 1% (w/v), more preferably about 0.1% to about 0.5% (w/v) more preferably about 0.1% to about 0.3% (w/v).
- Another aspect of the present invention is the compound, the modified chitosan, the hydro colloid and/or the composition of the present invention for use in human and/or veterinary medicine.
- the compound, the modified chitosan, the hydro colloid or the composition of the present invention is for use as a vaccine in human and/or veterinary medicine.
- the present invention also refers to the compound, the modified chitosan, the hydro colloid and/or the composition of the present invention for use in a method of treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis, interdigital phlegmon, trichophytosis, microsporosis, mycosis of skin, allergies, as well as diseases complicated by allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease,
- the present invention also refers to the compound, the modified chitosan, the hydro colloid and/or the composition of the present invention for use in a method of modulating the immune response in a subject and/or for enhancing reproduction efficiency, preferably reproduction efficiency in animal breeding.
- the subject may for example be a human or an animal, in particular a mammal, more preferably bovidae and/or pigs, most preferably cattle, but also dogs, cats or other farm or domestic animals.
- the invention refers to a composition
- a composition comprising the modified chitosan, the hydro colloid or compound according to the present invention and inactivated dermatophyte microconidia of Trichophyton mentagrophytes, in particular of Trichophyton mentagrophytes DSM - 7279, for use in a method of treating and/or preventing interdigital dermatitis, digital dermatitis and/or interdigital phlegmon in animals, in particular in bovidae and/or pigs, most preferably in cattle.
- the invention refers to a composition
- a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and inactivated dermatophyte microconidia of Trichophyton verrucosum, in particular of Trichophyton verrucosum DSM - 28406, for use in a method of treating and/or preventing interdigital dermatitis, digital dermatitis, interdigital phlegmon, and/or trichophytosis in animals, in particular in bovidae and/or pigs, most preferably in cattle.
- the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and inactivated yeast blastospores of Candida albicans, in particular of Candida albicans DSM - 9456, for use in a method of treating and/or preventing interdigital dermatitis, digital dermatitis and/or interdigital phlegmon, in particular in bovidae and/or pigs, most preferably in cattle.
- the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and ASMP of Candida albicans, in particular of Candida albicans DSM - 9456, for use in a method of treating and/or preventing allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, ear erythema, rhinitis, conjunctivitis, dermatophytosis or warts, in particular Common warts, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, in particular dermatitis, ear erythema, rhinitis or con
- the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and ANMP of Candida albicans, in particular of Candida albicans DSM - 9456, for use in a method of treating and/or preventing interdigital dermatitis, digital dermatitis and/or interdigital phlegmon in animals, in particular in bovidae and/or pigs, most preferably in cattle.
- the invention refers to a composition
- a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and a mixture of homogenised inactivated dermatophyte microconidia of Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton equinum, Trichophyton sarkisovii, Microsporum canis, Microsporum canis var.obesum, Microsporum canis var. distortum and Microsporum gypseum and optionally ASMP of Candida albicans, in particular of Candida albicans DSM - 9456.
- the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid or compound of the present invention the vaccine Polivac-TM and optionally ASMP of Candida albicans, in particular of Candida albicans DSM - 9456, for use in a method of treating and/or preventing trichophytosis or dermatophytosis in animals, in particular in bovidae and/or pigs, most preferably in cattle.
- the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and AEMP of Chrisporium tropicum, in particular of Chrisporium tropicum DSM - 28405 or Microsporum canis BINO 483, for use in a method of treating and/or preventing allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, ear erythema, rhinitis, conjunctivitis, dermatophytosis, mycosis of skin or warts, in particular Common warts, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases,
- the modified chitosan, the hydro colloid, the compound and the compositions of the present invention are able to modulate the immune system, i.e. they have immunostimulatory properties. They can be used as a vaccine for preventing the subject from the diseases as outlined herein. Alternatively or in addition, they can be used to treat and cure the subject from the diseases as outlined herein.
- the modified chitosan, the hydro colloid and the compositions can be administered by known administration routes as e.g.
- intramuscular injection by intracutaneous injection, by percutaneous injection, by instillation, intracisternally, intrauterine, rectal, subcutaneous and/or topically, preferably cutaneously, more preferably intramuscular injection and/or intracutaneous injection and/or topically on the skin and/or topically on the mucous membrane.
- additional immunostimulatory substances are administered separately to the modified chitosan, compound or compositions of the present invention.
- the one or more additional immunostimulatory substances are comprised in or added to the compositions of the present invention.
- Said one or more immunostimulatory substance is preferably an adjuvant, preferably selected from the group consisting of vitamin-E acetate, o/w-emulsion, aluminium phosphate, aluminium oxide, aluminium hydroxide/methyl cellulose gel, an oil-emulsion, muramil-dipeptides, Freund's adjuvants and saponins and/or at least one cytokine, preferably selected from the group consisting of IL 2, IL 12 and INF-Gamma.
- an adjuvant preferably selected from the group consisting of vitamin-E acetate, o/w-emulsion, aluminium phosphate, aluminium oxide, aluminium hydroxide/methyl cellulose gel, an oil-emulsion, muramil-dipeptides, Freund's adjuvants and saponins and/or at least one cytokine, preferably selected from the group consisting of IL 2, IL 12 and INF-Gamma.
- compositions of the present invention is a vaccine and/or is used as a vaccine.
- the present invention relates to a modified chitosan, a hydro colloid a compound or a composition of the present invention for use in a method of treatment of the animal and/or human body by therapy.
- Such method typically comprises administering to a subject an effective amount of the modified chitosan a composition, preferably a pharmaceutical composition, or the hydro colloid of the present invention.
- the subject may for example be a human or an animal, in particular a mammal, more preferably bovidae and/or pigs, most preferably cattle, but also dogs, cats or other farm or domestic animals.
- the modified chitosan, the hydro colloid or the compositions, in particular pharmaceutical compositions, of the present invention may be used in methods for the treatment or prevention of the diseases as outlined above.
- the method of treatment may comprise the treatment and/or prevention of bacterial, mycotic and/or viral infections of the skin, the ear, the lung, the nose, the leg, the hoof, the claws, the back of the foot and/or the interdigital space.
- Said infections may be caused by Dichelobacter nodosus, Fusobacterium necroforun, Fusobacterium spp, Treponema spp such as T. phagedenis, T. vincentii, and T.
- Trichophyton spp. such as T. verrucosum, T. mentagrophytes, T. sarkisovii, T. equinum, T. parameterleinii, T. rubrum,T. tonsurans, T. interdigitale, and/or Microsporum spp. such as M. canis, M. canis var. distortum, M. canis var. obesum, M. gypseum, and / or Malassezia spp. such as M.
- pachydermatitis M. furfur, M. dermatitis and / or HPV- Human Papillomavirus from genera Papillomavirus family Papovaviridae such as HPV-2, HPV-3, HPV-4, HPV-6, HPV-11.
- the dosage and route of administration used in a method of treatment and/or prophylaxis according to the present invention depends on the specific disease/site of infection to be treated.
- the route of administration may be for example oral, parenterally, by intramuscular injection, by intracutaneous injection, by percutaneous injection, by instillation, intracisternally, intrauterine, rectal, subcutaneous and/or topically, preferably cutaneously, more preferably intramuscular injection and/or intracutaneous injection and/or topically on the skin and/or topically on the mucous membrane or any other route of administration.
- Preferred doses for the composition of the present invention are about 0.001 to about 0.5 ml/kg with a concentration of about 0.1 mg/ml to about 1.0 mg/ml and/or about 30x10 6 to about 80x10 6 microconidia and/or blastospores and/or particles of ANMP.
- the composition of the present invention is administered about 1 to about 5 times.
- the interval between the administrations is preferably about 12 hours to about 21 days.
- the obtained suspended material was homogenized in a closed sterile homogenizer in 7 liters of sterile water for injection. 8 mL of 98% valerianic acid chloride (valeryl chloride, pentanoyl chloride) were added dropwise to the suspension under constant stirring. Subsequently, the suspension was stirred for 24 hours. To support the dissolution of flakes and unsolved particles 4N hydrochloric acid solution was added under stirring until the suspension had a pH of 5.8. Sterile water for injection was added to obtain an end volume of 8 liters. After that the modified polysaccharide was used to prepare the final product.
- valerianic acid chloride valeryl chloride, pentanoyl chloride
- Characteristics of the obtained biological material comprising modified chitosan Parameters Characteristics Chemical formula unknown Appearance Clear gel Smell Absent or faint smell of acetic acid Deacetylation > 93% Mineral content >0.9% Solubility in water Soluble Solubility in 1% solution of acetic acid Soluble
- the second stage For obtaining the final product 2 liters of the biological material comprising modified chitosan were adjusted to a volume of 15 liters by adding sterile water for injection under stirring. Then 500 ml of chlorocresol solution containing 30 grams chlorocresol were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant suspension was sterilized by heating for 40 minutes at 70°C three times at intervals of 24 hours. The resultant sterile product was dispensed into vials under aseptic conditions.
- the obtained suspended material was homogenized in a closed sterile homogenizer in 4 liters of sterile water for injection.
- 0.8 mL of 98% valerianic acid chloride (valeryl chloride, pentanoyl chloride) were added dropwise to the suspension under constant stirring. Subsequently, the suspension was stirred for 24 hours.
- 4N hydrochloric acid solution was added under stirring until the suspension had a pH of 5.5. After that the modified polysaccharide was used to prepare the final product.
- Characteristics of the obtained biological material comprising modified chitosan Parameters Characteristics Chemical formula unknown Appearance Clear gel Smell Absent or faint smell of acetic acid Deacetylation > 93% Mineral content >0.9% Solubility in water Soluble Solubility in 1% solution of acetic acid Soluble
- the second stage For obtaining the final product 200 ml of the modified chitosan were resuspended in 1.5 liters of sterile water for injection and 50 ml of chlorocresol solution containing 2g of the active substance were added under stirring. The obtained suspension was adjusted to a volume of 2 liters. The obtained suspension was sterilized by heating for 40 minutes at 70°C three times with intervals of 24 hours. The resultant sterile product was dispensed into vials under aseptic conditions.
- 80 g of the polysaccharide chitosan was sterilized by autoclavation and added under stirring to 16 liters of sterile water for injection acidified with 80 ml of 100% acetic acid to obtain a suspension.
- the suspension was mixed in a sterile tank for 24 hours to obtain a gel suspension. Undissolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m. 4 N sodium hydroxide (NaOH) were added dropwise to the gel to obtain a final pH of 8.0. Upon that white flakes precipitated.
- the suspension was stirred for 50 minutes.
- the resultant biological material of the precipitate contained in its structure diacetylated chitosan.
- the precipitate was harvested by centrifugation for 60 minutes at 5000 revolutions per minutes.
- the obtained suspended material was homogenized in a closed sterile homogenizer in 4 liters of sterile water for injection. 16 mL of 98% valerianic acid chloride (valeryl chloride, pentanoyl chloride) were added dropwise to the suspension under constant stirring. Moreover, 4 liters of sterile water for injection was added and 3% solution of glutamic acid was added under stirring until the suspension had a pH of 5.0. Sterile water for injection was added to obtain an end volume of 8 liters. The suspension was stirred after that for 24 hours. After that the modified polysaccharide was used to prepare the final product.
- valerianic acid chloride valeryl chloride, pentanoyl chloride
- Characteristics of the obtained biological material comprising modified chitosan Parameters Characteristics Chemical formula unknown Appearance Clear gel Smell Absent or faint smell of acetic acid Deacetylation > 90% Mineral content >0.8% Solubility in water Soluble Solubility in 1% solution of acetic acid Soluble
- the second stage For obtaining the final product 4000 ml of the modified chitosan were resuspended in 30 liters of sterile water for injection and 50 ml of chlorocresol solution containing 40g of the active substance were added under stirring. The obtained suspension was adjusted to a volume of 40 liters. The obtained suspension was sterilized by heating for 45 minutes at 72°C three times with intervals of 24 hours. The resultant sterile product was dispensed into vials under aseptic conditions.
- 16 g of the polysaccharide chitosan (deacetylation of 65%-72%, viscosity of 151 - 350 mPas, 80-200 kDa) was sterilized by autoclavation and added under stirring to 3 liters of sterile water for injection acidified with 164 ml of 100% acetic acid to obtain a suspension.
- the suspension was mixed in a sterile tank for 24 hours to obtain a gel suspension. Undissolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m. 4 N sodium hydroxide (NaOH) were added dropwise to the gel to obtain a final pH of 8.5. Upon that white flakes precipitated.
- the suspension was stirred for 30 minutes.
- the resultant biological material of the precipitate contained in its structure diacetylated chitosan.
- the precipitate was harvested by centrifugation for 50 minutes at 5000 revolutions per minutes.
- the obtained suspended material was homogenized in a closed sterile homogenizer in 1 liters of sterile water for injection.
- 0.6 mL of 98% valerianic acid chloride (valeryl chloride, pentanoyl chloride) were added dropwise to the suspension under constant stirring.
- a 0.5% solution of paraaminobenzoic acid was added under stirring until the suspension had a pH of 5.4.
- Sterile water for injection was added to obtain an end volume of 1.6 liters. The suspension was stirred after that for 24 hours. After that the modified polysaccharide was used to prepare the final product.
- Characteristics of the obtained biological material comprising modified chitosan Parameters Characteristics Chemical formula unknown Appearance Clear gel Smell Absent or faint smell of acetic acid Deacetylation > 89% Mineral content >1,0% Solubility in water Soluble Solubility in 1% solution of acetic acid Soluble
- the second stage For obtaining the final product 1000 ml of the modified fraction were resuspended in 8 liters of sterile water for injection and 200 ml of chlorocresol solution containing 10g of the active substance were added under stirring. The obtained suspension was adjusted to a volume of 10 liters. The obtained suspension was sterilized by heating for 45 minutes at 65°C three times with intervals of 24 hours. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product is prepared from chitosan.
- the product is prepared in two stages. The first stage is oriented to obtain a chitosan solution; the second stage is oriented to obtain the final product.
- chitosan (deacetylation of 82%-87%, a viscosity of 151 - 350 mPas, molecular weight 150-300 kDa) was sterilized by autoclavation and added under stirring to 3.5 liters of sterile water for injection. 40 ml of 100% acetic acid were added to the obtained suspension and the volume was adjusted to an final volume of 4 liters with water for injection. The suspension was stirred in a sterile container for 24 hours until a gel suspension was obtained. 4 N sodium hydroxide (NaOH) were added dropwise to the obtained suspension to obtain a final pH of 8.0. Upon that white flakes precipitated. The suspension was stirred for 30 minutes.
- NaOH sodium hydroxide
- the resultant biological material of the precipitate contained in its structure a linear diacetylated polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine (chitosan).
- the precipitate was harvested by centrifugation for 55 minutes at 4500 revolutions per minutes.
- the precipitate was suspended in 4 liters of sterile water for injections and 4N hydrochloric acid were added under stirring to obtain a pH of 5.4. The suspension was stirred for 24 hours until all flakes were dissolved and a gel suspension was obtained. The gel suspension was used to prepare the final product.
- the second stage For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture under stirring. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared from chitosan.
- the product was prepared in two stages. The first stage is oriented to obtain a solution of modified chitosan; the second stage is oriented to obtain the final product.
- the first stage Chitosan with a deacetylation of 62%-67%, a viscosity of 70 - 200 mPas and a molecular weight of 100-250 kDa was used as raw material.
- 40 grams of the polysaccharide was sterilized by autoclaving and added into 3.5 liters of water for injection under stirring. 40 ml of 100% acetic acid were added to the obtained suspension. The final volume was adjusted with water for injection to 4 liters. Suspended polysaccharide was stirred in a sterile container for 24 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell size of 200 ⁇ m - 300 ⁇ m.
- the second stage For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under sterile conditions.
- the product was prepared from chitosan.
- the product was prepared in two stages. The first stage was oriented to obtain a solution of modified chitosan; the second stage was oriented to obtain the final product.
- the first stage Chitosan with a deacetylation of 77%-82%, a viscosity of 2700 - 3300 mPas and a molecular weight of 300-700 kDa was used as raw material.
- 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 40 ml of 100% acetic acid were added to the obtained suspension. The final volume was adjusted to 4 liters with water for injection. Suspended polysaccharide was stirred in a sterile container for 30 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m.
- the second stage For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared from chitosan.
- the product was prepared in two stages. The first stage was oriented to obtain a solution of modified chitosan, the second stage was oriented to obtain the final product.
- the first stage Chitosan with a deacetylation of 82%-87%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material.
- 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 40 ml of 100% acetic acid were added to the obtained suspension. The final volume was adjusted to 4 liters with water for injection.
- the suspended polysaccharide was stirred in a sterile container for 36 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m.
- a 0.2% solution of paraaminobenzoic acid was added to the precipitate under constant stirring up to 4 liters. The obtained suspended material was stirred for one hour. Flakes and unsolved particles were suspended in solution of paraaminobenzoic acid and 4N hydrochloric acid were added under stirring until a pH of 5.6 is obtained. The suspension was stirred for 70 hours until all flakes were dissolved and a gel suspension was obtained.
- the second stage For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared from chitosan.
- the product was prepared in two stages. The first stage was oriented to obtain a solution of modified chitosan; the second stage was oriented to obtain the final product.
- the first stage Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material.
- 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 40 ml of 100% acetic acid were added to the obtained suspension. The final volume was adjusted with water for injection to 4 liters. Suspended polysaccharide was stirred in a sterile container for 24 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m.
- a 0.1% solution of sodium salt of glucuronic acid was added to the precipitate under constant stirring up to 4 liters.
- the obtained suspended material was stirred for one hour. Flakes and unsolved particles were resuspended in solution of glucuronic acid and 4N hydrochloric acid were added under stirring until a pH of 5.6 was obtained.
- the suspension was stirred for 72 hours until all flakes were dissolved and a gel suspension was obtained.
- the second stage For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared from chitosan.
- the product was prepared in two stages. The first stage was oriented to obtain a solution of chitosan; the second stage was oriented to obtain the final product.
- the first stage Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material.
- 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 8 ml of 98% sodium salt of valerianic acid were added to the obtained suspension. The final volume was adjusted to 4 liters with water for injection.
- the suspended polysaccharide was stirred in a sterile container for 48 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m.
- the second stage For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared from chitosan.
- the product was prepared in two stages. The first stage was oriented to obtain a solution of chitosan; the second stage was oriented to obtain the final product.
- the first stage Chitosan with deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material.
- 40 grams of polysaccharide was sterilized by autoclaving and added to 3.9 liters of 0.2 % paraaminobenzoic acid in water for injection under stirring. 4N hydrochloric acid solution were added under stirring until getting a pH of 5.6 and to obtain a gel suspension. The final volume was adjusted to 4 liters with water for injection. Suspended polysaccharide was stirred in a sterile container for 72 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m.
- the second stage For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared from chitosan.
- the product was prepared in two stages. The first stage was oriented to obtain a solution of chitosan; the second stage was oriented to obtain the final product.
- the first stage Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material.
- 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of a 0.1% solution of sodium salt of glucuronic acid under stirring.
- 4N hydrochloric acid solution was added under stirring until getting a pH of 5.0.
- the final volume was adjusted with water for injection to 4 liters.
- Suspended polysaccharide was stirred in a sterile container for 78 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m.
- the second stage For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared from chitosan.
- the product was prepared in two stages. The first stage was oriented to obtain a solution of chitosan; the second stage was oriented to obtain the final product.
- the first stage Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material.
- 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 8 ml of 90% lactic acid were added to the obtained suspension.
- 4N hydrochloric acid solution was added until getting a pH of 5.7.
- the final volume was adjusted with water for injection to 4 liters.
- Suspended polysaccharide was stirred in a sterile container for 36 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m.
- the second stage For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1 st stage of example 1 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 5.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.6 grams of active substance were added to the mixture. The resultant suspension was adjusted to the volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1 st stage of example 5 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 6.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 2 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- Product prepared was prepared by performing the 1 st stage of the example 5 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 7.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.8 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1 st stage of example 5 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 8.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.8 grams of active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1 st stage of example 5 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 9.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1st stage of example 6 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 9.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1st stage of example 6 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 8.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1st stage of example 6 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 8.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of formalin containing 80 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1st stage of example 6 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 9.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of formalin solution containing 85 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 5 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 15 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 6 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 15 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 7 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of thimerosal containing 1.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of formalin solution containing 30 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 9 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of thimerosal containing 0.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 6 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 5 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 6 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 7 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 5 liters by adding sterile water for injection under stirring. Then, 500 ml of thimerosal containing 0.24 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 6 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 5 liters by adding sterile water for injection under stirring. Then, 500 ml of formalin solution containing 12 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 6 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 9 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 5 liters by adding sterile water for injection under stirring. Then, 500 ml of merthiolate solution containing 0.24 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 6 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of neomycin solution containing 150 g of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of penicillin sodium and potassium salts solution containing 300 g (300.000.000 UE) of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of penicillin sodium and potassium salts solution containing 300 g (300.000.000 UE) of the active substance and 500 ml of neomycin solution containing 150 g of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1st stage of example 7 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 8.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 15 liters by adding sterile water for injection under stirring. Then, 500 ml of formalin solution containing 30 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 20 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1st stage of example 7 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 6.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 15 liters by adding sterile water for injection under stirring. Then, 500 ml of formalin solution containing 30 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 20 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- the product was prepared by performing the 1st stage of example 7 in the volume of 5 liters.
- the second stage For obtaining the final product 4 liters of the modified polysaccharide were adjusted to a volume of 15 liters by adding sterile water for injection under stirring. Then 500 ml of formalin solution containing 30 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 20 liters. The resultant sterile product was dispensed into vials under aseptic conditions.
- Dermatophyte culture of the species Trichophyton mentagrophytes DSM - 7279 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of the product obtained according to example 6, but with the following difference in the second stage: The second stage.
- 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture.
- the resultant suspension was adjusted to a volume of 30 liters.
- the resultant sterile product was added to the fungal suspension to obtain a concentration of 45-80 million microconidia per ml for each homogenate.
- the homogenates were inactivated by adding formaldehyde directly to the cell suspension so that the cell suspension contained 0.2% (v/v) formaldehyde in the end. The mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- Dermatophyte culture of the species Trichophyton verrucosum DSM - 28406 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of the product prepared according to example 8 but with the following difference in the second stage: The second stage. For obtaining the final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture.
- aqueous solution for example 100-500 ml
- the resultant suspension was adjusted to a volume of 30 liters.
- the resultant sterile product was added to the suspension to obtain a concentration of 45-80 million per ml for homogenate.
- the homogenates were inactivated by adding formaldehyde directly to the cell suspension so that the cell suspension contained 0.4% (v/v) formaldehyde in the end. The mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon and/or trihophytosis in animals.
- Candida albicans DSM - 9456 was cultivated on malt extract-agar or agar Sabouraud, for example in 3-10 Roux flasks.
- the Culture was cultivated for 4 -7 days at 28-37°C.
- the blastospores were washed off with a physiological solution of sodium chloride or another suitable solution.
- the fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of the product prepared according to example 9 but with the following difference in the second stage: The second stage.
- 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- Candida albicans DSM - 9456 was cultivated on malt extract-agar from Oxoid in 40 Roux flasks. The culture was cultivated for 4 -7 days at 28-37°C as described in EP 0564620 . The resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with a concentration of 3% (w/v). Said alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of allergies.
- Candida albicans DSM - 9456 was cultivated on malt extract-agar from Oxoid in 50 Roux flasks. The culture was cultivated for 4 -7 days at 28-37°C as described in EP 0564620 . The resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with a concentration of 3% (w/v). Alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of allergies.
- Candida albicans DSM - 9456 was cultivated on malt extract-agar from Oxoid in 50 Roux flasks. Culture was cultivated for 4 -7 days at 28-37°C as described in EP 0564620 . The resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with concentrations of 3% (w/v). Alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of allergies.
- the fraction preparable according to this process consists of antigenic nonsoluble material comprising polysaccharide and/or glycopeptides (ANMP) according to PCT/EP96/03535 .
- the species Candida albicans DSM - 9456 was cultivated on malt extract-agar from Oxoid in 50 Roux flasks. The culture was cultivated for 4 -7 days at 28-37°C as described in EP 0564620 . The resulting fungal biomass was lifted off and treated with an aqueous solution of alkali with concentrations of 4%(w/v) NaOH. The treatment was performed at 80°C for up to 6h.
- the solid and liquid phases of the preparation were separated by centrifugation at forces of about 3500g.
- the solid phase was treated with a 50% solution of acetic acid.
- acidic treatment the solid phase was washed with distilled water for five times.
- the solid phase was lifted off and homogenised in the product obtained according to example 6, but with the following difference in the second stage: The second stage.
- 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture.
- the resultant suspension was adjusted to a volume of 30 liters.
- the concentration of particles was adjusted to 30-90 million per ml.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- Dermatophyte culture of the species Trichophyton verrucosum DSM - 28406 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte was lifted off and homogenised in an aqueous solution (for example 100-500 ml) of the product obtained according to example 6, but with the following difference in the second stage: The second stage.
- 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then 500 ml of a chlorocresol solution containing 30 grams of the active ingredient were added to the mixture.
- the resultant suspension was adjusted to a volume of 15 liters.
- the resultant sterile product was added to the fungal suspension to obtain a concentration of 45-60 million microconidia per ml for each homogenate.
- the homogenates were inactivated by adding formaldehyde directly to the cell suspension so that the cell suspension contained 0.2% (v/v) formaldehyde in the end. The mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of trichophytosis in cattle.
- a solution of biological material containing in its structure a linear polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine modified by 0.2% of paraaminobenzoic acid was added to the vaccine Polivac-TM against dermatophytosis of animals (manufacturer: "Vetbiochim” LLC, Moscow; Distributor: “Prostore” LLC, Moscow) to reach a final concentration of 0.3% (w/v).
- the pH of the solution was about 5.6.
- the concentration of microconidia was 40 million per ml.
- Vaccine preparable according to this method can be used for the prophylaxis and treatment of dermatophytosis in animals.
- Candida albians DSM - 9456 was cultivated on Agar plates as described in EP 0564620 .
- One preferred medium was for example malt extract agar from Oxoid.
- the resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with a concentration of 3% (w/v).
- Alkaline treatment was performed at 80°C for 6h.
- the solid and liquid phases of the preparation were separated by centrifugation at 3500g.
- the resulting supernatant was treated under acidic aqueous conditions, e.g. 50% acetic acid at pH 4.0 for 2 hours at a temperature of 4° to 8°C, whereafter separation of the solid and liquid layers took place.
- the supernatant from the separation step was subjected to a precipitation step.
- a ratio of one volume supernatant to 3 volumes of alcohol resulted in good precipitation of the antigenic material.
- ASMP preparation was lyophilised.
- a solution of biological material containing in its structure a linear polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine modified by 0.5% of paraaminobenzoic acid was added to the vaccine Polivac-TM against dermatophytosis of animals (manufacturer: "Vetbiochim” LLC, Moscow; Distributor: “Prostore” LLC, Moscow) to reach a final concentration of 0.3% (w/v).
- the pH of the solution was about 5.8.
- the concentration of microconidia was 40 million per ml.
- the solid phase of ASMP was mixed with modified vaccine Polivac-TM.
- the concentration of ASMP was adjusted to 400 ⁇ g per ml.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of dermatophytosis in animals.
- Keratinase Pure 70 produced by PROTEOS Biotech, 14 Almansa Street, 02006 Albacete, Spain was used to prepare a solution containing 2 U/ml.
- Candida albians DSM - 9456 was cultivated on Agar plates as described in EP 0564620 .
- One preferred medium was for example malt extract agar from Oxoid.
- the resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with concentrations of 3% (w/v).
- Alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g.
- the resulting supernatant was treated under acidic aqueous conditions, e.g. 50% acetic acid at pH 4.0 for 2 hours at temperatures of 4° to 8°C, whereafter separation of the solid and liquid layers took place. Then, the supernatant from the separation step was subjected to a precipitation step. A ratio of one volume supernatant to 3 volumes of alcohol resulted in good precipitation of the antigenic material. Finally the ASMP preparation was lyophilised.
- Keratinase Pure 70 was mixed in an aqueous solution (for example 100-500 ml) of 0.3% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine modified of paraaminobenzoic acid prepared according to example 8 (First stage).
- the concentration of Keratinase Pure 70 was adjusted to 1-1.2 U per ml.
- Formalin was added to reach 0.2% (v/v) in end suspension. The mixture was incubated for 5-7 days at 37°C.
- ASMP modified linear polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine.
- concentration of ASMP was adjusted to 200 ⁇ g per ml.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of dermatophytosis in animals.
- Dermatophyte culture of the species Microsporum canis BINO 483 was cultivated on agar/wort, for example in 3-10 Roux flasks for 21 day at 26-28°C.
- Suspension of the microconidia was cultivated in media with keratin and dermatophytes exoantigens were obtained according to RF patent 2219945 as follows: The obtained suspension with concentration of microconidia of 40x10 6 to 50x10 6 was cultivated for 7 days under stirring at a temperature of 29°C. Subsequently, formalin was added to obtain an end concentration of 0.4%.
- the liquid phase was separated by three steps of filtration - through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m, than through Whatman paper filter No.4 (size 20 ⁇ m to 25 ⁇ m) and in end through nylon filter for sterilisation with size 0.22 ⁇ m, but in the process of formalin preservation surprisingly found increased antigenic activity of the fractions obtained (AEMP).
- the dermatophytes exoantigens AEMP were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine modified of paraaminobenzoic acid according to example 8.
- the concentration of AEMP was adjusted to 1-1.2 U per ml.
- Formalin was added to reach 0.2% (v/v) in the end suspension. The mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of dermatophytosis in animals.
- Fungi culture of the species Chrisporium tropicum DSM-28405 was cultivated on agar/wort, for example in 3-10 Roux flasks for 21 days at 26-28°C. Subsequently, the obtained suspension of microconidia was cultivated in media with keratin and exoantigens were prepared according to RF patent 2219945 as follows: The obtained suspension with a concentration of microconidia of 50x10 6 to 60x10 6 was cultivated for 7 days under stirring at a temperature of 30°C. Then, formalin in end concentration of 0.4% was added.
- the liquid phase was separated by three steps of filtration - through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m, than through Whatman paper filter No.4 (size 20 ⁇ m to 25 ⁇ m) and in end through nylon filter for sterilisation with size 0.22 ⁇ m, but in the process of formalin preservation surprisingly found increased antigenic activity of the fractions of exoantigens (AEMP).
- AEMP exoantigens
- the soluble exoantigens of fungi AEMP were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine modified of paraaminobenzoic acid according to example 8.
- the concentration of AEMP was adjusted to 1-1.2 U per ml.
- Formalin was added to reach 0,2% (v/v) in end suspension. The mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the treatment of dermatophytosis and allergic diseases in animals.
- Dermatophyte culture of the species Trichophyton verrucosum DSM - 28406 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine modified by valeric acid chloride according to example 6. The concentration of microconidia was adjusted to 250-300 thousand per ml. The homogenates were inactivated by adding formaldehyde directly to the cell suspension to reach 0.2% (v/v) in end. The mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- Dermatophyte culture of the species Trichophyton mentagrophytes DSM -7279 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine modified of paraaminobenzoic acid according to example 8. The concentration of microconidia was adjusted to 250-300 thousand per ml.
- the homogenates were inactivated by adding formaldehyde to reach 0.2% (v/v) in end directly to the cell suspension.
- the mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- Dermatophyte culture of the species Trichophyton verrucosum DSM - 28406 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4- ⁇ -D-glucopyranosamine modified by glucuronic acid according to example 9. The concentration of microconidia was adjusted to 250-300 thousand per ml. The homogenates were inactivated by adding formaldehyde directly to the cell suspension to reach 0.1% (v/v) in end. The mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- the first stage Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material.
- 40 grams of the polysaccharide was sterilized by autoclaving and 3.9 liters of 0.2 % paraaminobenzoic acid in water for injection were added under stirring.
- 4N hydrochloric acid solution was added under stirring until getting a pH of 5.6.
- the final volume was adjusted with water for injection to 4 liters. Suspended polysaccharide was stirred in a sterile container for 72 hours until a gel suspension was obtained.
- Unsolved particles were removed by filtration through a metal grid with a cell of 200 ⁇ m - 300 ⁇ m.
- Candida albians DSM - 9456 was cultivated on Agar plates as described in EP 0564620 .
- One preferred medium was for example malt extract agar from Oxoid.
- the resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with a concentration of 3% (w/v).
- Alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of allergies.
- the 1,3- ⁇ -D-analyses (Cape Cod, USA). The test was performed as described in the manufacturer's Glucan content in antigen samples was determined using the CE-marked Fungitell® assay for serum Instructions. In brief, the test is a protease zymogen-based colorimetric assay and makes use of a modification of the Limulus Amebocyte Lysate (LAL) pathway. The Fungitell reagent is modified to eliminate Factor C and, thus, to only react with 1,3- ⁇ -D-Glucan. Unknown samples are mixed with the assay reagent and the mean rate of optical density change is calculated for all datapoints over an interval of 40 min. By comparison to an in parallel generated Standard curve, the amount of 1,3- ⁇ -D-Glucan in the samples can be calculated.
- LAL Limulus Amebocyte Lysate
- Test Solutions of the antigens No.1-13 were prepared in sterile ddH 2 0 and, subsequently, further dilutions were prepared in pyrogen-free LAL reagent grade water. Based on the results of the endotoxin testing, the highest dilution with detectable gel-clotting and one dilution above and below were measured in the Fungitell assay. Each sample was measured in duplicate in a 20 sec interval in a total of 40 min.
- Example 1,3- ⁇ -D-Glucan content Analyzed dilutions based on the test Solution (bold indicates dilution for 1 1 115 ng/ml 1:100, 1:1000, 1:10,000 2 2 133 ng/ml 1:100, 1:1000, 1:10,000 3 3 123 ng/ml 1:100, 1:1000, 1:10,000 4 4 110 ng/ml 1:100, 1:1000, 1:10,000 5 7 45 pg/ml 1:10, 1:100, 1:1000 6 20 55 pg/ml 1:10, 1:100, 1:1000 7 18 25 pg/ml 1:10, 1:100, 1:1000 8 20 21 pg/ml 1:10, 1:100, 1:1000 9 26 50 pg/ml 1:10, 1:100, 1:1000 10 27 70 pg/ml 1:10, 1:100, 1:1000 11 28 110 pg/ml 1:10, 1:100, 1:1000 12 29 90 pg/ml 1:10, 1:100, 1:1000 13 30 120 pg/ml 1:10,
- Endotoxin content in antigen samples was determined using the gel-clot method according to EP 2.6.14.
- the antimicrobial activity of compounds was analyzed by the "Test for efficacy of antimicrobial preservation" according to the following procedure.
- To count the viable microorganisms in the inoculated products the agar medium used for the initial cultivation of the respective microorganisms was used.
- a series of containers of the product to be examined was inoculated, each with a suspension of one of the test organisms to give an inoculum of 10 5 to 10 6 microorganisms per millilitre or per gram of the preparation.
- the volume of the suspension of inoculum did not exceed 1 per cent of the volume of the product. To ensure homogeneous distribution it was thoroughly mixed.
- the inoculated product was maintained at 20-25°C, protected from light.
- a suitable sample was removed from each container, typically 1 mL or 1 g, at zero hour and at appropriate intervals according to the type of the product and the number of viable microorganisms was determined by plate count or membrane filtration (2.6.12). It was ensured that any residual antimicrobial activity of the product was eliminated by dilution, by filtration or by the use of a specific inactivator. When dilution procedures was used, due allowance was made for the reduced sensitivity in the recovery of small numbers of viable microorganisms. When a specific inactivator was used, the ability of the system to support the growth of the test organisms was confirmed by the use of appropriate controls. The procedure was validated to verify its ability to demonstrate the required reduction in count of viable microorganisms.
- test Solution prepared with ddH 2 0
- test-microorganisms Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans and Aspergillus brasiliensis.
- 6 hpi hours post inoculation
- 24 hpi 7 dpi (days post inoculation)
- 14 dpi samples were drawn and numbers of viable microorganisms were determined by plating a dilution series on agar plates.
- Cows with latent (subclinical) mastitis were treated. The diagnosis was made by a usual procedure with 2% solution of mastidin. The animals were divided into 13 groups with 6 animals in each group. All groups of cows were treated by 10 ml of the preparation intracisternally twice with an interval of 24 hours. All the animals were re-tested with a 2% solution of mastidin by the standard procedure on day 7 and day 14.
- Cows with latent (subclinical) mastitis were treated. The diagnosis was made by a usual procedure with 2% solution of mastidin. The animals were divided into 14 groups with 10 animals in each group. All groups of cows were treated by 10 ml of the preparation intracisternally thrice with an interval of 24 hours. All the animals were re-tested with a 2% solution of mastidin by the standard procedure on day 5.
- Cows with latent (subclinical), clinical mastitis and purulent-catarrhal endometritis were treated.
- the diagnosis was made by a usual procedure with 5% solution of dimastin for mastitis and clinical symptoms for endometritis.
- All cows were administered by 10 ml of the preparation manufactured according to example 13 intracisternally or intrauterine twice or trice with the interval of 24 hours. All the animals were re-tested with a 5% solution of dimastin by the standard procedure and clinical observation on day 7.
- Cows with latent (subclinical) mastitis were treated. The diagnosis was made by a usual procedure with 5% solution of dimastin for mastitis and clinical symptoms for endometritis. All cows were administered by 10 ml of the preparation manufactured according to example 26 intracisternally or intrauterine twice or trice with the interval of 24 hours. All the animals were re-tested with a 5% solution of dimastin by the standard procedure and clinical observation on day 7.
- the obtained immunobiological preparation makes possible treatment of mastitis of cows, which can be widely used in controlling of this widespread disease.
- Cows with latent (subclinical) mastitis were treated. The diagnosis was made by a usual procedure with 5% solution of dimastin for mastitis and clinical symptoms for endometritis. All cows were administered by 10 ml of the preparation manufactured according to example 26 intracisternally or intrauterine twice or trice with the interval of 24 hours. All the animals were re-tested with a 5% solution of dimastin by the standard procedure and clinical observation on day 7.59% of animals were recovered after treatment.
- Therapeutic application of vaccine 3 times with an interval of 7 days with a dose of 5 ml.
- Vaccine was prepared according to examples 45, 40 and 6.
- Therapeutic application of vaccine 3 times with an interval of 10 days of vaccine prepared according to example 45.
- Therapeutic application of vaccine 3 times with an interval of 10 days of vaccine prepared according to example 45.
- Therapeutic application of vaccine 3 times with an interval of 7 days in a dose of 5 ml.
- Vaccine was prepared according to examples 38, 39, 40 and 44.
- Vaccine was prepared according to examples 51 and 52.
- Vaccination of cows against DD, ID and IP was done.
- Prophylactic application of vaccine 3 times intracutaneous with a dose of 0.4 ml in an interval of 10 days of vaccine prepared according to example 51.
- Vaccination of cows against DD, ID and IP was done.
- Prophylactic application of vaccine 3 times intracutaneous with dose 0.4 ml with an interval of 10 days of vaccine prepared according to example 52.
- the challenge of Trichophyton mentagrophytes and Microsporum canis microconidiae consisted of 100-200 thousand microconidia per cm 2 (300-600 thousand microconidia) applied topically to each animal.
- the challenge of Trichophyton verrucosum consisted of 500 thousand microconidia per cm 2 (1.5 million microconidia) applied topically to each animal.
- a single dose of 1.0 ml of the vaccine was applied by intramuscular injection on the same day as the challenge and a second dose after 7 days. The observation was continued for 4 weeks after the initial injection of the vaccine.
- Vaccines prepared according examples 38, 39, 46, 47, 48, 49, 50 were tested.
- a single dose of 1.0 ml of the vaccine was applied through intramuscular injection on the same day as the challenge and a second dose after 7 days. The observation was continued for 4 weeks after the initial injection of vaccine.
- Trichophyton verrucosum Trichophyton mentagrophytes ( Tm )
- Microsporum canis Mc
- Trichophyton verrucosum 1220 Volume: 0.5 ml Infection dose (1000 cells): 500-600/cm 2 Area of skin for infection: 2-4 cm 2.
- Trichophyton mentagrophytes Strain number: 1440 Volume: 0.5 ml Infection dose (1000 cells): 100-200/cm 2 Area of skin for infection: 2-4 cm 2 3.
- Table 31 The dynamics of the intensity of the clinical symptoms of allergic bronchitis in horses after application of the vaccine prepared according to example 41 (experimental group) and without vaccination (control group).
- the vaccine was injected intramuscular 3 times with an interval of 4 days with a dose of 1.0 ml.
- Ear erythema was determined by visual inspection and detection of presence (+) or absence (-) signs.
- the intensity of the ear oedema was significantly higher in the control animals and in groups vaccinated with diluted vaccine and vaccine in dose of 1.0 ml, than in other vaccinators.
- the amount of unreacted animals in control and test groups ranged from 65 to 81%, which is permitted by the method.
- the vaccine was injected 3 times with an interval of 7 days.
- the animals were treated by instillation of the nose the vaccine for five days at a dose of 1-2 drops into each nasal passage 1-2 times a day, other animals from control group were treated by the same way but with physiological sodium chloride solution (placebo).
- the animals were examined with a description of the clinical manifestations of the disease before treatment and on day 5, 10 20 and 30 after first application. In the case of aggravation of allergic rhinitis the second course of treatment for five days was done. The results are also shown in Figure 7. No.
- Chitosan 80/ 100 and 80/200, AS-No.: 9012-76-4, Amino-N-acetyl-D-glucosamine is sterilized in a separate vessel and is carried out to obtain Chitosan in pharmaceutical quality.
- the precipitate is resuspended in an equal amount of purified (sterile) water (water for injection (Pharm. Eur.)) (401, initial amount).
- 80 ml of Pentanoyl chloride is measured. Under stirring conditions the Pentanoyl chloride is added drop by drop to the suspension. The obtained suspension is stirred until the solution is clear. 1.6g Thiomersal is added (40 ⁇ g/mL). The clear solution is the active ingredient (Hydro-Colloid).
- the obtained polysaccharide colloid (CVHC) is stored under 4°C to 8°C. For an endproduct a aqueous solution is done with defined biological activity.
- the production is a combination of a purification step of the basic material Chitosan and in process reaction with the second reagent Pentanoyl chloride.
- This first critical step is the precipitation of Chitosan to obtain the total amount of the purified chitosan in pharmaceutical quality.
- process control The reaction time and the pH-value are monitored to get a quantitative precipitation.
- Test for the pharmaceutical quality of chitosan Test for the quality of the intermediate (Chitosan pharm quality)
- Solubility in water A sample of about 250 mg of the precipitate of Chitosan is resuspended in 1 ml of purified water Target: No solubility can be obtained Quality: is fulfilled if no reduction of the amount of the solid material can be detected.
- Solubility in stronger acids In parallel same amount of precipitate is suspended in 1 ml HCl (3N) Target: Total solution Quality: is fulfilled if a solution of the total amount of the solid material can be detected.
- the second critical step is the dissolution process to the active ingredient.
- the control is done visually: The total amount of the precipitate should be solubilized.
- Test solution An adequate sample of Chitosan HCl, Chitosan-HAc, Chitosan, Chitosan-Valeric acid-Hydro Colloid and valeric acid, respectively was dissolved in the solvent above. This mixture was shacked and afterwards sonified in an ultrasonic bath for 5 min.
- the absorption maxima according to the general fundamentals of spectroscopy and the chemical structure with specific chromophore groups and substituents can be expected at:200 nm for Chitosan HCl, Chitosan-HAc, Chitosan-Valeric acid-Hydro Colloid and valeric acid, respectively UV- Maximum Chitosan HCl Chitosan HAc Chitosan CVHC Valeric acid nm 200 200 - 200 211
- Chitosan is a water insoluble solid, which can also not be solubilized in typical organic solvents.
- Apparatus Infrared-Spectrometer FT/IR 410 Jasco Range 4000 cm -1 to 600 cm -1
- Test sample A mixture of 4.8 mg of Chitosan, or a mixture of 4 mg of Chitosan-HCl or a mixture of 3.8 mg of Chitosan Acetate and 100 mg KBr is carefully grinded and pressed to a suitable potassium bromide disk, or a film of Chitosan-Valeric acid-Hydro Colloid or NaCl plate for valeric acid
- the measured spectrum corresponds directly to the literature spectra from database. Result: The measured data above confirms the identity of the tested substances.
- Measurement in solution According to the missing solubility in neutral solvents a measurement in solution is not possible. Measurement in solid state: A measurement in solid state was not possible. Also after long measurement conditions (time) no acceptable signals appeared. Result: NMR-Identification of Chitosan is not possible.
- Example 79 TLC-Method for the analysis of Chitosan and impurities in the new product Chitosan-Valeric acid-Hydro-Colloid (CVHC)
- This part presents the procedures and data of thin layer chromatography for the identification of CVHC along with the Rf values in the used solvent mixtures and spot colors when detected under UV-light (365 nm and 254 nm), visible light and with typical visualisation reagents.
- the original based raw material for any kind of glucosamines is the natural material Chitin from insects or crabs.
- the monomeric structure of these biopolymers is N-Acetyl-Glucosamine.
- deacetylated Chitin is typical.
- This resulting biopolymer is the so called Chitosan, which can be modified into water soluble ionic compounds.
- the monomeric structure of this Chitosan should be theoretically Glucosamine. Because the deacetylation step does not run totally, Chitosan has a mixed structure of N-Acetyglucosamine (acetylated) and Glucosamine (deacetylated) units.
- Chitosan-Valeric acid-Hydro-Colloid is a new Polyaminosugar-valeric acid hydro-complex. Therefore no positive analytical test results for N-Acetyl-Glucosamine and Glucosamine should be possible. If monomeric fragments are embedded as residual impurities, it should be possible to identify Chitosan in form of its water soluble ionic compounds Chitosan HCl and Chitosan HAc.
- CVHC is a high viscous waterish gel. Two drops of CVHC was used for analysis. Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent 1 Group specific reagent 2 Anisaldehyde-Sulfuric acid reagent Iodine Compound signal No No Grey spot Brown spot Impurities No No No No Group specific reagent 1: Naturstoff-Reagent / DT / 366 nm Group specific reagent 2: 5% Ninhvdrine / EtOH Rf-value Chitosan-Valeric acid-Hydro-Colloid 0.0 Non specified impurities: Not detected Literature Value Not available data from - Target Compound purity One main spot Anisaldehyd-Sulfuric acid-reagent respectively Iodine as non-selective reagents for detection of non-spec
- Example 80 TLC-Method for the analytical detection of Valeric acid in Chitosan- Valeric acid-Hydro-Colloid
- Pure Valeric acid can be identified with this TLC-System. Colloidal integrated Valeric acid can not be detected in the pure compound Chitosan-Valeric acid-Hydro-Colloid. The detection and the Rf value of "0" show the similarity of Chitosan-Valeric acid-Hydro-Colloid to other related Chitosan compounds. Chitosan-Valeric acid-Hydro-Colloid can only be a Poly-Amino-sugar colloid, but not a solution of Chitosan or a Chitosan derivate with Valeric acid in water. The results above confirm the identity of the proposed structure.
- Example 81 Elimination of Valeric acid from Chitosan-Valeric acid-Hydro-Colloid with high vacuum and higher temperature
- Detection limit of Valeric acid with this visualization reagent after TLC- chromatography: 0.03 ⁇ g Result: With high vacuum and higher temperature a disproportion of Chitosan-Valeric acid-Hydro-Colloid takes place.
- the elimination of Valeric acid can be shown by absolutely no typical odor from Valeric acid.
- the elimination of Valeric acid can be shown by TLC analysis: no typical spot of free valeric acid at Rf-value 0.56.
- Chitosan or Chitosan compounds can be identified at Rf-value 0.
- Chitosan-Valeric acid-Hydro-Colloid can only be a Poly-Amino-sugar-colloid, but not a solution of Chitosan or a Chitosan derivate with valeric acid in water.
- Apparatus separating funnel, evaporator Liquid-liquiddistribution: 20ml Chitosan-Valeric acid-Hydro-Colloid and 10ml Ethyl acetate Conditions: Shaking for about 5 minutes and wait for phase separation Separation of phases: The ethyl acetate phase was collected Concentration step: The about 10 ml were concentrated to liquid residue (waterish) with an evaporator Resolubilization: in 1 ml Methanol Homogenization: Centrifugation step about 5 min 12.000 rpm Phase separation: Upper phase: clear methanolic solution Lower phase: high viscous gel
- Detection limit with visualisation reagent 0.03 ⁇ g Result: The upper phase is a clear methanolic solution. Valeric acid can be identified after decomposition of the Hydro-Colloid in this solution with TLC. No Chitosan or Chitosan compound can be detected with TLC.
- the lower phase is a high viscous gel, soluble in water. No Valeric acid can be detected in this phase by TLC.
- Chitosan or a Chitosan compound can be identified in the lower phase (gel) by TLC.
- Results from TLC analysis A disproportion of Chitosan-Valeric acid-Hydro-Colloid is possible with typical solvents like Ethyl acetate and afterwards with Methanol A re-solubilization of from disproportioned Chitosan-Valeric acid-Hydro-Colloid can be realized with Methanol
- the decomposition of Chitosan-Valeric acid-Hydro-Colloid in Ethyl acetate shows two phases Upper phase Lower phase Ethyl acetate phase Aqueous Colloid residue After concentration the Ethyl acetate phase was redissolved in Methanol and results also two phases Upper phase Lower phase clear methanolic solution high viscous gel This gel can be re-dissolved totally in water can be identified No
- Chitosan-Valeric acid-Hydro-Colloid can only be a Poly-Amino- sugar-colloid, but not a solution of Chitosan or a Chitosan derivate with valeric acid in water.
- the results above confirm the identity of the proposed structure.
- the active principle is a hydrogel, so the theoretical density should be higher than 1.0.
- the measured data confirms the identity of the proposed substance.
- the active principle is a hydrogel, so the theoretical density should be higher than 1.0.
- the measured data confirms the identiy of the proposed substance.
- Pretreatment of container The substance is placed in a suitable weighing bottle, previously dried under the conditions used afterwords Filling: the material is filled not higher than 5 millimeter Transport: The weighing bottle is closed with a suitable cover PC-method: A "under higher vaccum” modified Pharmacopoeia-method 2.2.32 (EP)"in vacuum in a desiccator " Apparatus: desiccator Drying time: to constant weight Drying temperature: 25°C ⁇ 2°C Vacuum: permanent 4-8 mbar with specific pumps Drying reagent: Diphosporuspentoxide (freshly)
- the active principle should be a Hydro Colloid gel.
- the measured data confirm the structure of compound.
- the estimation of the Osmolarity can be done was an indirect measurement of the decrease of the melting point of a solution.
- Apparatus Halbmicro Osmometer Knauer Conditions of measurement: External cooling system Range: 0-1600 mOsmol Method: Freezing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Tires In General (AREA)
- Dental Preparations (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
- The invention relates to a method comprising the step of incubating chitosan in an aqueous solution of an organic carboxylic acid or a salt thereof, a modified chitosan obtainable by the method of the present invention, a hydro colloid, a compound of formula [X]n, a composition comprising the modified chitosan, the hydro colloid or compound according to the present invention, the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in human and/or veterinary medicine and the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in a method of treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis , interdigital phlegmon, trichophytosis, microsporosis, mycosis of skin, allergies, as well as diseases complicated by allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, in particular dermatitis, ear erythema, rhinitis, conjunctivitis, dermatophytosis or warts, in particular Common warts, in a subject and for modulating the immune response in a subject and/or for enhancing reproduction efficiency, preferably reproduction efficiency in animal breeding.
- Mastitis of cattle is distributed worldwide and causes extensive economic damage in agriculture. The damage caused by mastitis is caused in particular by a reduced milk yield and reduced milk quality. Mastitis causes hypogalactia and agalactia in animals. The loss of parts of secretory epithelial cells results in regeneration of connective tissue and to atrophy of the affected part of the udder.
- Endometritis is the inflammation of a mucous membrane of the uterus, which is followed by a more or less significant change of the endometria and an increased activity of the healthy or regenerated uterine glands. The uteritis is most frequently followed by reproduction of polymorphic microflora. Chronic endometritis is a very widespread gynecological disease: it is registered at 12-40% of infertile cows.
- About 15-25% of cows suffer from clinically apparent and hidden mastitis and in particular cattle with a very high milk production are most exposed to this illness. Milk failure of convalescent cows makes up to 20% of the general milk yield on a farm. The existing control methods and treatments of mastitis inevitably lead to high losses of animals and milk. Postpartum diseases of cows comprising endometritis as the most common disease bring about huge economic damages. There are various reasons for endometritis. The treatment by veterinary physicians is time and cost consuming.
- The most common form of mastitis is the hidden (subclinical) mastitis. The hidden mastitis of cows is followed by a softly proceeding inflammatory process with only few or no clinical signs of mastitis. Treatment of animals with this form of mastitis is complicated. This form is very common on large dairy units and is usually only diagnosed during monthly performed examinations for the hidden form of mastitis of the milking herd. About 15% of the lactating cows are affected by the latent mastitis during machine milking. The reasons of the hidden mastitis developing are manifold. The hidden mastitis mostly appears due to non-compliance with veterinary health regulations by operators of machine milking, due to the wrong start and non-compliance with a course of the mastitis animal treatment. At the same time chronic endometritis is a very common gynecological disease: it is registered at 12-40% of infertile cows.
- An objective indicator for a healthy cow udder is the quantity of the contained somatic cells in the milk. Somatic cells in cow milk are presented by leukocytes and epithelium of mammary glands. Epithelial cells are dominated in the milk secretion from a healthy cow. The epithelial cells are formed in udder tissues during the process of natural aging and regeneration of tissues. During mastitis the migration of leukocytes increases in the inflammation area that finally leads to an acute increase of somatic cells in the milk. 1ml milk from clinically healthy cows contains 200 - 250 thousand somatic cells. During mastitis their quantity increases up to 900 thousand and more.
- The milk from cows affected with the hidden form of mastitis has hypoacidity since there is comprises an increased content of chlorides, albumin and globulins. The quantity of cell elements increases several times, especially the quantity of leukocytes. At the same time the content of solids (casein, lactose, calcium and phosphorus) is reduced. When milk from cows affected with the hidden form of mastitis is combined with milk of healthy cows the overall quality of the milk is reduced. It cannot be used for cheese preparation and sour milk products and has an extreme adverse effect on human health.
- Currently, antibiotics, sulfanilamide preparations or mixtures thereof are used for treating the various forms of mastitis and endometritis. Also extracts of plants comprising essential oils with antimicrobic effect are used. In recent years enzyme preparations and immunobiological products comprising probiotics and interferon were used.
- There are a lot of methods and agents for treating mastitis with clinical signs, but treatment of the hidden forms of mastitis is complicated and the distribution of this form of mastitis is much higher than other forms. There are known methods of treating subclinical mastitis by physical therapy (applications of ozokerite, paraffin, warming bandages, compresses, warming by lamps solux, infrared radiation on an udder) and also the use of laser devices of various modifications are applied. The course of treatment consists of 3-4 sessions, wherein only one session is performed per day. The efficiency of these methods is between 60 - 85%, but they are very time and cost consuming. Known is also a method of intramuscular administration of antibiotics: A dose of 8-10 ml of Tilozin 200 once a day over three days, a dose of 0.5ml/10kg body weight of Bilozin 200 twice a day (milk can't be used for food purposes during 7 days), a subcutaneous dose of 1ml/50kg body weight of Efikur during 2-3 days. When using antibiotics there is a need to check preliminary the activators from the affected quarter of an udder on sensitivity to antibiotics. Moreover, milk and products of slaughter from the treated animals can't be used within several days or week. Known is also a method of an intramammary application of the preparation Mastiyet-forte in a plastic syringe which contains oxytetracycline, Neomycin, bacitracin and Prednisolone. The preparation is very effective but milk and products of slaughter from the treated animals can't be used within several days. Known is also a way of treating subclinical mastitis by a procaine blockade of an udder according to D. D. Logvinov. Injections of 0.5% solution of procaine are carried out every 48 hours. Using this method recovery lasts 3-5 days. Disadvantages of this method are that it is labor intensive and that it bears the risk of microbial contamination by injection. Also known is a way of treating sick cows by using 1% solution of collargol and preparations comprising silver. Preparations are injected into the abdominal aorta. If necessary, the injection is repeated after 48 hours. Preparations comprising silver have high anti-bacterial activity and can be used in the treatment of any etiology mastitis. However, this method labor intensive. Also known is a method of using intramammary introduction of the pair milk containing large amounts of lysozyme (received from healthy cows) 1-2 times a day during 2-3 days. The method is not very effective, but milk and products of slaughter can be used after this treatment without any restriction. Also known is a method of treatment of subclinical mastitis using preparations on the basis of probiotics comprising a culture of Str. thermophilus and other bifido-lactobacilli. These drugs are injected intracisternally 1-2 times per day. At the hidden mastitis recovery begins after 1-2 injections for 2-3 days. Disadvantages of this method are an accident bacterial contamination of milk, appearing of new irritation of parenchymatous tissue of lactiferous gland, and as a consequence and potential exacerbation of the pathologic process. Also known is a method of treating mastitis of cows by using interferon solutions. These solutions increase the protective function of leukocytes which are present in a large amount in milk of animals with mastitis. The solutions contain at least 1000 units of recombinant bovine interferon which is packed in 10g injectors. The solutions are used intracisternally twice a day with an interval of 8-14 hours for 3 days or until complete recovery. Recovery time is 4-12 days. The advantages of this method is the absence any limits for the use of milk and meat from treated animals, it doesn't lead to resistance of pathogenic organisms and it has no locally-irritating and resorptive-toxic properties. The disadvantages of this method are the necessity of repeated application of the preparation and the presence of protein components that can provoke allergic reactions.
- DD, ID and IP, which are the most common infectious hoof and claw diseases, are sporadically distributed worldwide but may be endemic in particular in intensive beef or dairy cattle production units. The incidence depends amongst other on weather, season of year, grazing periods, and housing system. DD usually leads to lameness and to a significant decrease in body weight, loss of fertility and decrease of milk production. The incidence can be between 5% and 30%. In the first epidemic cases about 30% to 80% animals can show clinical sings of the disease. However, on an average IP accounts only for up to 15% of the claw diseases.
- It was surprising that a lot of researchers suggest that the etiological factors of DD, ID and IP are the same microorganisms, such as Dichelobacter nodosus, Fusobacterium necroforun and Fusobacterium, spp which first destroy the epidermis and allow the spirochetes from Treponema spp such as T. phagedenis, T. vincentii, and T. denticola to gain entrance into deeper tissues for developing the clinical sings of DD. Other bacterial species isolated from pathological material from tissues affected with DD, ID and IP are Campylobacter spp, Staphylococcus aureus, Escherichia coli, Arcanobacterium pyogenes, and Prevotella spp. Also, it was suggested that a virus plays an important role in the pathogenesis of the diseases.
- The typical treatment strategy for DD, ID and IP is the application of antibiotics, antibacterial preparations and topical applications pads with antibiotics, antiseptics and astringent solutions. All known vaccines often fail to elicit a sufficient immune response and to protect the animals against interdigital dermatitis and interdigital phlegmone. There are no effective vaccines against digital dermatitis.
- Many treatments of allergy are known and depend on the clinical picture of the allergy. For the treatment of acute allergic contact dermatitis, chronic allergic contact eczema and/or atopic eczema usually lipophilic creams comprising glucocorticosteroids, anti-microbial substances, anti-inflammatory drugs and/or calcium are used. For the treatment of other allergic dermatitis various compounds have been applied locally or parenterally, for example steroid preparations, salicylates, oils or peptides isolated from micro-organisms. All of the above methods only treated the symptoms and not the causes of allergy. Also known are agents for treating allergy comprising antigenic material from keratinophilic fungi and
- yeasts as described in
WO 97/07232 WO 97/07232 - Kuen Y L et al. (Biomaterials, Elsevier Science Publishers BV., vol. 16, no. 16, 1 January 1995, pages 1211-1216) discloses chitosan derivatives wherein chitosan was acylated to various degrees with acetic, propionic, n-butyric, n-valeric and n-hexanoic reagents. Biocompatibility of said derivatives was tested e.g. in combination with enzymes. Kuen Y L et al. discloses that the degree of deacetylation of chitosan should be kept less than 50% for prevention of gelation.
-
CN 102 727 887 A discloses an immunological adjuvant in a mouse allergic asthma model comprising preparation of an acetylated chitosan-derivative prepared by using a chitosan-acetic acid solution neutralized by NaOH. OVA is used as a model antigen. - Seferian P G et al. (Vaccine, Elsevier Ltd, GB, vol. 19, no. 6, 8 November 2000, pages 661-668) describes a chitosan antigen mixture wherein the antigen was mixed with a sterile 2% solution in 2% acetic acid solution followed by neutralization with NaOH thereby forming a fine gelatinous precipitate that was used for vaccination.
- Huadong Wang et al. (BMC Infectious Diseases, vol. 14, no. 1, 11 April 2014, page 195) discloses the preparation of a murine cytomegalovirus vaccine comprising preparing an antigen solution mixed with a chitosan adjuvant 0.2%(w/v) diluted in a 25 mM sodium acetate solution (pH 5.0). The chitosan was prepared by: adding 0.04 g chitosan to 20 ml of a 0.1 M solution of glacial acetic acid [concentration 0.2%(w/v)], mixing it for about an hour to dissolve it and adjusting its pH with NaOH.
-
WO 2013/033400 describes in detail the preparation of a murine cytomegalovirus vaccine comprising preparing an antigen solution mixed with a Chitosan adjuvant 0.2% (w/v) diluted in a 25 mM sodium acetate solution (pH 5.0). The chitosan was prepared by: adding 0.04 g chitosan to 20 ml of a 0.1 M solution of glacial acetic acid [concentration 0.2% (w/v)], mixing it for about an hour to dissolve it, adjusting its pH with NaOH. - The object of the present invention is the provision of a more effective immunobiological product/preparation. It is also an object of the present invention to provide a new agent for use in veterinary and/or human medicine. Another object of the present invention is the provision of new agents for treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis , interdigital phlegmon, trichophytosis, microsporosis, mycosis of skin, allergies, as well as diseases complicated by allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, in particular dermatitis, ear erythema, rhinitis, conjunctivitis, dermatophytosis or warts, in particular Common warts, in a subject and for modulating the immune response in a subject and/or for enhancing reproduction efficiency, preferably reproduction efficiency in animal breeding.
- These objects are solved by the subject matter defined in the claims.
- The following figures serve to illustrate the invention.
-
Figure 1 illustrates a standard curve for 1,3-β-D-Glucan quantification. Shown is the mean rate of optical density change plotted over known concentrations [pg/ml] of 1,3-β-D-Glucan Standard Solutions. ForStandard curve generation 1,3-β-D-Glucan Solutions of 100 pg/ml, 50 pg/ml, 25 pg/ml, 12.5 pg/ml and 6.25 pg/ml were prepared as recommended by the manufacturer. The measured curve was linear over the entire range and meets the quality control acceptance criteria (R2 > 0.980). -
Figure 2 illustrates the dynamics of the intensity of the clinical symptoms of allergic bronchitis in horses after application of the composition prepared according to example 41 (experimental group) and without vaccination (control group). The composition was injected 3 times with an interval of 4 days. The score of clinical symptoms is as follows: 0 = no symptoms; 1 = weak wheeze, without coughing; 2 = weak wheeze, with coughing; 3 = expressed wheeze; 4 = expressed wheeze with clinical symptoms of depression. -
Figure 3 illustrates the dynamics of the intensity of the clinical symptoms of chronic obstructive pulmonary disease in horses after application of the composition prepared according to example 41_(experimental group) and without vaccination (control group). The composition was injected 3 times with an interval of 4 days. The score of clinical symptoms is as follows: 0 = no symptoms; 1 = weak wheeze, without coughing; 2 = weak wheeze, with coughing; 3 = expressed wheeze; 4 = expressed wheeze with clinical symptoms of depression. -
Figure 4 illustrates the dynamics of clinical signs of skin diseases in dogs immunized with the composition according to Example 42 in doses of 0.5 ml and 1.0 ml (Mean score of clinical symptoms in each group was shown; n=10). The composition was injected 3 times with an interval of 7 days. The score of clinical symptoms is as follows: 0 = no symptoms; 1 = hair growth, active rejection of crusts or excessive flaking; 2 = alopecia, no hair growth, rejection of crusts; 3 = desquamation, swelling or swelling with crust, crust not rejected; 4 = desquamation or swelling, pain on palpation; 5 = inflammatory response, necrotic crust. -
Figure 5 illustrates the dynamics of clinical signs of skin diseases in dogs immunized with the composition according to Example 50 in doses of 0.5 ml. (Mean score of clinical symptoms in each group was shown; in vaccinators n=15 and in control group n=15). The composition was injected 3 times with an interval of 3 to 4 days. The score of clinical symptoms is as follows: 0 = no symptoms; 1 = hair growth, active rejection of crusts or excessive flaking; 2 = alopecia, no hair growth, rejection of crusts; 3 = desquamation, swelling or swelling with crust, crust not rejected; 4 = desquamation or swelling, pain on palpation; 5 = inflammatory response, necrotic crust. -
Figure 6 illustrates the dynamics of clinical signs of skin diseases in dogs immunized with composition according to Examples 41 and 43 in a dose of 0.5 ml (Mean score of clinical symptoms in each group was shown; n=10). The score of clinical symptoms is as follows: 0 = no symptoms; 1 = hair growth, active rejection of crusts or excessive flaking; 2 = alopecia, no hair growth, rejection of crusts; 3 = desquamation, swelling or swelling with crust, crust not rejected; 4 = desquamation or swelling, pain on palpation; 5 = inflammatory response, necrotic crust. -
Figure 7 illustrates the dynamics of clinical signs of rhinitis in cats treated with the composition prepared according to Example 42. Experimental group of cats was treated with the composition. Two courses according to study protocol every day with 1-2 drops into the nose were done. The score of symptoms is as follows: 0 = no symptoms; 1 = hyperemia and / or swelling of the mucous membranes of the nasal passages; 2 = slight discharge from the nose; 3 = hyperemia and / or swelling of the mucous membranes of the nasal passages discharge from the nose; 4 = difficulty breathing, hyperemia and swelling of the mucous membranes of the nasal passages, heavy discharge from the nose; 5 = death of animals. -
Figure 8 illustrates the dynamics of clinical signs of rhinitis in dogs treated with the composition prepared according to Example 43. Experimental group of dogs was treated with the composition. Two courses according to study protocol every day with 1-2 drops into the nose were done. The score of symptoms is as follows: 0 = no symptoms; 1 = hyperemia and / or swelling of the mucous membranes of the nasal passages; 2 = slight discharge from the nose; 3 = hyperemia and / or swelling of the mucous membranes of the nasal passages discharge from the nose; 4 = difficulty breathing, hyperemia and swelling of the mucous membranes of the nasal passages, heavy discharge from the nose; 5 = death of animals -
Figure 9 illustrates the dynamics of clinical signs of conjunctivitis in cats treated with the composition prepared according to Example 54. Experimental group of cats was treated with the composition according to study protocol every day by instilling 1-2 drops on the conjunctiva. The score of symptoms is as follows: 0 = no symptoms; 1 = hyperemia and / or swelling of the conjunctiva; 2 = slight lacrimation; discharge from the eyes; 3 = hyperemia and / or swelling of the conjunctiva, discharge from the eyes; 4 = hyperemia and swelling of the conjunctiva, intensive discharge from the eyes; 5 = destruction of eyeball. - The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the description may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."
- The term "about" means that the value stated, plus or minus 5% of the stated value, or the standard error for measurements of the given value, are contemplated.
- The term "comprising" as used herein shall not be construed as being limited to the meaning "consisting of" (i.e. excluding the presence of additional other matter). Rather, "comprising" implies that optionally additional matter may be present. The term "comprising" encompasses as particularly envisioned embodiments falling within its scope "consisting of" (i.e. excluding the presence of additional other matter) and "comprising but not consisting of" (i.e. requiring the presence of additional other matter), with the former being more preferred.
- The term "chitosan" as used herein refers to a copolymer of 2-amino-2-deoxy-D-Glucopyranose and 2-acetamido-2-deoxy-D-glucopyranose, where the degree of deacetylation is more than 50%, preferably more than 60%, 70%, 80% or 90%. Chitosan may be chemically derived from chitin which is a poly-1,4- β-N-acetyl- D-glucosamine, more particularly a N-acetyl-1,4-β-D-glucopyranosamine by deacetylation. Typical chitosan preparations have varying molecular weights depending on the method of manufacture.
- The term "mastitis" as used herein refers an inflammation of breast and udder tissue. It preferably comprises latent mastitis and/or acute mastitis. Latent mastitis may also be called hidden mastitis and/or subclinical mastitis. Preferably, latent mastitis can be diagnosed by a well-known method in the art with 2% solution of mastidin. Acute mastitis may also be fibrinous, catarrhal, purulent-catarrhal, hemorrhagic mastitis with visual typical clinical symptoms of disease.
- The term "endometritis" as used herein refers to an inflammation of the endometrium. More preferably, it refers to an inflammation of a mucous membrane of the uterus, which may be followed by a more or less significant change of the endometria and an increased activity of the healthy or regenerated uterine glands. Preferably, it comprises chronic endometritis, subacute, acute and subclinical (hidden) endometritis. The nature of inflammation is divided into catarrhal, catarrhal-purulent, purulent, fibrinous and hidden. Endometritis may also be called uteritis. Uteritis is most frequently followed by reproduction of polymorphic microflora.
- The term "trichophytosis" as used herein refers to a disease due to an infection with fungi from genera Trichophyton. Cattle is usually infected by Trichophyton verrucosum while humans, dogs, cats, horses, fur-bearing and other animals are usually infected by T. mentagrophytes. Humans can also be infected by T. rubrum. It may also be called Trichophyton disease.
- The terms "microsporosis" or "Microsporum canis disease" as used herein refer to a disease due to an infection with genera Microsporum, more preferably with Microsporum canis. Typically cats, dogs, horses and other animals are infected by this disease. It is especially common in pigs, which are mostly infected by Microsporum nanum.
- The term "warts" as used herein refers in general to a small, rough growth resembling a cauliflower or to a solid blister. Normally, warts are caused by a viral infection. Preferably, the term "warts" refers to Common warts, in particular verrucae volgares and paronychial warts.
- The term "hoof- and claw disease" as used herein refers in particular to infectious hoof- and claw diseases in bovidae and/or pigs. Said diseases are in particular caused by bacteria, fungi and/or viruses. In particular the term "hoof- and claw diseases" refers to digital dermatitis, interdigital dermatitis and interdigital phlegmone.
- The term "bovidae" as used herein refers in particular to cloven-hoofed, ruminant mammals including includes bison, African buffalo, water buffalo, antelopes, gazelles, sheep, goats, muskoxen, and cattle.
- The term "lameness" as used herein refers in particular to lameness as a result of an infection and damage to tissue. In particular, the term "lameness" refers to lameness due to hoof and claw diseases, more particularly due to digital dermatitis (DD), interdigital dermatitis (ID) and interdigital phlegmone (IP).
- It was now surprisingly found, that a composition comprising chitosan modified by an organic carboxylic acid or a salt thereof stimulates the immune response and can be used in a method of treating and/or preventing a number of different diseases. In addition, it was surprisingly found that if already known active agents are administered in combination with a modified chitosan of the present invention, said active agents can be used in an up to 50 times less dose.
- Thus, the present invention relates to a method for preparing chitosan modified by an organic carboxylic acid, or a salt thereof, a hydro colloid, a compound and a composition all as defined in the claims. In addition, the present invention relates to the hydro colloid, the compound or the composition as defined in the claims for use as defined in the claims. Preferably, the modified chitosan is a clear gel with an absent or faint smell of acetic acid. The modified chitosan prepared by the method of the present invention has preferably a molecular weight or an average molecular weight of about 50 Da to about 700kDa, in particular of about 15 kDa to about 500 kDa, more particular of about 15kDa to about 150kDa, or of about 80 kDa to about 200 kDa, of about 150 kDa to about 300 kDa, of about 100 kDa to about 250 kDa or of about 300 kDa to about 700 kDa. The mass content of ashes of the modified chitosan according to the present invention is preferably about 0.2 to 2%, more preferably about 0.8 to about 1.2% and most preferably 0.22%. The modified chitosan according to the present invention may also be called chitosan derivative or chitosan variant.
- Preferably, the modified chitosan has reactive amino groups in an amount of about 100 to about 500 per 100 kDa of chitosan. The modified chitosan prepared by the method according to the present invention has a degree of deacetylation of 62% to 98%, more preferably of 80 to 95 %, more preferably of about 89% to about 93 %, or of about 89% to about 98%, of about 93% to about 98%, of about 93% to 95% or of about 95% to 98%.
- The modified chitosan, chitosan derivative or chitosan variant prepared by the method according to the present invention is preferably a compound of formula [X]n, in which n represents an integer of about 1 to about 5000, in particular an integer of about 300 to about 4000, and X has the following formula (1):
- Thus, the present invention also refers to a compound of formula [X]n, in which n represents an integer of 1 to 5000, in particular an integer of 300 to 4000, and X has the following formula (1):
- The formula X refers to a deacetylated 2-amino-2-deoxy-D-glucose unit and a D-glucosamine unit, respectively, which is the monomer of 100% deacetylated chitosan. Accordingly, the formula X may also refer to the formula represented in the square brackets of the following formula (2) representing the structural formula of a chitosan with a degree of deacetylation of 100%:
- As outlined above n represents an integer of about 1 to about 5000. Within that limit n is preferably at least about 10, about 50, about 80, about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900 or about 1000 and/or at most about 4000, about 3000, about 2500, about 2000 or about 1500. In further preferred embodiments of the present invention n represents an integer of about 50 to about 2500, in particular of about 50 to about 1000, or of about 300 to about 1500, of about 1000 to about 2000, of about 400 to about 1700, of about 50 to about 1700 or of about 1000 to about 5000.
- In a further preferred embodiment of the present invention about 5% to about 35 %, more preferably about 5% to about 20%, more preferably about 7% to about 11% or about 2% to about 7%, about 5% to about 7% or about 2% to about 5% of the X residues constituting the compound as defined above are modified by acetylation, which means that they are acetylated. A modification by acetylation refers to the introduction of an acetyl functional group into the residue according to formula (1) which results in a N-acetyl-D-glucosamine-residue.
- In a preferred embodiment of the present invention the organic carboxylic acid has a pKs of about 2 to about 5, more preferably of about 2.3 to about 4.9. More preferably, the organic carboxylic acid, or a salt thereof is selected form the group consisting of valeric acid, valeric acid chloride, para-aminobenzoic acid, glucuronic acid, and lactic acid. The modification with the organic carboxylic acid or a salt thereof is preferably obtainable by the contact or a reaction with said organic carboxylic acid or a salt thereof or an aqueous solution comprising said organic carboxylic acid or a salt thereof. Preferably, the modification takes place by the contact with an aqueous solution comprising about 0.2 M to about 22.5 M of said organic carboxylic acid or a salt thereof, or in an aqueous solution comprising about 1 mM to about 100 mM of the organic carboxylic acid or a salt thereof, more preferably about 1 mM to about 10 mM.
- The modified chitosan, chitosan derivative or chitosan variant prepared by the method according to the present invention is preferably a Polyamino-sugar colloid, preferably a hydro colloid. Preferably, the modified chitosan, chitosan derivative or chitosan variant is a Chitosan-Glucuronic acid-Hydro-Colloid or Chitosan-p-Aminobenzoic acid-Hydro-Colloid or Chitosan-Valeric acid-Hydro-Colloid. The Chitosan-Glucuronic acid-Hydro-Colloid has preferably the chemical formula: (C6H11O4N)x(C8H13O5Ny(C6H10O7)z(H2O)m.. Preferably, the Chitosan-Glucuronic acid-Hydro-Colloid has the following molecular weight: x∗(161)+y∗(203)+z∗(194.14)+m∗(18). Alternatively, the Chitosan-p-Aminobenzoic acid-Hydro-Colloid has the chemical formula: (C6H11O4N)x(C8H13O5N)y(C7H7O2N)z(H2O)m.. Preferably, the Chitosan-p-Aminobenzoic acid-Hydro-Colloid has the following molecular weight: x∗(161)+y∗(203)+z∗(137.14)+m∗(18). Alternatively, the Chitosan-Valeric acid-Hydro-Colloid has the chemical formula: (C6H11O4N)x(C8H13O5N)y(C5H10O2)z(HCl)z(H2O)m.. Preferably, Chitosan-Valeric acid-Hydro-Colloid has the following molecular weight: x∗(161)+y∗(203)+z∗(102)+z∗(36.5)+m∗(18).
- Thus, the present invention also refers to a hydro colloid comprising:
- (i) 0.1% to 5% (w/v) chitosan and 0.001 to 5% (w/v) valeric acid, or a salt thereof, preferably chloride of valeric acid or
- (ii) 0.1% to 5% (w/w) chitosan and 0.001 to 5% (w/w) glucuronic acid or p-aminobenzoic acid or a salt thereof.
- A preferred embodiment of the present invention refers to a hydro colloid comprising:
- (i) 0.1% to 3% (w/v) chitosan and 0.001 to 2% (w/v) valeric acid or a salt thereof, preferably chloride of valeric acid, or
- (ii) 0.1% to 3% (w/w) chitosan and 0.001 to 2% (w/w) glucuronic acid or p-aminobenzoic acid or a salt thereof.
- Another preferred embodiment of the present invention refers to a hydro colloid comprising:
- (i) 0.1% to 1.2% (w/v) chitosan and 0.001 to 1% (w/v) valeric acid or a salt thereof, preferably chloride of valeric acid, or
- (ii) 0.1 to 1.2% (w/w) chitosan and 0.001 to 1% (w/w) glucuronic acid or p-aminobenzoic acid or a salt thereof.
- Another preferred embodiment of the present invention refers to a hydro colloid comprising:
- (i) 0.1% to 1.2% (w/v) chitosan and
- (ii) 0.01 to 0.44% (w/v) valeric acid, or a salt thereof, preferably chloride of valeric acid.
- Another preferred embodiment of the present invention refers to a hydro colloid comprising:
- (i) 0.1% to 1.2% (w/w) chitosan and
- (ii) 0.001 to 0.6% (w/w) glucuronic acid or a salt thereof.
- Another preferred embodiment of the present invention refers to a hydro colloid comprising:
- (i) 0.1% to 1.2% chitosan and
- (ii) 0.006 to 1% (w/w) p-aminobenzoic acid or a salt thereof.
- Preferably the chitosan of the hydro colloid is a compound of formula [X]n, in which n represents an integer of about 1 to about 5000, in particular an integer of about 300 to about 4000, and X has the following formula (1):
- In a preferred embodiment, the remaining percentage of the hydro colloid according to the present invention is provided by the dispersion media, preferably water or water and hydrogenchloride (HCl).
- In a preferred embodiment, the hydro colloid according to the present invention is used as a dilution, preferably in a dilution of 0 to 10 times.
- The modified chitosan, chitosan derivative or chitosan variant prepared by the method according to the present invention is preferably a natural white to yellowish viscous liquid. Preferably, the modified chitosan, chitosan derivative or chitosan variant has typical odor of the carboxylic acid, preferably the typical odor of valeric acid.
- The modified chitosan, chitosan derivative or chitosan variant contains preferably about 0.2 % pentanoly chloride, or 0.2% Glucuronic acid, or 0.2% p-Aminobenzoic acid.
- The modified chitosan, chitosan derivative or chitosan variant contains preferably 1% chitosan residue from drying chitosans.
- The modified chitosan, chitosan derivative or chitosan variant has preferably about 10 to about 1000 mOsmol, preferably about 10 to about 200 mOsmol, most preferably about 100 mOsmol.
- The modified chitosan prepared by the method according to the present invention is preferably further modified by a mineral acid. Said modification may result from the contact or a reaction with said mineral acid or an aqueous solution comprising said mineral acid. Said mineral acid is preferably HCl or H2SO4. Preferably, the modification takes place by incubating the modified chitosan in an aqueous solution comprising about 0.05 M to about 1 M of said mineral acid, preferably HCl or H2SO4.
- The present invention also refers to a composition comprising a modified chitosan, chitosan derivative or chitosan variant or a hydro colloid according to the present invention. Preferably, the composition comprising said modified chitosan is a clear gel with an absent or faint smell of acetic acid which is soluble in water and in 1% solution of acetic acid. The composition has preferably a molecular weight or an average molecular weight of about 50 Da to about 700kDa, in particular of about 15 kDa to about 500 kDa, more particular of about 15 kDa to about 150kDa, or of about 80 kDa to about 200 kDa, of about 150 kDa to about 300 kDa, of about 100 kDa to about 250 kDa or of about 300 kDa to about 700 kDa. The mass content of ashes of the composition according to the present invention is 0.1 to 2%, preferably about 0.8 to about 1.2%, more preferably about 0.22%.
- Preferably, the modified chitosan of said composition has reactive amino groups in an amount of about 100 to about 500 per 100 kDa of chitosan. The modified chitosan of the composition according to the present invention has preferably a degree of deacetylation of about 65% to about 98%, more preferably of about 80% to about 95 %, more preferably of about 89% to about 93 %, or of about 89% to about 98%, of about 93% to about 98%, of about 93% to about 95% or of about 95% to about 98%.
- In further preferred embodiment of the present invention, the composition comprises additionally a mineral acid. Said mineral acid supports the solubility of the modified chitosan and/or may further modify the chitosan. Said mineral acid is preferably HCl or H2SO4. The aqueous solution comprises preferably 0.05 M to about 1 M mineral acid, preferably HCL or H2SO4.
- The present invention also relates to a method for preparing a modified chitosan, chitosan variant or chitosan derivative comprising the step of:
- (a) incubating chitosan in an aqueous solution of an organic carboxylic acid or a salt thereof as defined in the claims.
- In a preferred embodiment the chitosan is firstly dissolved under acidic aqueous conditions and subsequently precipitated by increasing the pH value to a pH value of about 8.0 to about 8.5 before it is incubated in the aqueous solution of the organic carboxylic acid or the salt thereof as described above.
- Thus, the present disclosure also relates to a modified chitosan obtainable by a method comprising
- (i) dissolving chitosan in an aqueous solution of an acid
- (ii) increasing the pH value until chitosan is precipitated
- (iii) recovering the precipitated chitosan, and
- (a) incubating the recovered chitosan of step (iii) in an aqueous solution of an organic carboxylic acid or a salt thereof as further defined below.
- The present invention also relates to a method comprising the steps of:
- (i) dissolving chitosan in an aqueous solution of an acid
- (ii) increasing the pH value until chitosan is precipitated
- (iii) recovering the precipitated chitosan, and
- (a) incubating the recovered chitosan of step (iii) in an aqueous solution of an organic carboxylic acid or a salt thereof as further defined below.
- The organic carboxylic acid or a salt thereof of step (a) has preferably a pKs of about 2 to about 5, more preferably of about 2.3 to about 4.9. Said organic carboxylic acid is valeric acid, lactic acid, para-aminobenzoic acid or glucuronic acid or a salt thereof, in particular chloride of valeric acid. Said carboxylic organic acid or a salt thereof is preferably used in a concentration of about 0.2 M to about 22.5 M. The incubation of chitosan and the recovered chitosan of step (iii), respectively, and the aqueous solution of the organic carboxylic acid or a salt thereof as outlined in step (a) results in the solution of the chitosan, the modification of the chitosan and/or the formation of a gel. Preferably, the pH value of the aqueous solution in step (a) is about 5 to about 6 or about 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9 or 6.0. Preferably, the modification of the chitosan takes place in an aqueous solution comprising about 1 mM to about 100 mM of the organic carboxylic acid or a salt thereof, more preferably about 1 mM to about 10 mM.
- Preferably, step (a) is performed until the chitosan is modified and dissolved. It is preferably performed by mixing chitosan with an aqueous solution of the organic carboxylic acid or a salt thereof or by suspending chitosan under aqueous conditions and adding the organic carboxylic acid to the suspension. It is preferably performed under stirring for about 1 to about 72 hours, more preferably for about 24 to about 48 hours. Step (a) may comprise the addition of a further acid or may be performed in the presence of a further acid. Said further acid is preferably a mineral acid, an organic acid or a salt of said mineral acid or organic acid. Preferably, the mineral acid is HCl or H2SO4 and the organic acid is glutamic acid, para-aminobenzoic acid or lactic acid. The mineral or organic acid is preferably added or present in an amount to adjust the pH value of the mixture of step (a) to a pH value of about 5 to about 6 or about 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9 or 6.0. The addition of a further acid may support the dissolution and/or the modification of the chitosan e.g. by decreasing the time which is necessary to dissolve the modified chitosan.
- The concentration of chitosan in step (a), or if the method comprises a step (i) for step (i), is preferably about 1g to about 20 g chitosan per liter, more preferably about 5g to about 15 g chitosan per liter, most preferably about 8 to about 10 g chitosan per liter.
- The chitosan used for step (a), or if the method comprises a step (i) for step (i), may be commercially available chitosan or chitosan isolated from any natural source comprising chitosan such as biomass comprising chitosan. Alternatively, chitin may be used which is deacetylated to obtain chitosan prior to step (a), or if the method comprises a step (i) prior to step (i). Said chitin may be commercially available or it may be isolated from a natural source comprising chitin such as biomass comprising chitin. The biomass for chitin and/or chitosan isolation is preferably biomass of fungi, insects and/or crustaceans.
- The deacetylation of chitin can be performed by known methods in the art as e.g. by using sodium hydroxide (NaOH) in excess as a reagent and water as a solvent or by enzymatic methods. The isolation of chitosan and/or chitin from natural sources can also be performed by known methods in the art and by the methods described in the Examples of the present invention.
- The chitosan used for step (a), or if the method comprises a step (i) for step (i), has a degree of deacetylation of 62% to 95%, more preferably of 80% to 94 %, more preferably of about 89% to about 93 % or of about 93% to about 98%, of about 93% to 95%, of about 95% to about 98%, or of at least 70%, 80%, 90% or 95%, or a degree of deacetylation of about 80% to about 95%, even more preferably of about 90% to about 95%, most preferably about 77% to about 80%.
- The chitosan used for step (a), or if the method comprises a step (i) for step (i), has preferably a viscosity of about 50 to 400 MPas, more preferably about 70 to about 150 MPas or about 151 to about 350 MPas.
- The chitosan used for step (a), or if the method comprises a step (i) for step (i), has preferably a molecular weight or an average molecular weight of about 50 Da to about 700kDa, in particular of about 15 kDa to about 500 kDa, more particular of about 15 kDa to about 150kDa, or of about 80 kDa to about 200 kDa, of about 150 kDa to about 300 kDa, of about 100 kDa to about 250 kDa or of about 300 kDa to about 700 kDa.
- Before the chitosan is used in step (a), or if the method comprises a step (i) in step (i), the chitosan may be sterilized by autoclaving. Said sterilization may result in that the modified chitosan according to the present invention is less toxic, better tolerated by any subject and/or results in less unintended side-effects.
- Preferably, step (i) is performed by the use of an aqueous solution of an weak acid, preferably by an organic acid or a salt thereof, more preferably by acetic acid, valeric acid, lactic acid, para-aminobenzoic acid or glucuronic acid or a salt thereof, in particular chloride of valeric acid. The acid is preferably used in a concentration of about 0.8% to about 2%. Step (i) is preferably performed under stirring. The stirring may be performed for about 2 hour to about 24 hours. Preferably, step (i) is performed until a gel or gel suspension is obtained. Unsolved particles may be removed, e.g. by filtration. For example, a metal grid with a cell of 200µm to 300µm may be used for such a filtration.
- Step (ii) is preferably performed by increasing the pH value of the gel or gel suspension obtained in step (i) until a precipitate is formed. It is preferably performed under stirring. It is preferably performed by treating chitosan under aqueous alkaline conditions, more preferably under aqueous alkaline conditions comprising about 0.1 to about 25.0% alkali. In a preferred embodiment the alkali is NaOH. Preferably, said step is performed at a temperature of about 4°C to about 55°C. Preferably, the treatment is performed for about 20 min to about 2 hours, more preferably for about 30 min to about 70 min, but it may also take up to about 24 h. Preferably, the pH value is increased by adding the alkali to the gel or gel suspension of step (i). Preferably, the pH value is increased to obtain a pH of about 8.0 to about 8.5. Step (ii) may result in a further deacetylation of the chitosan. It may also result in that the modified chitosan according to the present invention is less toxic, better tolerated by any subject and/or results in less unintended side-effects.
- Step (iii) is preferably performed by centrifuging the mixture or suspension obtained in step (ii). The centrifugation is preferably performed at about 4000 to about 6000 revolution/min, more preferably at about 5000 revolution/min. The centrifugation is preferably performed for up to 60 minutes.
- The methods by which the modified chitosan of the present invention is obtainable and the methods of the present invention may comprise additional steps. For example, the product obtained in step (ii), may be homogenized. Preferably, the step of homogenization is performed in a closed sterile homogenizer.
- Alternatively or in addition, the product obtained in step (a) may be dialyzed. The dialysis is preferably performed in a closed system to remove free ions of salts and low molecular weight compounds. Preferably, the dialysis is performed by cross filtration for about 1 to about 6 hours or by membrane filtration against distillate water for about 24 to about 48 hours.
- Alternatively or in addition, the methods by which the modified chitosan of the present invention is obtainable and the methods of the present invention may comprise a further step of preparing the final product. The preparation of the final product may comprise the dilution of the obtained product. Preferably, the product is diluted by the addition of water, more preferably of sterile water for injection. However, the product may also be diluted in any other suitable aqueous solution. Alternatively or in addition, the preparation of the final product may comprise the addition of one or more further compounds, such as diluents, preservatives, antibiotics, further active substances and/or antigenic material from microorganism and/or enzymes. Suitable preservatives are for example chlorocresol, thiomersal and formalin. Suitable antibiotics are for example neomycin, penicillin, gentamycin, cloxacillin, cephapirin and cephalosporin. Finally, the final product may be sterilized. Preferably the sterilization is performed by heating, preferably for about 40 to 50 minutes at a temperature of about 65°C to about 80°C. Preferably, said sterilization is repeated one, two, three, four or five times.
- Preferably, the final product has a concentration of about 0.02g to about 2g modified chitosan per liter, more preferably of about 0.04 to about 1g modified chitosan per liter.
- In a preferred embodiment the methods of the present invention comprise the steps as described in the claims. For example, the methods may comprise the following steps:
- optionally sterilizing chitosan e.g. by autoclaving,
- (i) dissolving chitosan in an aqueous solution of an acid, in particular in the presence of an acetic acid,
- optionally removing undissolved particles e.g. by filtration,
- (ii) increasing the pH value until chitosan is precipitated,
- (iii) recovering the precipitated chitosan,
- optionally homogenizing the recovered chitosan under aqueous conditions,
- (a) incubating the recovered chitosan of step (iii) or the homogenized recovered chitosan in an aqueous solution of an organic carboxylic acid or a salt thereof as defined in the claims, optionally in the presence of a further mineral acid or organic acid,
- optionally dialyzing the product obtained in step (a),
- optionally adding further compounds, such as diluents, preservatives, antibiotics, further active compounds such as chemotherapeutic preparations, and/or antigenic material from microorganism and/or enzymes, and
- optionally sterilizing the final product e.g. by heating.
- Preferably, the order of the steps as outlined above corresponds to the order as listed above. However, as known by the person skilled in the art the order of single steps may be varied as long as the same effects are achieved. For example, diluents such as water may be added in various stages of the method as described above.
- If no specific temperature ranges are given for the method steps as described above, the steps are preferably performed at room temperature and/or in a range of about 10°C to about 40°C, more preferably in a range of about 20°C to about 30°C.
- In a further preferred embodiment the present invention refers to a composition comprising a modified chitosan, chitosan derivative or chitosan variant or a hydro colloid according to the present invention.
- In addition, the composition of the present invention may comprise further active substances. Preferably, the composition of the present invention may additionally comprise a chemotherapeutic preparation, in particular if it is used for the treatment of mastitis.
- In a further preferred embodiment of the present invention the composition of the present invention may additionally comprise antigenic material from microorganism and/or enzymes, in particular antigenic material of keratinophilic fungi and/or keratinophilic yeast-like fungi and/or yeasts.
- The antigenic material of keratinophilic fungi or yeasts may be derived from any parts of keratinophilic fungi or yeasts comprising antigens such as from the mycelium, artrospores, dermatophyte microconidia, yeast blastospores or others. The antigens are preferably polysaccharides and/or glycopeptides. Preferably, the antigenic material of keratinophilic fungi or yeasts is selected from the group consisting of: homogenised inactivated dermatophyte microconidia, homogenised inactivated yeast blastospores, antigenic material of yeast blastospores and antigenic material of dermatophyte microconidia. Thus, the composition of the present invention may additionally comprise homogenised inactivated dermatophyte microconidia and/or homogenised inactivated yeast blastospores and/or antigenic material of yeast blastospores and/or dermatophyte microconidia.
- The antigenic material of keratinophilic yeasts, in particular the yeast blastospores, belong preferably to the genus Candida and more preferably to the species Candida albicans. The antigenic material of keratinophilic dermatophyte, in particular the dermatophyte microconidia, belong preferably to the genera Trichophyton, Microsporum and/or Chrisporium. More preferably, the dermatophyte microconidia belong to the species Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton equinum, Trichophyton sarkisovii, Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Microsporum gypseum and/or Chrisporium tropicum. In particular, the species Microsporum canis can be Microsporum canis var. obesum and/or Microsporum canis var. distortum.
- In a preferred embodiment of the present invention the yeast blastospores and the dermatophyte microconidia are obtained from strains of the above mentioned species which has been obtained by directed selection based on spore production and/or attenuation. It is highly preferred to use a strain which grow faster in nutrient medium, produces more microconidia and blastospores, respectively, has a lower virulence and/or no adverse reactions after its intramuscular application in comparison to any epizootic strain from which it is derived. Examples of such strains are the strains Trichophyton mentagrophytes DSM - 7279, Trichophyton verrucosum DSM - 28406, Trichophyton rubrum DSM - 9469, Trichophyton rubrum DSM - 9470, Trichophyton rubrum DSM - 9471, Trichophyton rubrum DSM - 9472, Candida albicans DSM - 9456, Candida albicans DSM - 9457, Candida albicans DSM - 9458, and Candida albicans DSM - 9459, Chrisporium tropicum DSM-28405 and Microsporum canis BINO 483. Thus, in especially preferred embodiments of the present invention the yeast blastospores and the dermatophyte microconidia are obtained from strains Trichophyton mentagrophytes DSM - 7279, Trichophyton verrucosum DSM - 28406, Trichophyton rubrum DSM - 9469, Trichophyton rubrum DSM - 9470, Trichophyton rubrum DSM - 9471, Trichophyton rubrum DSM - 9472, Candida albicans DSM - 9456, Candida albicans DSM - 9457, Candida albicans DSM - 9458, Candida albicans DSM - 9459, Chrisporium tropicum DSM-28405 and Microsporum canis BINO 483.
- The strains Trichophyton rubrum DSM - 9469, Trichophyton rubrum DSM - 9470, Trichophyton rubrum DSM - 9471, Trichophyton rubrum DSM - 9472, Candida albicans DSM - 9456, Candida albicans DSM - 9457, Candida albicans DSM - 9458, and Candida albicans DSM - 9459 have been deposited according to the Budapest Treaty at the "Deutsche Sammlung von Mikroorganismen und Zellkulturen" (DSM), Mascheroder Weg 1B, W-38124 Braunschweig, Germany (which current name and address is "Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH" (DMSZ), InhoffenstraBe 7B, 38124 Braunschweig, GERMANY) on 05 October 1994 by the Basotherm GmbH,
Eichendorffweg 5, 88396 Biberach an der Riss. The current depositors of said strains are the applicants, namely Dr. Igor Polyakov and Dr.sc.Dr. Liudmila Ivanova, Eberhardtstr. 40, 89073 Ulm. - The strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9469. The strain was obtained by directed selection based on spore production and attenuation of the epizootic strain No. 533, which was identified on a skin of man in 1985. The strain was identified using the "Rebell-Taplin" key (Rebell, G., Taplin, D.: Dermatophytes, their recognition and identification, 3rd Print, University of Miami Press. Coral Gables, Florida, USA, 1978). The biological properties of the strain are described in Table A. Strain No. DSM-9469 differs from the epidemic strain in its faster growth in nutrient medium, an enormous production of microconidia and lower virulence.
TABLE A Properties and characteristics of the strains Strain No. DSM-9469 Epidemic Strain No. 533 Description of the culture Mature 15-day colony on agar Sabouraud: white, velvety, flat, margin of the colony fringed, under surface yellow, in centre deep purple, diameter of colony 60 - 63 mm 20-day colony on agar Sabouraud: white, downy, elevated, margin of colony regular, under surface purple, diameter of colony 30 - 35 mm Morphological characteristics Mature 15-day culture with septate branching hyphae 1 - 3 µm wide, numerous obovate oval microconidia measuring 2 - 3 x 3 - 5 µm, macroconidia long clavate pencil-shaped with 4-5 cross walls measuring 4 - 6 x 15 - 40 µm. 20-day culture with septate branching hyphae 1 - 3 µm wide, microconidia clavate to round in small open clusters and along the hyphae measuring 2 - 3 x 3 - 6 µm; macroconidia are rare, long and pencil-shaped with 3 - 5 cross walls measuring 4 - 7 x 15 - 50 µm. Pathogenic characteristics The strain is weakly virulent. 9 - 10 days after application of a dose of 500 -600 thousand cells of fungal material per cm2 on scarified skin of guinea pigs, scales are formed. Spontaneous recovery after 18 - 20 days. The strain is virulent. 9 -10 days after application of a dose of 500-600 thousand cells of fungal material per cm2 on scarified skin of guinea pigs, thin necrotic scabs are formed. Spontaneous recovery after 25 - 30 days. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: inflammation at point of injection, oedema Immunogenic response Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity - The strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9470. The strain was obtained by directed selection based on spore production and attenuation of the epizootic strain No. 535, which was identified on a skin of man in 1990. The strain was identified using the "Rebell-Taplin" key (Rebell, G., Taplin, D.: Dermatophytes, their recognition and identification, 3rd Print, University of Miami Press. Coral Gables, Florida, USA, 1978). The biological properties of the strain are described in Table B. Strain No. DSM-9470 differs from the epidemic strain in its faster growth in nutrient medium, an enormous production of microconidia and lower virulence.
TABLE B Properties and characteristics of the strains Strain No. DSM-9470 Epidemic Strain No. 535 Description of the culture Mature 15-day colony on agar Sabouraud: white velvety-fluffy in centre, folded, margin of colony regular, under surface colourless or rose, diameter of colony 25 - 30 mm 20-day colony on agar Sabouraud: white, fluffy, margin of colony regular, under surface yellow, 20 mm in diameter Morphological characteristics Mature 15-day culture with septate branching hyphae 1 - 3 µm wide, round oval puriform microconidia measuring 2 - 3 x 3 - 7 µm. 20-day culture with septate branching hyphae 1 - 3 µm wide, microconidia clavate to round in small open clusters and along the hyphae measuring 2 - 3 x 3 - 6 µm; macroconidia are absent. Pathogenic characteristics The strain is weakly virulent. 9 - 10 days after application of a dose of 500 - 600 thousand cells of fungal material per cm2 on scarified skin of guinea pigs, necrotic scabs are formed. Spontaneous recovery after 22 - 25 days. The strain is virulent. 9 - 10 days after application of a dose of 500-600 thousand cells of fungal material per cm2 on scarified skin of guinea pigs, thin necrotic scabs are formed. Spontaneous recovery after 25 - 30 days. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: inflammation at point of injection, oedema Immunogenic response Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity - The strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9471. The strain was obtained by directed selection based on spore production and attenuation of the epizootic strain No. 620, which was identified on a nail of man in 1989. The strain was identified using the "Rebell-Taplin" key (Rebell, G., Taplin, D.: Dermatophytes, their recognition and identification, 3rd Print, University of Miami Press. Coral Gables, Florida, USA, 1978). The biological properties of the strain are described in Table C. Strain No. DSM-9471 differs from the epidemic strain in its faster growth in nutrient medium, an enormous production of microconidia and lower virulence.
TABLE C Properties and characteristics of the strains Strain No. DSM-9471 Epidemic Strain No. 620 Description of the culture Mature 15-day colony on agar Sabouraud: white, velvety, elevated, margin of colony regular, under surface yellow, in centre deep purple, diameter of colony 32 - 35 mm 20-day colony on agar Sabouraud: white, downy, elevated, margin of colony regular, under surface purple, diameter of colony 20 - 25 mm Morphological characteristics Mature 15-day culture with septate branching hyphae 1 - 3 µm wide, round oval puriform microconidia measuring 2 - 3 x 3 - 7 µm. 20-day culture with septate branching hyphae 1 - 3 µm wide, microconidia clavate to round in small open clusters and along the hyphae measuring 2 - 3 x 3 - 6 µm; macroconidia are rare, long and pencil-shaped with 3 - 5 cross walls measuring 4 - 7 x 15 - 50 µm. Pathogenic characteristics The strain is weakly virulent. 9 - 10 days after application of a dose of 500 - 600 thousand cells of fungal materials per cm2 on scarified skin of guinea pigs, scales are formed. Spontaneous recovery after 18 - 20 days. The strain is virulent. 9 - 10 days after application of a dose of 500 - 600 thousand cells of fungal materials per cm2 on scarified skin of guinea pigs, thin necrotic scabs are formed. Spontaneous recovery after 25 - 30 days. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: inflammation at point of injection, oedema Immunogenic response Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity - The strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9472. The strain was obtained by directed selection based on spore production and attenuation of the epizootic strain No. 754, which was identified on a nail of man in 1990. The strain was identified using the "Rebell-Taplin" key (Rebell, G., Taplin, D.: Dermatophytes, their recognition and identification, 3rd Print, University of Miami Press. Coral Gables, Florida, USA, 1978). The biological properties of the strain are described in Table D. Strain No. DSM-9472 differs from the epidemic strain in its faster growth in nutrient medium, an enormous production of microconidia and lower virulence.
TABLE D Properties and characteristics of the strains Strain No. DSM-9472 Epidemic Strain No. 754 Description of the culture Mature 15-day colony on agar Sabouraud: white, velvety, in centre folded, margin of colony regular, under surface yellow in centre purple, diameter of colony 35 - 40 mm 20-day colony on agar Sabouraud: white-rose, downy, margin of colony regular, under surface purple, diameter of colony 20 - 25 mm Morphological characteristics Mature 15-day culture with septate branching hyphae 1 - 3 µm wide, round oval puriform microconidia measuring 2 - 3 x 3 - 7 µm. 20-day culture with septate branching hyphae 1-3 µm wide, microconidia clavate to round in small open clusters and along the hyphae measuring 2 - 3 x 3 - 6 µ m; macroconidia are rare, long and pencil-shaped with 3 - 5 cross walls measuring 4 - 7 x 15 - 50 µm. Pathogenic characteristics The strain is weakly virulent. 9 -10 days after application of a dose of 500-600 thousand cells of fungal materials per cm2 on scarified skin of guinea pigs, scales are formed. Spontaneous recovery after 18 - 20 days. The strain is virulent. 9 - 10 days after application of a dose of 500 - 600 thousand cells of fungal materials per cm2 on scarified skin of guinea pigs, thin necrotic scabs are formed. Spontaneous recovery after 25 - 30 days. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: inflammation at point of injection, oedema Immunogenic response Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity - The strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9456. The strain was obtained by directed selection based on stabilization of cultural-morphological characteristics and attenuation of epidemic strain No. 008-L, which was identified on man in 1990. The strain was identified using the Lodder's key (Lodder,J: The yeast: A Taxonomic Study. North-Holland Publ. Co., Amsterdam - London (1970). The biological properties of the strain are described in Table E. Strain No. DSM-9456 differs from the epidemic strain in its faster growth in nutrient medium, stabile biological properties, an enormous production of biomass and lower virulence.
TABLE E Properties and characteristics of the strains Strain No. DSM-9456 Epidemic Strain No. 008-L Description of the culture 10-day single-spore colony on agar Sabouraud: cream smooth and pasty glistening, elevated, margin of colony regular, diameter of colony 20 - 30 mm 10-day single-spore colony on agar Sabouraud: cream soft and smooth with feathery offshots at the edges, diameter of colony 10 - 15 mm Morphological characteristics 10-day culture with spherical oval blastospores measuring 3.5 - 6 x 6 - 10 µm, chlamidospores 12 -15 µm wide, pseudohyphae 5 - 8 µ m wide, hyphae 1.5 - 3 µm wide 10-day single-spore culture on agar Sabouraud with spherical oval budding blastospores measuring 3 -5 x 5 -8 µm, chlamidospores 10 - 15 µm diameter, pseudohyphae 5 - 8 µm wide, hyphae 1.5 - 3 µm wide. Pathogenic characteristics The strain is weakly virulent. 30 days after intraperitoneal injection of a dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 50% of animals are formed. Lethal effect was not observed. The strain is weakly virulent. 30 days after intraperitoneal injection of a dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 80 -100% of animals are formed. Lethal effect in 50 - 70% was observed. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: inflammation at point of injection, oedema Immunogenic response Results of immunisation of a group of white mice with inactivated antigen from cultures (repeated not less than 10 times): establishes immunity Results of immunisation of a group of white mice with inactivated antigen from cultures (repeated not less than 10 times): establishes immunity - The strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9457. The strain was obtained by directed selection based on stabilization of cultural-morphological characteristics and attenuation of epidemic strain No. 012, which was identified on man in 1992. The strain was identified using the Lodder's key (Lodder,J: The yeast: A Taxonomic Study. North-Holland Publ. Co., Amsterdam - London (1970). The biological properties of the strain are described in Table F. Strain No. DSM-9457 differs from the epidemic strain in its faster growth in nutrient medium, stabile biological properties, an enormous production of biomass and lower virulence.
TABLE F Properties and characteristics of the strains Strain No. DSM-9457 Epidemic Strain No. 012 Description of the culture 10-day single-spore colony on agar Sabouraud: cream rough elevated, margin of colony lobulated, diameter of colony 20 - 23 mm 10-day single-spore colony on agar Sabouraud: cream rough elevated, margin of colony fringed and lobulated, diameter of colony 15 - 20 mm Morphological characteristics 10-day single-spore culture with spherical oval blastospores measuring 3.5 - 5 x 5 -10 µm, chlamidospores 12 -15 µm wide, pseudohyphae 4 - 7 µ m wide, hyphae 2 - 3 µm wide 10-day single-spore culture on agar Sabouraud with spherical oval budding blastospores measuring 3 - 5 x 5 -8 µm, chiamidospores 10 - 15 µm diameter, pseudohyphae 5 - 8 µm wide, hyphae - 1.5 - 3 µm wide Pathogenic characteristics The strain is weakly virulent. 30 days after intraperitoneal injection of a dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs in 30% of animals are formed. Lethal effect was not observed. The strain is weakly virulent. 30 days after intraperitoneal injection by dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 50% of animals are formed. Lethal effect not more 50 % were observed. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Immunogenic response Results of immunisation of a group of white mice with inactivated antigen from cultures (repeated not less than 10 times): establishes immunity Results of immunisation of a group of white mice with inactivated antigen from cultures (repeated not less than 10 times): establishes immunity - The strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9458. The strain was obtained by directed selection based on stabilization of cultural-morphological characteristics and attenuation of epidemic strain No. 047, which was identified on man in 1989. The strain was identified using the Lodder's key (Lodder,J: The yeast: A Taxonomic Study. North-Holland Publ. Co., Amsterdam - London (1970). The biological properties of the strain are described in Table G. Strain No. DSM-9458 differs from the epidemic strain in its faster growth in nutrient medium, stabile biological properties, an enormous production of biomass and lower virulence.
TABLE G Properties and characteristics of the strains Strain No. DSM-9458 Epidemic Strain No. 047 Description of the culture 10-day single-spore colony on agar Sabouraud: cream smooth and pasty glistening, elevated, margin of colony regular, diameter of colony 16 - 18 mm 10-day single-spore colony on agar Sabouraud: cream soft and smooth with feathery offshots at the edges, diameter of colony 10 - 15 mm Morphological characteristics 10-day culture with spherical oval blastospores measuring 3.6 - 6 x 6 - 11 µm, chlamidospores 12 -15 µm wide, pseudohyphae 4 - 8 µ m wide, hyphae 1.5 - 3 µm wide 10-day single-spore culture on agar Sabouraud with spherical oval budding blastospores measuring 3 - 5 x 5 - 8 µm, chlamidospores 10 - 15 µm diameter, pseudohyphae 5 - 8 µm wide, hyphae 1.5 - 3 µm wide. Pathogenic characteristics The strain is weakly virulent. 30 days after intraperitoneal injection of a dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 50 - 100% of animals are formed. Lethal effect in 50% were observed. The strain is weakly virulent. 30 days after intraperitoneal injection by dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 80 -100% of animals are formed. Lethal effect in 70 - 100 % were observed. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: inflammation at point of injection, oedema Immunogenic response Results of immunisation of a group of white mice with inactivated antigen from cultures (repeated not less than 10 times): establishes immunity Results of immunisation of a group of white mice with inactivated antigen from cultures (repeated not less than 10 times): establishes immunity - The strain was deposited at the DSM on 05.10.1994 under Serial No. DSM-9459. The strain was obtained by directed selection based on stabilization of cultural-morphological characteristics and attenuation of epidemic strain No. 158, which was identified on man in 1990. The strain was identified using the Lodder's key (Lodder,J: The yeast: A Taxonomic Study. North-Holland Publ. Co., Amsterdam - London (1970). The biological properties of the strain are described in Table H. Strain No. DSM-9459 differs from the epidemic strain in its faster growth in nutrient medium, stable biological properties, an enormous production of biomass and lower virulence.
TABLE H Properties and characteristics of the strains Strain No. DSM-9459 Epidemic Strain No. 158 Description of the culture 10-day single-spore colony on agar Sabouraud: cream smooth pasty glistening, elevated, margin of colony regular, diameter of colony 16 - 18 mm 10-day single-spore colony on agar Sabouraud: cream smooth pasty, margin of colony lobulated and with feathery offshots at the edges, diameter of colony 10 - 15 mm Morphological characteristics 10-day culture with spherical oval blastospores measuring 3.6 - 6 x 6 - 11 µm, chlamidospores 12 -15 µm wide, pseudohyphae 4 - 8 µ m wide, hyphae 1.5 - 3 µm wide 10-day single-spore culture on agar Sabouraud with spherical oval budding blastospores measuring 3 - 5 x 5 -8 µm, chlamidospores 10 - 15 µm diameter, pseudohyphae 5 - 8 µm wide, hvphae 1.5 - 3 µm wide. Pathogenic characteristics The strain is weakly virulent. 30 days after intraperitoneal injection by dose of 10 -100 million fungal cells to white mice, granuloma in abdominal organs of 40% of animals are formed. Lethal effect was not observed. The strain is weakly virulent. 30 days after intraperitoneal injection by dose of 10 - 100 million fungal cells to white mice, granuloma in abdominal organs of 50% of animals are formed. Lethal effect in 20 - 50% was observed. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: inflammation at point of injection, oedema Immunogenic response Results of immunisation of a group of white mice with inactivated antigen from cultures (repeated not less than 10 times): establishes immunity Results of immunisation of a group of white mice with inactivated antigen from cultures (repeated not less than 10 times): establishes immunity Table I Properties and characteristics of strain Strain No. VKPGF-930/1032 Epizootic Strain No. 1032 Description of culture Mature 10-15 day colony in agar/wort; cream, velvety/powdered, flat with slight flat elevation in center, narrow growing margin, fringed, undersurface light brown, colony diameter 25-30 mm Mature 25-30 day colony in agar/wort; white, flat, narrow, growing margin, undersurface reddish-brown, colony diameter 15-20 mm Morphological characteristics Septate, branching hyphae 1-3 µm wide, numerous pyriform, oval microconidia measuring 1 to 3 × 2 to 6 µm, no macroconidia Septate, branching straight and spiral hyphae 1-3 µm wide, round, flattened pyriform microconidia measuring 1 to 3 × 2 to 6 µm, few elongate-oval macroconidia with 2-5 septates, measuring 2 to 6 × 15 to 25 µm Pathogenic characteristics Necrotic scabs Dense, asbestos-like scabs 9 to 10 days after application of a dose of 500-600 thousand cells of fungal matter per cm2 to the scarified skin of a rabbit Spontaneous recovery after 22-25 days 30-35 days Reaction response No observed changes in clinical state Inflammation at point of injection, edema Results of subcutaneous and intramuscular injection of inactivated corpuscular antigens from cultures Antigen response 20 to 25 days after injecting rabbits with corpuscular antigens, antibody titers observed in blood serum By PHR 1:320 to 1:640 1:320 to 1:640 By ELISA 1:400 to 1:1600 1:400 to 1:1600 Immunogenic response Establishes immunity Establishes immunity Immunization of a group of rabbits with inactivated antigens from cultures (repeated at least 5 times) - Strain Trichophyton mentagrophytes DSM-7279 has been deposited according to the Budapest Treaty at the "Deutsche Sammlung von Mikroorganismen und Zellkulturen" (DSM), Mascheroder Weg 1B, W-38124 Braunschweig, Germany (which current name and address is "Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH" (DMSZ), InhoffenstraBe 7B, 38124 Braunschweig, GERMANY) on 1 October 1992 by Boehringer Ingelheim Vetmedica GmbH, 6507 Ingelheim am Rhein (which current address is Boehringer Ingelheim Vetmedica GmbH, 55216 Ingelheim am Rhein). The current depositors of said strain are the applicants, namely Dr. Igor Polyakov and Dr.sc.Dr. Liudmila Ivanova, Eberhardtstr. 40, 89073 Ulm.
- The strain Trichophyton verrucosum BINO 348 was deposited by the Binomed GmbH (EinsteinstraBe 59, 89077 Ulm) according to the Budapest Treaty at the - Leibniz-Institut DSMZ - Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, InhoffenstraBe 7B, 38124 Braunschweig, Germany under Serial No. DSM-28406 on 12 February 2014. The depositor has authorized the applicants to refer to the deposited biological material in the application and has given his unreserved and irrevocable consent to the deposited material being made available to the public in accordance with Rule 31 EPC. The strain was obtained by directed selection based on spore production and attenuation of epizootic strain Nr. 348, which was isolated from cattle in 1997. The strain was identified using the Rebell-Taplin key (Rebell,G.,Taplin, D.: Dermatophytes, their recognition and identification, 1978) and according to Kashkin, P.N. et.al. (opredelitel patogennykh, toksigenykh vrednykh dlya cheloveka gribov, 1979). The biological properties of the strain are described in Table J. Strain BINO 348-DSM 28406 differs from the epizootic strain in its faster growth in nutrient medium, the enormous production of microconidia, lower virulence and the absence of any adverse reactions after intramuscular application of antigens.
Table J Properties and characteristics of the strains Strain No. DSM-28406 Epidemic Strain No. 348 Description of the culture 20-day colony on Malt Extract Agar: white or light-yellow, velvety, furrowed, diameter of colony 15 - 20 mm 25-30-day colony in Malt Extract Agar: light-yellow crearn, velvety, folded, undersurface colorless, diameter of colony 10-12 mm Morphological characteristics Mature 20-day culture with numerous oval, pyriform microconidia measuring 1,5 -3 x 3 - 5 µm. Mature 25-30 day culture with septate branching mycelium, few oval, pyriform microconidia 1 to 3 µm x 3 to 6 µm, macroconidia with 2 to 6 septates, few arthrospores and chlamydospores 9-11 µm.Pathogenic characteristics The strain is weakly virulent. 9 -10 days after application of a dose of 500 -600 thousand cells of fungal material per cm2 on scarified skin of guinea pigs, scales are formed. Spontaneous recovery after 15 - 20 days. The strain is virulent. 9-10 days after application of a dose of 500-600 thousand cells of fungal material per cm2 on scarified skin of guinea pigs, thin necrotic scabs are formed. Spontaneous recovery after 25 - 30 days. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: inflammation at point of injection, oedema Immunogenic response Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity against dermatophytos cause by T.verrucosum Results of immunisation of a group of guinea pigs with inactivated antigen from cultures (repeated not less than 5 times): establishes immunity against dermatophytos cause by T.verrucosum - The strain Chrisporium tropicum BINO 122 was deposited by the Binomed GmbH (EinsteinstraBe 59, 89077 Ulm) according to the Budapest Treaty at the - Leibniz-Institut DSMZ - Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, InhoffenstraBe 7B, 38124 Braunschweig, Germany under Serial No. DSM-28405 on 12 February 2014. The depositor has authorized the applicants to refer to the deposited biological material in the application and has given his unreserved and irrevocable consent to the deposited material being made available to the public in accordance with Rule 31 EPC. The strain was obtained by directed selection based on spore production of field strain Nr.122, which was isolated from the soil in 1993. The strain was identified using the Rebell-Taplin key (Rebell,G.,Taplin, D.:Dermatophytes, their recognition and identification, 1978) and according to Carmichael, J.N. Chrysosporium and some other aleuriosporic hyphomycetes. - Can.J.Bot., 1962, 40, 1137-1173. The biological properties of the strain are described in Table K. Strain BINO 122-DSM 28405 is differ from the field strain in its faster growth in nutrient medium, the enormous production of conidia, weak virulence and the production of enzymes.
Table K Properties and characteristics of the strains Strain No. DSM-28405 Field Strain No. 122 Description of the culture 15-day colony on Malt Extract Agar is white, felty, powdery, diameter of colony 60 - 70 mm. Good growth at 26 C° as well as 37 C°. 15-day colony on Malt Extract Agar is white, felty, powdery, diameter of colony 55 - 65 mm. Good growth at 26 C° and 37 C°. Morphological characteristics Mature 15-day culture with numerous terminal and lateral conidia sessile or on short protrusions or side branches, smooth-walled, clavate or obovoidal, 3-6 x 6-9 µm. Mature 15-day culture with terminal and lateral conidia sessile or on short protrusions or side branches, smooth-walled, clavate or obovoidal, 3-6 x 6-9 µm. Pathogenic characteristics The strain is weakly virulent. 9 -10 days after application of a dose of 500 -600 thousand cells of fungal material per cm2 on scarified skin of guinea pigs, hyperemia and scales are formed. Spontaneous recovery after 13 - 15 days. The strain is weakly virulent. 9 - 10 days after application of a dose of 500 -600 thousand cells of fungal material per cm2 on scarified skin of guinea pigs, hyperemia and scales are formed. Spontaneous recovery after 13 - 15 days. Reaction response Result of cutaneous application of filtrate of culture: quick epithelium regeneration Result of cutaneous application of filtrate of culture: epithelium regeneration Biological properties - enzymatic activity; - enzymatic activity; - immunogenic activity against dermatophytosis; - immunogenic activity against dermatophytosis; - immunocorrection in allergy; - immunocorrection in allergy; - increased regeneration of the skin - regeneration of the skin - The strain Microsporum canis BINO 483 was deposited by the Binomed GmbH (EinsteinstraBe 59, 89077 Ulm) according to the Budapest Treaty at the - Leibniz-Institut DSMZ - Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, InhoffenstraBe 7B, 38124 Braunschweig, Germany under under Serial No. DSM-32271 on 25 February 2016. The depositor has authorized the applicants to refer to the deposited biological material in the application and has given his unreserved and irrevocable consent to the deposited material being made available to the public in accordance with Rule 31 EPC. The strain was obtained by directed selection based on spore production and attenuation of epizootic strain Nr. 483, which was isolated from cat in 1990. The strain was identified using the Rebell-Taplin key (Rebell,G.,Taplin, D.: Dermatophytes, their recognition and identification, 1978) and according to Kashkin, P.N. et.al. (opredelitel patogennykh, toksigenykh vrednykh dlya cheloveka gribov, 1979). The biological properties of the strain are described in Table L. vaccine strain 483 differs from the epizootic strain in its faster growth in nutrient medium, the enormous production of microconidia, lower virulence and the absence of any adverse reactions after intramuscular application of antigens.
Table L Properties and characteristics of the strains Vaccine Strain No. BINO 483 Epidemic Strain No. 483 Description of the culture 10-15-day colony on Malt Extract Agar: white, fluffy, convex, narrow growing margin, arachnoid, undersurface yellowish, diameter of colony 35 - 40 mm 15-day colony in Malt Extract Agar: greyish-beige, arachnoid, powdery in centre, growing margin fringed, undersurface brown, diameter of colony 25-30 mm Morphological characteristics Mature 15-day culture with septate branching hyphae 1 to 4 µm wide, numerous oval, pyriform, cylindrical microconidia measuring 1 µm to 3 µm x 3 µm to 7 µm, few fusiform macroconidia with 3 to 10 septates measuring 10 µm to 20 µm x 40 µm to 70µmMature 15-day culture with branching hyphae 2 to 6 µm wide, few pyriform, cylindrical microconidia measuring 1µm to 3 µm x 3 µm to 7 µm, numerous fusiform macroconidia with 3 to 11 septates measuring 10 µm to 20 µm x 45 µm to 85 µmPathogenic characteristics The strain is weakly virulent. 9 -11 days after application of a dose of 500 -600 thousand cells of fungal material per cm2 on scarified skin of a rabbit: necrotic scabs are formed. Spontaneous recovery after 15 - 25 days. The strain is virulent. 9 -11 days after application of a dose of 500 - 600 thousand cells of fungal material per cm2 on scarified skin of a rabbit: dense asbestos-like scabs are formed. Spontaneous recovery after 25 - 38 days. Reaction response Result of intramuscular injection of inactivated corpuscular antigens from cultures: no observed changes in clinical state of animals Result of intramuscular injection of inactivated corpuscular antigens from cultures: oedema and inflammation at point of injection, Immunogenic response Results of immunisation of a group of rabbits (5 animals in group) with life or inactivated antigen from cultures: establishes immunity against dermatophytos cause by Microsporum canis Results of immunisation of a group of rabbits (5 animals in group) with life or inactivated antigen from cultures: establishes immunity against dermatophytos cause by Microsporum canis - In a preferred embodiment the composition of the present invention comprises homogenised inactivated dermatophyte microconidia of one microconidia or a mixture of microconidia of two, three, four, five, six, seven, eight, nine or ten of the above listed strains of dermatophytes. In a further preferred embodiment the composition comprises a mixture of homogenised inactivated dermatophyte microconidia of one, two, three, four, five, six, seven, eight, nine or ten of the above listed dermatophytes and homogenised inactivated yeast blastospores of one, two, three, or four of the above listed yeasts. In a further preferred embodiment the composition comprises homogenised inactivated dermatophyte microconidia of one or a mixture of two, three, or four of the above listed yeasts. The compositions may additionally comprise antigenic material of dermatophyte microconidia and/or antigenic material of yeast blastospores.
- In a further preferred embodiment the composition comprises antigenic material of one dermatophyte microconidia or a mixture of antigenic material of dermatophyte microconidia of two, three, four, five, six, seven, eight, nine or ten of the above listed strains of dermatophyte. In a further preferred embodiment the composition comprises a mixture of antigenic material of dermatophyte microconidia of one, two, three, four, five, six, seven, eight, nine or ten of the above listed dermatophytes and antigenic material of yeast blastospores of one, two, three, or four of the above listed yeasts. In a further preferred embodiment the composition comprises antigenic material of yeast blastospores of one or a mixture of two, three, or four of the above listed yeasts. The compositions may additionally comprise homogenised inactivated dermatophyte microconidia of one, two, three, four, five, six, seven, eight, nine or ten of the above listed dermatophytes and/or homogenised inactivated yeast blastospores of one, two, three, or four of the above listed yeasts.
- In a preferred embodiment the composition for use of the present invention comprises a mixture of homogenised inactivated dermatophyte microconidia of Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton equinum, Trichophyton sarkisovii, Microsporum canis, Microsporum canis var.obesum, Microsporum canis var. distortum and Microsporum gypseum. For example, the vaccine Polivac-TM (manufacturer: "Vetbiochim" LLC, Moscow; Distributor: "Prostore" LLC, Moscow) is in accordance with this embodiment and can be comprised in a composition of the present invention. Polivac-TM is a vaccine designed for animals such as cats, dogs, horses and others.
- In a further preferred embodiment the composition of the present invention comprises a mixture of homogenised inactivated dermatophyte microconidia of Trichophyton mentagrophytes, Trichophyton verrucosum and Trichophyton sarkisovii. For example, the vaccine Polivac-T (manufacturer: "Vetbiochim" LLC, Moscow; Distributor: "Prostore" LLC, Moscow) is in accordance with this embodiment and can be comprised in the composition of the present invention. Polivac-T is a vaccine specifically designed for cattle.
- If the composition of the present invention comprises dermatophyte microconidia of only one strain or yeast blastospores of only one strain said dermatophyte microconidia or yeast blastospores can be prepared as follows:
- (i) growing a dermatophyte and a yeast, respectively, on suitable solid medium, harvesting and homogenising the dermatophyte, and
- (ii) inactivating the homogenate obtained in step (i)
- If the composition of the present invention comprises a mixture of dermatophyte microconidia and/or yeast blastospores said mixture can be prepared as follows:
- (i) growing one dermatophyte strain and two, three, four, five, six, seven, eight, nine or ten distinct strains of dermatophytes, respectively, separately on suitable solid medium, harvesting each culture and homogenising each culture separately, and
- (ii) optionally, growing one yeast strain and two, three or four distinct strains of yeast, respectively, separately on suitable solid medium, harvesting each culture and homogenising each culture separately, and
- (iii) combining and inactivating the homogenates obtained in step (i) and optionally obtained in step (ii).
- The growing of the dermatophytes of the above described preparation processes is preferably done on agar and wort in culture flasks. Preferably, the culture is performed for about 15 to about 30 days. Preferably, the cultivation is performed at a temperature of about 26°C to about 28°C. The growing of the yeasts of the above described preparation processes is preferably done on malt extract-agar or agar Sabouraud in culture flasks. Preferably, the culture is performed for about 4 to about 7 days. Preferably, the cultivation is performed at a temperature of about 28 to about 37°C.
- After cultivation the dermatophytes and yeasts, respectively, are homogenized to obtain a fine suspension. Preferably the homogenization is performed in deionized water, in an aqueous solution comprising about 0.1 to 0.3% fermented hydrolysed muscle protein or about 0.1 to 1 % soy or pork peptone in combination with about 5 to 6% glucose and about 0.1 to 1 % yeast extract, or in an aqueous solution comprising 0.1-0.9% (w/v) modified chitosan according to the present invention.
- Suitable volumes for homogenization are about 100 to 500 ml. Preferably, the concentration of microconidia and blastospores, respectively, is adjusted to about 30 to about 90 million microconidia and blastospores, respectively, per ml or to about 250 to about 500 thousand, more preferably about 250 to about 400 thousand microconidia and blastospores, respectively, per ml. Then, the suspension may optionally be additional adjusted to about 40, 50 or 60 million of microconidia and blastopores, respectively, per ml or to about 250 to about 500 thousand, more preferably to about 250 to about 400 thousand microconidia and blastospores, respectively, per ml with distilled water, physiological salt solution as e.g. sodium chloride or another suitable solution. In case of the preparation of a mixture, the single suspensions are preferably adjusted to the same amount of microconidia and blastospores, respectively, per ml and equal volumes of each culture in suspension are mixed in a single container.
- The inactivation is preferably performed by using thiomersal, formaldehyde and/or 2-propiolactone. The agents for inactivating can be added directly to the cell suspension. Preferred is an inactivation by adding thiomersal in a ratio of about 1:11000 to about 1:2500 (w/v). Also preferred is an inactivation by adding formaldehyde to reach an end concentration of about 0.2% to about 0.4% (v/v). Subsequently, the mixture is preferably incubated. The incubation can be performed for about 1 to 30 days at a temperature of about 20°C to about 37°C. Preferred is incubation for about 1 to 3 days at room temperature, for about 5 to 7 days at 37°C, for about 30 days at room temperature or for about 30 days at about 26°C to 28 °C.
- In a preferred embodiment the microconidia of the compositions of the present invention are in a swollen condition and/or have germ tubes. More preferably, at least 50% of the blastospores and/or microconidia are in a swollen condition and/or have germ tubes. The swollen condition and/or the germ tubes of dermatophytes can e.g. be obtained by a second incubation step. Said second incubation step is preferably performed after the homogenization and before inactivation as described above. For performing the second cultivation step the microconidia suspension is placed in a separate vessel containing the same medium of the first incubation step. The second cultivation step is preferably performed for about 10 to about 48 hours. The second cultivation step is preferably performed at a temperature of about 28°C. Preferably, the second cultivation step is continued until at least 50% of the microconidia display a swollen or germinating condition and no more than about 7 to 10% of the cells display a second mycelial branch. The diameter of swollen and germinated microconidia is increased by about 1.2 or more compared to regular microconidia.
- The antigenic material of yeast blastospores and/or dermatophyte microconidia preferably comprises polysaccharides and/or glycopeptides isolated from keratinophilic fungi or yeasts. Preferably, said antigenic material can be antigenic nonsoluble material (ANMP), antigenic soluble material (ASMP) or antigenic exogenous material (AEMP). The keratinophilic fungi are preferably of the species Trichophyton or Microsporum, more preferably Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton equinum, Trichophyton sarkisovii, Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum gypseum, Microsporum canis and Chrisporium tropicum, and the keratinophilic yeasts are preferably of the species Candida, more preferably Candida albicans. Especially preferred is antigenic material derived from Trichophyton mentagrophytes DSM - 7279, Trichophyton verrucosum DSM - 28406, Trichophyton rubrum DSM - 9469, Trichophyton rubrum DSM - 9470, Trichophyton rubrum DSM - 9471, Trichophyton rubrum DSM - 9472, Chrisporium tropicum DSM-28405, Candida albicans DSM - 9456, Candida albicans DSM - 9457, Candida albicans DSM - 9458, and Candida albicans DSM - 9459. The antigenic material is, for example, obtainable by the method disclosed in
WO 97/07232 - In general for obtaining ANMP, the fungal cells belonging to the group of keratinophilic fungi or yeasts are treated under aqueous alkaline conditions, the solid and liquid phases of the preparation are separated, and after separation the solid phase is treated with mineral or organic acid. The treatment under aqueous alkaline conditions is preferably performed with about 0.1 to 5 % (w/v) KOH or NaOH at about 20°C to 150°C for up to 30h. The solid phase is preferably treated with 0.2 to 1.5 M organic acid or 0.05 to 1 M mineral acid and washed with an aqueous solution. More specifically, the keratinophilic fungi or yeasts are preferably cultivated on Agar plates. One preferred medium is for example malt extract agar from Oxoid. Other media that will ensure growth of keratinophilic fungi or yeast may be used as well. The resulting fungal biomass was lifted off and treated with the aqueous solution of alkali. Subsequently, the solid and liquid phases of the preparation are separated, for example by centrifugation, filtration or sedimentation. Preferably, the separation is performed by centrifugation, e.g. at 3500g, which allows good separation of the fungal cell debris. Both the treatment under aqueous alkaline conditions and the separation step may be repeated several times. After alkaline treatment, the resulting supernatant is treated under the acidic aqueous conditions as outlined above. For example, HCl or acetic acid can be used. The treatment with acid is preferably performed for about 0.5 to about 3 hours. The temperature is preferably in the range of about 70 to about 100°C. The aqueous solution for washing is preferably distilled water. Advantageously, the washing is repeated about five times. Finally, the solid phase is lifted off and homogenized in water for injection or in an aqueous solution of 0.1-0.9% solution of the modified chitosan, chitosan variant or chitosan derivative according to the present invention. The homogenization is preferably performed in a volume of about 100 to about 500 ml. The concentration of particles is then preferably adjusted to about 30 to 90 million particles per ml. Finally, the preparation comprising the antigenic material can be lyophilised and stored under dry conditions.
- ASMP can generally be obtained as follows: Fungal cells of keratinophilic fungi or yeasts are treated under aqueous alkaline conditions, the solid and liquid phases of the preparation are separated, after separation the supernatant is treated with mineral or organic acid, and after separation ASMP is precipitated from the supernatant. More particularly, keratinophilic fungi or yeasts are cultivated on Agar plates, for example as described in
EP 0564620 . One preferred medium is for example malt extract agar from Oxoid. Other media that will ensure growth of keratinophilic fungi or yeast may be used as well. The resulting fungal biomass was lifted off and treated with an aqueous solution of alkali. Preferred aqueous alkaline solutions are NaOH or KOH at preferred concentrations of 0.1-5% (w/v). Alkaline treatment is preferably performed at about 20 -150°C for up to 30h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation are separated, for example, by centrifugation, filtration or sedimentation. Preferably, the separation is achieved by centrifugation, which ensures good separation of the fungal cell debris, for example, at forces of about 3500g. The treatment under aqueous alkaline conditions, as well as the separation step, may be repeated several times. After the alkaline treatment and separation, the resulting supernatant is treated under acidic aqueous conditions, e.g. 0.2-1.5M organic acid or 0.05-1M mineral acid. For example, HCl or acetic acid can be used, preferably at pH values of about pH 2.5 to pH 4.5. Preferably, the treatment under aqueous acidic conditions is for about 2 to 4 hours at temperatures of about 4 to 8°C, where after separation of the solid and liquid layers took place. The treatment under aqueous acidic conditions, as well as the separation step, may be repeated several times, preferably under conditions as above indicated. Then, the supernatant from the separation step was subjected to a precipitation step. Preferably, the precipitation was performed by adding a suitable organic solvent, e.g. an alcohol such as a lower alkanol, for example methanol or ethanol. A ratio of one volume supernatant to 2-5 volumes of alcohol will result in a good precipitation of the antigenic material. Other nonalcoholic precipitation procedures known to the person skilled in the art may be used as well, for example, ammonium sulphate or other salt precipitation. The solid phase is then subject to a further separation step, preferably under conditions as described above. The resulting solid phase is recovered and, if desired, dissolved in an aqueous solution, preferably in distilled water, typically in a volume of about 25 to 100 ml. Finally, the ASMP preparation can be lyophilized and stored for prolonged time periods under dry conditions. - AEMP can generally be obtained as follows: fungal cells of keratinophilic fungi or yeasts are cultivated in liquid medium, the solid phase and liquid phases of the preparation are separated, and after separation AEMP is precipitated from the supernatant. More particularly, keratinophilic fungi or yeasts may be incubated in aqueous solution or cultivated in liquid medium. As well as the keratinophilic fungi may be incubated in aqueous solution with keratin. The cultivation may be for up to about 240 to 250 hours. The volume of the solution or culture is here defined as primary volume (PV). Distilled water can be used as well as media described in
EP 0564620 . After incubation or cultivation, the fungal cells are separated, for example, by centrifugation, filtration or sedimentation, preferably by centrifugation under conditions as described above. Optionally, the resulting supernatant is then lyophilized and subsequently dissolved in aqueous solution, preferably in water. Preferably, the volume of water is about 0.1 to 0.2 volumes of the primary volume (PV). The resulting solution or the resulting supernatant obtained after separation is then subject to a precipitation step. Preferably, the precipitation was performed by adding a suitable organic solvent, e.g. an alcohol such as a lower alkanol, for example methanol or ethanol. A ratio of one volume supernatant to about 1 to 5 volumes of alcohol will result in a good precipitation of the antigenic material. Other nonalcoholic precipitation procedures known to the person skilled in the art may be used as well, for example ammonium sulphate or other salt precipitation. The resulting precipitate is recovered and, if desired, dissolved in an aqueous solvent, preferably in distilled water. Preferably, about 0.5 to 50mg of the precipitate are dissolved in 1 ml aqueous solvent. Finally, the AEMP solution can be lyophilized and stored for prolonged time periods under dry conditions, preferably at about 2 to 10°C. - In a particularly preferred embodiment the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention inactivated dermatophyte microconidia of Trichophyton mentagrophytes, in particular of Trichophyton mentagrophytes DSM - 7279.
- In a further particularly preferred embodiment the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention inactivated dermatophyte microconidia of Trichophyton verrucosum, in particular of Trichophyton verrucosum DSM - 28406.
- In a further particularly preferred embodiment the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention inactivated yeast blastospores of Candida albicans, in particular of Candida albicans DSM - 9456.
- In a further particularly preferred embodiment the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention ASMP of Candida albicans, in particular of Candida albicans DSM - 9456.
- In a further particularly preferred embodiment the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention ANMP of Candida albicans, in particular of Candida albicans DSM - 9456.
- In a further particularly preferred embodiment the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention a mixture of homogenised inactivated dermatophyte microconidia of Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton equinum, Trichophyton sarkisovii, Microsporum canis, Microsporum canis var.obesum, Microsporum canis var. distortum and Microsporum gypseum and optionally ASMP of Candida albicans, in particular of Candida albicans DSM - 9456. More preferably, the composition of the present invention comprises the vaccine Polivac-TM and optionally ASMP of Candida albicans, in particular of Candida albicans DSM - 9456.
- In a further particularly preferred embodiment the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid of the present invention AEMP of Chrisporium tropicum, in particular of Chrisporium tropicum DSM - 28405, or of Microsporum canis BINO 483.
- The concentration of inactivated dermatophyte microconidia and/or yeast blastospores in the composition of the present invention is preferably about 30 to about 90, more preferably about 45 to about 80 million microconidia and blastospores, respectively, per ml or about 250 to about 500 thousand, more preferably about 250 to about 300 thousand microconidia and blastospores, respectively, per ml. The concentration of ASMP in the composition of the present invention is preferably about 50 to about 500 µg/ml, more preferably about 100 to about 400 µg/ml. The concentration of ANMP in the composition of the present invention is preferably about 30 to about 90, more preferably about 40 to about 80 million per ml. The concentration of Polivac-TM in the composition of the present invention is preferably about 40 million per ml to about 50 million per ml, more preferably about 40 million per ml to about 45 million per ml. The concentration of AEMP in the composition of the present invention is preferably 0.5 to about 2 U/ml, more preferably about 1 to about 1.2 U/ml.
- The composition of the present invention is preferably a pharmaceutical composition which comprises a pharmaceutical acceptable diluent, excipient and/or carrier. Thus, the present invention also refers to a pharmaceutical composition comprising a modified chitosan or the hydro colloid according to the present invention and a pharmaceutical acceptable diluent, excipient and/or carrier.
- The concentration of the modified chitosan or the hydro colloid in the compositions or pharmaceutical compositions of the present invention is preferably about 0.1% to about 2.0% (w/v), more preferably about 0.1% to about 1.4% (w/v), more preferably about 0.1% to about 1% (w/v), more preferably about 0.1% to about 0.5% (w/v) more preferably about 0.1% to about 0.3% (w/v).
- Another aspect of the present invention is the compound, the modified chitosan, the hydro colloid and/or the composition of the present invention for use in human and/or veterinary medicine. Preferably, the compound, the modified chitosan, the hydro colloid or the composition of the present invention is for use as a vaccine in human and/or veterinary medicine.
- The present invention also refers to the compound, the modified chitosan, the hydro colloid and/or the composition of the present invention for use in a method of treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis, interdigital phlegmon, trichophytosis, microsporosis, mycosis of skin, allergies, as well as diseases complicated by allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, in particular dermatitis, ear erythema, rhinitis, conjunctivitis, dermatophytosis or warts, in particular Common warts, in a subject.
- The present invention also refers to the compound, the modified chitosan, the hydro colloid and/or the composition of the present invention for use in a method of modulating the immune response in a subject and/or for enhancing reproduction efficiency, preferably reproduction efficiency in animal breeding.
- The subject may for example be a human or an animal, in particular a mammal, more preferably bovidae and/or pigs, most preferably cattle, but also dogs, cats or other farm or domestic animals.
- In a particularly preferred embodiment the invention refers to a composition comprising the modified chitosan, the hydro colloid or compound according to the present invention and inactivated dermatophyte microconidia of Trichophyton mentagrophytes, in particular of Trichophyton mentagrophytes DSM - 7279, for use in a method of treating and/or preventing interdigital dermatitis, digital dermatitis and/or interdigital phlegmon in animals, in particular in bovidae and/or pigs, most preferably in cattle.
- In a further particularly preferred embodiment the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and inactivated dermatophyte microconidia of Trichophyton verrucosum, in particular of Trichophyton verrucosum DSM - 28406, for use in a method of treating and/or preventing interdigital dermatitis, digital dermatitis, interdigital phlegmon, and/or trichophytosis in animals, in particular in bovidae and/or pigs, most preferably in cattle.
- In a further particularly preferred embodiment the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and inactivated yeast blastospores of Candida albicans, in particular of Candida albicans DSM - 9456, for use in a method of treating and/or preventing interdigital dermatitis, digital dermatitis and/or interdigital phlegmon, in particular in bovidae and/or pigs, most preferably in cattle.
- In a further particularly preferred embodiment the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and ASMP of Candida albicans, in particular of Candida albicans DSM - 9456, for use in a method of treating and/or preventing allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, ear erythema, rhinitis, conjunctivitis, dermatophytosis or warts, in particular Common warts, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, in particular dermatitis, ear erythema, rhinitis or conjunctivitis in humans and/or animals, in particular a mammals, more preferably in companion animals, most preferably dogs, cats and/or horses, but also cattle, pigs or other farm or domestic animals.
- In a further particularly preferred embodiment the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and ANMP of Candida albicans, in particular of Candida albicans DSM - 9456, for use in a method of treating and/or preventing interdigital dermatitis, digital dermatitis and/or interdigital phlegmon in animals, in particular in bovidae and/or pigs, most preferably in cattle.
- In a further particularly preferred embodiment the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and a mixture of homogenised inactivated dermatophyte microconidia of Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton equinum, Trichophyton sarkisovii, Microsporum canis, Microsporum canis var.obesum, Microsporum canis var. distortum and Microsporum gypseum and optionally ASMP of Candida albicans, in particular of Candida albicans DSM - 9456. More preferably, the composition of the present invention comprises in addition to the modified chitosan or the hydro colloid or compound of the present invention the vaccine Polivac-TM and optionally ASMP of Candida albicans, in particular of Candida albicans DSM - 9456, for use in a method of treating and/or preventing trichophytosis or dermatophytosis in animals, in particular in bovidae and/or pigs, most preferably in cattle.
- In a further particularly preferred embodiment the invention refers to a composition comprising the modified chitosan or the hydro colloid or compound according to the present invention and AEMP of Chrisporium tropicum, in particular of Chrisporium tropicum DSM - 28405 or Microsporum canis BINO 483, for use in a method of treating and/or preventing allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, ear erythema, rhinitis, conjunctivitis, dermatophytosis, mycosis of skin or warts, in particular Common warts, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, in particular dermatitis, ear erythema, rhinitis or conjunctivitis in humans and/or animals, in particular a mammals, more preferably bovidae and/or pigs, most preferably cattle or horses, but also dogs, cats or other farm or domestic animals.
- The modified chitosan, the hydro colloid, the compound and the compositions of the present invention are able to modulate the immune system, i.e. they have immunostimulatory properties. They can be used as a vaccine for preventing the subject from the diseases as outlined herein. Alternatively or in addition, they can be used to treat and cure the subject from the diseases as outlined herein. The modified chitosan, the hydro colloid and the compositions can be administered by known administration routes as e.g. oral, parenterally, by intramuscular injection, by intracutaneous injection, by percutaneous injection, by instillation, intracisternally, intrauterine, rectal, subcutaneous and/or topically, preferably cutaneously, more preferably intramuscular injection and/or intracutaneous injection and/or topically on the skin and/or topically on the mucous membrane. They may be administered in the absence or in the presence of one or more additional immunostimulatory substances. In one embodiment said one or more additional immunostimulatory substances are administered separately to the modified chitosan, compound or compositions of the present invention. In another embodiment the one or more additional immunostimulatory substances are comprised in or added to the compositions of the present invention.
- Said one or more immunostimulatory substance is preferably an adjuvant, preferably selected from the group consisting of vitamin-E acetate, o/w-emulsion, aluminium phosphate, aluminium oxide, aluminium hydroxide/methyl cellulose gel, an oil-emulsion, muramil-dipeptides, Freund's adjuvants and saponins and/or at least one cytokine, preferably selected from the group consisting of
IL 2, IL 12 and INF-Gamma. - In a preferred embodiment the compositions of the present invention is a vaccine and/or is used as a vaccine.
- In a further aspect the present invention relates to a modified chitosan, a hydro colloid a compound or a composition of the present invention for use in a method of treatment of the animal and/or human body by therapy. Such method typically comprises administering to a subject an effective amount of the modified chitosan a composition, preferably a pharmaceutical composition, or the hydro colloid of the present invention. The subject may for example be a human or an animal, in particular a mammal, more preferably bovidae and/or pigs, most preferably cattle, but also dogs, cats or other farm or domestic animals. In particular, the modified chitosan, the hydro colloid or the compositions, in particular pharmaceutical compositions, of the present invention may be used in methods for the treatment or prevention of the diseases as outlined above. The method of treatment may comprise the treatment and/or prevention of bacterial, mycotic and/or viral infections of the skin, the ear, the lung, the nose, the leg, the hoof, the claws, the back of the foot and/or the interdigital space. Said infections may be caused by Dichelobacter nodosus, Fusobacterium necroforun, Fusobacterium spp, Treponema spp such as T. phagedenis, T. vincentii, and T. denticola, Campylobacter spp, Staphylococcus aureus, Escherichia coli, Arcanobacterium pyogenes, Prevotella spp., Trichophyton spp. such as T. verrucosum, T. mentagrophytes, T. sarkisovii, T. equinum, T. schonleinii, T. rubrum,T. tonsurans, T. interdigitale, and/or Microsporum spp. such as M. canis, M. canis var. distortum, M. canis var. obesum, M. gypseum, and/or Malassezia spp. such as M. pachydermatitis, M. furfur, M. dermatitis and/or HPV- Human Papillomavirus from genera Papillomavirus family Papovaviridae such as HPV-2, HPV-3, HPV-4, HPV-6, HPV-11.
- The dosage and route of administration used in a method of treatment and/or prophylaxis according to the present invention depends on the specific disease/site of infection to be treated. The route of administration may be for example oral, parenterally, by intramuscular injection, by intracutaneous injection, by percutaneous injection, by instillation, intracisternally, intrauterine, rectal, subcutaneous and/or topically, preferably cutaneously, more preferably intramuscular injection and/or intracutaneous injection and/or topically on the skin and/or topically on the mucous membrane or any other route of administration.
- Preferred doses for the composition of the present invention are about 0.001 to about 0.5 ml/kg with a concentration of about 0.1 mg/ml to about 1.0 mg/ml and/or about 30x106 to about 80x106 microconidia and/or blastospores and/or particles of ANMP. Preferably, the composition of the present invention is administered about 1 to about 5 times. The interval between the administrations is preferably about 12 hours to about 21 days.
- The following examples explain the present invention but are not considered to be limiting.
- 40 g of the polysaccharide chitosan was sterilized by autoclavation and added under stirring to 8 liters of sterile water for injection acidified with 40 ml of 100% acetic acid to obtain a suspension. The suspension was mixed in a sterile tank for 24 hours to obtain a gel suspension. Undissolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm. 4 N sodium hydroxide (NaOH) were added dropwise to the gel to obtain a final pH of 8.0. Upon that white flakes precipitated. The suspension was stirred for 30 minutes. The resultant biological material of the precipitate contained in its structure diacetylated chitosan. The precipitate was harvested by centrifugation for 50 minutes at 4500 revolutions per minutes.
- The obtained suspended material was homogenized in a closed sterile homogenizer in 7 liters of sterile water for injection. 8 mL of 98% valerianic acid chloride (valeryl chloride, pentanoyl chloride) were added dropwise to the suspension under constant stirring. Subsequently, the suspension was stirred for 24 hours. To support the dissolution of flakes and unsolved particles 4N hydrochloric acid solution was added under stirring until the suspension had a pH of 5.8. Sterile water for injection was added to obtain an end volume of 8 liters. After that the modified polysaccharide was used to prepare the final product.
- Characteristics of the obtained biological material comprising modified chitosan:
Parameters Characteristics Chemical formula unknown Appearance Clear gel Smell Absent or faint smell of acetic acid Deacetylation > 93% Mineral content >0.9% Solubility in water Soluble Solubility in 1% solution of acetic acid Soluble - The second stage. For obtaining the
final product 2 liters of the biological material comprising modified chitosan were adjusted to a volume of 15 liters by adding sterile water for injection under stirring. Then 500 ml of chlorocresol solution containing 30 grams chlorocresol were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant suspension was sterilized by heating for 40 minutes at 70°C three times at intervals of 24 hours. The resultant sterile product was dispensed into vials under aseptic conditions. - 4 g of the polysaccharide chitosan was added under stirring to 0.8 liters of sterile water for injection to obtain a suspension. 4 ml of 100% acetic acid were added and the suspension was mixed in a sterile tank for 24 hours to obtain a gel suspension. Undissolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm. 4 N sodium hydroxide (NaOH) were added dropwise to the gel to obtain a final pH of 8.0. Upon that white flakes precipitated. The suspension was stirred for 40 minutes. The resultant biological material of the precipitate contained in its structure diacetylated chitosan. The precipitate was harvested by centrifugation for 45 minutes at 4500 revolutions per minutes.
- The obtained suspended material was homogenized in a closed sterile homogenizer in 4 liters of sterile water for injection. 0.8 mL of 98% valerianic acid chloride (valeryl chloride, pentanoyl chloride) were added dropwise to the suspension under constant stirring. Subsequently, the suspension was stirred for 24 hours. To support the dissolution of flakes and unsolved particles 4N hydrochloric acid solution was added under stirring until the suspension had a pH of 5.5. After that the modified polysaccharide was used to prepare the final product.
- Characteristics of the obtained biological material comprising modified chitosan:
Parameters Characteristics Chemical formula unknown Appearance Clear gel Smell Absent or faint smell of acetic acid Deacetylation > 93% Mineral content >0.9% Solubility in water Soluble Solubility in 1% solution of acetic acid Soluble - The second stage. For obtaining the final product 200 ml of the modified chitosan were resuspended in 1.5 liters of sterile water for injection and 50 ml of chlorocresol solution containing 2g of the active substance were added under stirring. The obtained suspension was adjusted to a volume of 2 liters. The obtained suspension was sterilized by heating for 40 minutes at 70°C three times with intervals of 24 hours. The resultant sterile product was dispensed into vials under aseptic conditions.
- 80 g of the polysaccharide chitosan was sterilized by autoclavation and added under stirring to 16 liters of sterile water for injection acidified with 80 ml of 100% acetic acid to obtain a suspension. The suspension was mixed in a sterile tank for 24 hours to obtain a gel suspension. Undissolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm. 4 N sodium hydroxide (NaOH) were added dropwise to the gel to obtain a final pH of 8.0. Upon that white flakes precipitated. The suspension was stirred for 50 minutes. The resultant biological material of the precipitate contained in its structure diacetylated chitosan. The precipitate was harvested by centrifugation for 60 minutes at 5000 revolutions per minutes.
- The obtained suspended material was homogenized in a closed sterile homogenizer in 4 liters of sterile water for injection. 16 mL of 98% valerianic acid chloride (valeryl chloride, pentanoyl chloride) were added dropwise to the suspension under constant stirring. Moreover, 4 liters of sterile water for injection was added and 3% solution of glutamic acid was added under stirring until the suspension had a pH of 5.0. Sterile water for injection was added to obtain an end volume of 8 liters. The suspension was stirred after that for 24 hours. After that the modified polysaccharide was used to prepare the final product.
- Characteristics of the obtained biological material comprising modified chitosan
Parameters Characteristics Chemical formula unknown Appearance Clear gel Smell Absent or faint smell of acetic acid Deacetylation > 90% Mineral content >0.8% Solubility in water Soluble Solubility in 1% solution of acetic acid Soluble - The second stage. For obtaining the final product 4000 ml of the modified chitosan were resuspended in 30 liters of sterile water for injection and 50 ml of chlorocresol solution containing 40g of the active substance were added under stirring. The obtained suspension was adjusted to a volume of 40 liters. The obtained suspension was sterilized by heating for 45 minutes at 72°C three times with intervals of 24 hours. The resultant sterile product was dispensed into vials under aseptic conditions.
- 16 g of the polysaccharide chitosan (deacetylation of 65%-72%, viscosity of 151 - 350 mPas, 80-200 kDa) was sterilized by autoclavation and added under stirring to 3 liters of sterile water for injection acidified with 164 ml of 100% acetic acid to obtain a suspension. The suspension was mixed in a sterile tank for 24 hours to obtain a gel suspension. Undissolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm. 4 N sodium hydroxide (NaOH) were added dropwise to the gel to obtain a final pH of 8.5. Upon that white flakes precipitated. The suspension was stirred for 30 minutes. The resultant biological material of the precipitate contained in its structure diacetylated chitosan. The precipitate was harvested by centrifugation for 50 minutes at 5000 revolutions per minutes.
- The obtained suspended material was homogenized in a closed sterile homogenizer in 1 liters of sterile water for injection. 0.6 mL of 98% valerianic acid chloride (valeryl chloride, pentanoyl chloride) were added dropwise to the suspension under constant stirring. Moreover, a 0.5% solution of paraaminobenzoic acid was added under stirring until the suspension had a pH of 5.4. Sterile water for injection was added to obtain an end volume of 1.6 liters. The suspension was stirred after that for 24 hours. After that the modified polysaccharide was used to prepare the final product.
- Characteristics of the obtained biological material comprising modified chitosan
Parameters Characteristics Chemical formula unknown Appearance Clear gel Smell Absent or faint smell of acetic acid Deacetylation > 89% Mineral content >1,0% Solubility in water Soluble Solubility in 1% solution of acetic acid Soluble - The second stage. For obtaining the final product 1000 ml of the modified fraction were resuspended in 8 liters of sterile water for injection and 200 ml of chlorocresol solution containing 10g of the active substance were added under stirring. The obtained suspension was adjusted to a volume of 10 liters. The obtained suspension was sterilized by heating for 45 minutes at 65°C three times with intervals of 24 hours. The resultant sterile product was dispensed into vials under aseptic conditions.
- The product is prepared from chitosan. The product is prepared in two stages. The first stage is oriented to obtain a chitosan solution; the second stage is oriented to obtain the final product.
- 40 g chitosan (deacetylation of 82%-87%, a viscosity of 151 - 350 mPas, molecular weight 150-300 kDa) was sterilized by autoclavation and added under stirring to 3.5 liters of sterile water for injection. 40 ml of 100% acetic acid were added to the obtained suspension and the volume was adjusted to an final volume of 4 liters with water for injection. The suspension was stirred in a sterile container for 24 hours until a gel suspension was obtained. 4 N sodium hydroxide (NaOH) were added dropwise to the obtained suspension to obtain a final pH of 8.0. Upon that white flakes precipitated. The suspension was stirred for 30 minutes. The resultant biological material of the precipitate contained in its structure a linear diacetylated polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine (chitosan). The precipitate was harvested by centrifugation for 55 minutes at 4500 revolutions per minutes.
- The precipitate was suspended in 4 liters of sterile water for injections and 4N hydrochloric acid were added under stirring to obtain a pH of 5.4. The suspension was stirred for 24 hours until all flakes were dissolved and a gel suspension was obtained. The gel suspension was used to prepare the final product.
- The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture under stirring. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared from chitosan. The product was prepared in two stages. The first stage is oriented to obtain a solution of modified chitosan; the second stage is oriented to obtain the final product.
- The first stage. Chitosan with a deacetylation of 62%-67%, a viscosity of 70 - 200 mPas and a molecular weight of 100-250 kDa was used as raw material. 40 grams of the polysaccharide was sterilized by autoclaving and added into 3.5 liters of water for injection under stirring. 40 ml of 100% acetic acid were added to the obtained suspension. The final volume was adjusted with water for injection to 4 liters. Suspended polysaccharide was stirred in a sterile container for 24 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell size of 200 µm - 300 µm. 4 N sodium hydroxide (NaOH) were added dropwise to the prepared suspension to obtain a final pH of 8.0. Upon that white flakes precipitated. The suspension was stirred for 30 minutes. The received biological material contained in its structure a linear diacetylated polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine (chitosan). The precipitate was harvested by centrifugation for 60 minutes at 4500 revolutions per minutes.
- 4 mL 98% of valerian acid chloride was add of dropwise to the suspension under the constant stirring. The obtained suspended material was stirred for one hour. Flakes and unsolved particles were resuspended in 4 liters of sterile water for injections and 4N hydrochloric acid was added under stiring to get a pH of 5.0. The suspension is stirred for 28 hours until all flakes were dissolved and a gel suspension was obtained.
- The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under sterile conditions. - The product was prepared from chitosan. The product was prepared in two stages. The first stage was oriented to obtain a solution of modified chitosan; the second stage was oriented to obtain the final product.
- The first stage. Chitosan with a deacetylation of 77%-82%, a viscosity of 2700 - 3300 mPas and a molecular weight of 300-700 kDa was used as raw material. 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 40 ml of 100% acetic acid were added to the obtained suspension. The final volume was adjusted to 4 liters with water for injection. Suspended polysaccharide was stirred in a sterile container for 30 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm. 4 N sodium hydroxide (NaOH) were added dropwise to the obtained suspension to obtain a final pH of 8.0. Upon that white flakes precipitated. The suspension was stirred for 30 minutes. The resultant biological material contained in its structure a linear diacetylated polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine (chitosan). The precipitate was harvest by centrifugation for 45 minutes at 5000 revolutions per minutes.
- 8 mL of 90% lactic acid were added dropwise to the suspension under the constant stirring. The obtained suspended material was stirred for one hour. Flakes and unsolved particles were resuspended in 4 liters of sterile water for injections and 4N hydrochloric acid were added under stirring until a pH of 5.6 is obtained. The suspension is stirred for 48 hours until all flakes were dissolved and a gel suspension was obtained.
- The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared from chitosan. The product was prepared in two stages. The first stage was oriented to obtain a solution of modified chitosan, the second stage was oriented to obtain the final product.
- The first stage. Chitosan with a deacetylation of 82%-87%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material. 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 40 ml of 100% acetic acid were added to the obtained suspension. The final volume was adjusted to 4 liters with water for injection. The suspended polysaccharide was stirred in a sterile container for 36 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm. 4 N sodium hydroxide (NaOH) were added dropwise to the obtained suspension to obtain a final pH of 8.0. Upon that white flakes precipitated. The suspension was stirred for 30 minutes. The resultant biological material contained in its structure a linear diacetylated polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine (chitosan). The precipitate was harvest by centrifugation for 50 minutes at 4500 revolutions per minutes.
- A 0.2% solution of paraaminobenzoic acid was added to the precipitate under constant stirring up to 4 liters. The obtained suspended material was stirred for one hour. Flakes and unsolved particles were suspended in solution of paraaminobenzoic acid and 4N hydrochloric acid were added under stirring until a pH of 5.6 is obtained. The suspension was stirred for 70 hours until all flakes were dissolved and a gel suspension was obtained.
- The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared from chitosan. The product was prepared in two stages. The first stage was oriented to obtain a solution of modified chitosan; the second stage was oriented to obtain the final product.
- The first stage. Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material. 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 40 ml of 100% acetic acid were added to the obtained suspension. The final volume was adjusted with water for injection to 4 liters. Suspended polysaccharide was stirred in a sterile container for 24 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm. 4 N sodium hydroxide (NaOH) were added dropwise to the obtained suspension to obtain a final pH of 8.0. Upon that white flakes precipitated. The suspension was stirred for 30 minutes. The resultant biological material contained in its structure a linear diacetylated polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine (chitosan). The precipitate was harvested by centrifugation for 60 minutes at 4500 revolutions per minutes.
- A 0.1% solution of sodium salt of glucuronic acid was added to the precipitate under constant stirring up to 4 liters. The obtained suspended material was stirred for one hour. Flakes and unsolved particles were resuspended in solution of glucuronic acid and 4N hydrochloric acid were added under stirring until a pH of 5.6 was obtained. The suspension was stirred for 72 hours until all flakes were dissolved and a gel suspension was obtained.
- The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared from chitosan. The product was prepared in two stages. The first stage was oriented to obtain a solution of chitosan; the second stage was oriented to obtain the final product.
- The first stage. Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material. 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 8 ml of 98% sodium salt of valerianic acid were added to the obtained suspension. The final volume was adjusted to 4 liters with water for injection. The suspended polysaccharide was stirred in a sterile container for 48 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm.
- The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared from chitosan. The product was prepared in two stages. The first stage was oriented to obtain a solution of chitosan; the second stage was oriented to obtain the final product.
- The first stage. Chitosan with deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material. 40 grams of polysaccharide was sterilized by autoclaving and added to 3.9 liters of 0.2 % paraaminobenzoic acid in water for injection under stirring. 4N hydrochloric acid solution were added under stirring until getting a pH of 5.6 and to obtain a gel suspension. The final volume was adjusted to 4 liters with water for injection. Suspended polysaccharide was stirred in a sterile container for 72 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm.
- The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared from chitosan. The product was prepared in two stages. The first stage was oriented to obtain a solution of chitosan; the second stage was oriented to obtain the final product.
- The first stage. Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material. 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of a 0.1% solution of sodium salt of glucuronic acid under stirring. To obtain a gel suspension 4N hydrochloric acid solution was added under stirring until getting a pH of 5.0. The final volume was adjusted with water for injection to 4 liters. Suspended polysaccharide was stirred in a sterile container for 78 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm.
- The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared from chitosan. The product was prepared in two stages. The first stage was oriented to obtain a solution of chitosan; the second stage was oriented to obtain the final product.
- The first stage. Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material. 40 grams of the polysaccharide was sterilized by autoclaving and added to 3.5 liters of water for injection under stirring. 8 ml of 90% lactic acid were added to the obtained suspension. For dissolving the flakes and particles 4N hydrochloric acid solution was added until getting a pH of 5.7. The final volume was adjusted with water for injection to 4 liters. Suspended polysaccharide was stirred in a sterile container for 36 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm.
- The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 1 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 5.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.6 grams of active substance were added to the mixture. The resultant suspension was adjusted to the volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 5 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 6.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 2 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - Product prepared was prepared by performing the 1st stage of the example 5 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 7.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.8 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 5 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 8.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.8 grams of active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 5 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 9.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 6 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 9.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 6 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 8.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of thimerosal containing 1.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 6 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 8.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of formalin containing 80 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 6 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 9.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 35 liters by adding sterile water for injection under stirring. Then, 500 mL of formalin solution containing 85 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 40 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 5 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 15 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 6 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 15 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 7 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of thimerosal containing 1.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of formalin solution containing 30 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 9 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of thimerosal containing 0.6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 6 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 5 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 6 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 6 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 7 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 5 liters by adding sterile water for injection under stirring. Then, 500 ml of thimerosal containing 0.24 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 6 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 5 liters by adding sterile water for injection under stirring. Then, 500 ml of formalin solution containing 12 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 6 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 9 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 5 liters by adding sterile water for injection under stirring. Then, 500 ml of merthiolate solution containing 0.24 grams of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 6 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of neomycin solution containing 150 g of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of penicillin sodium and potassium salts solution containing 300 g (300.000.000 UE) of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared according to the example 8 with the difference that in the second stage of preparation for obtaining the
resultant product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then, 500 ml of penicillin sodium and potassium salts solution containing 300 g (300.000.000 UE) of the active substance and 500 ml of neomycin solution containing 150 g of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 7 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 8.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 15 liters by adding sterile water for injection under stirring. Then, 500 ml of formalin solution containing 30 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 20 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 7 in the volume of 2 liters and by mixing it with 2 liters of the product prepared according to the example 6.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 15 liters by adding sterile water for injection under stirring. Then, 500 ml of formalin solution containing 30 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 20 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - The product was prepared by performing the 1st stage of example 7 in the volume of 5 liters.
- The second stage. For obtaining the
final product 4 liters of the modified polysaccharide were adjusted to a volume of 15 liters by adding sterile water for injection under stirring. Then 500 ml of formalin solution containing 30 mL of the active substance were added to the mixture. The resultant suspension was adjusted to a volume of 20 liters. The resultant sterile product was dispensed into vials under aseptic conditions. - Dermatophyte culture of the species Trichophyton mentagrophytes DSM - 7279 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of the product obtained according to example 6, but with the following difference in the second stage: The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was added to the fungal suspension to obtain a concentration of 45-80 million microconidia per ml for each homogenate. The homogenates were inactivated by adding formaldehyde directly to the cell suspension so that the cell suspension contained 0.2% (v/v) formaldehyde in the end. The mixture was incubated for 5-7 days at 37°C. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- Dermatophyte culture of the species Trichophyton verrucosum DSM - 28406 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of the product prepared according to example 8 but with the following difference in the second stage: The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was added to the suspension to obtain a concentration of 45-80 million per ml for homogenate. The homogenates were inactivated by adding formaldehyde directly to the cell suspension so that the cell suspension contained 0.4% (v/v) formaldehyde in the end. The mixture was incubated for 5-7 days at 37°C. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon and/or trihophytosis in animals.
- The species Candida albicans DSM - 9456 was cultivated on malt extract-agar or agar Sabouraud, for example in 3-10 Roux flasks. The Culture was cultivated for 4 -7 days at 28-37°C. The blastospores were washed off with a physiological solution of sodium chloride or another suitable solution. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of the product prepared according to example 9 but with the following difference in the second stage: The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The resultant sterile product was added to the suspension to obtain a concentration of 40-90 million microconidia per ml for the homogenate. The homogenates were inactivated by adding formaldehyde directly to the cell suspension so that the cell suspension contained 0.3% (v/v) formaldehyde in the end. The mixture was incubated for 5-7 days at 37°C. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- First step: The species Candida albicans DSM - 9456 was cultivated on malt extract-agar from Oxoid in 40 Roux flasks. The culture was cultivated for 4 -7 days at 28-37°C as described in
EP 0564620 . The resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with a concentration of 3% (w/v). Said alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g. 50% acetic acid at a pH of 4.0 for 2 hours at temperatures of 4° to 8°C, whereafter separation of the solid and liquid layers took place. Then, the supernatant from the separation step was subjected to a precipitation step. The precipitation was performed by adding ethanol. A ratio of one volume supernatant to 3 volumes of alcohol resulted in good precipitation of the antigenic material. Finally, the ASMP preparation was lyophilised. Finally, the solid phase was lifted off and homogenised in the product obtained according to example 6, but with the following difference in the second stage:
The second stage. For obtaining thefinal product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The concentration of ASMP was adjusted to 400 µg per ml. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of allergies.
- First step: The species Candida albicans DSM - 9456 was cultivated on malt extract-agar from Oxoid in 50 Roux flasks. The culture was cultivated for 4 -7 days at 28-37°C as described in
EP 0564620 . The resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with a concentration of 3% (w/v). Alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g. 50% acetic acid at a pH of 4.0 for 2 hours at temperatures of 4° to 8°C, whereafter separation of the solid and liquid layers took place. Then, the supernatant from the separation step was subjected to a precipitation step. The precipitation was performed by adding ethanol. A ratio of one volume supernatant to 3 volumes of alcohol resulted in good precipitation of the antigenic material. Finally the ASMP preparation was lyophilised. - Finally the solid phase was lifted off and homogenised in the product obtained according to example 8, but with the following difference in the second stage: The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The concentration of ASMP was adjusted to 200 µg per ml. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of allergies.
- First step: The species Candida albicans DSM - 9456 was cultivated on malt extract-agar from Oxoid in 50 Roux flasks. Culture was cultivated for 4 -7 days at 28-37°C as described in
EP 0564620 . The resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with concentrations of 3% (w/v). Alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g. 50% acetic acid at pH 4.0 for 2 hours at temperatures of 4° to 8°C, whereafter separation of the solid and liquid layers took place. Then, the supernatant from the separation step was subjected to a precipitation step. The precipitation was performed by adding ethanol. A ratio of one volume supernatant to 3 volumes of alcohol resulted in good precipitation of the antigenic material. Finally the ASMP preparation was lyophilised. - Finally the solid phase was lifted off and homogenised in the product obtained according to example 9, but with the following difference in the second stage: The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The concentration of ASMP was adjusted to 100 µg per ml. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of allergies.
- The fraction preparable according to this process consists of antigenic nonsoluble material comprising polysaccharide and/or glycopeptides (ANMP) according to
PCT/EP96/03535 . The species Candida albicans DSM - 9456 was cultivated on malt extract-agar from Oxoid in 50 Roux flasks. The culture was cultivated for 4 -7 days at 28-37°C as described inEP 0564620 . The resulting fungal biomass was lifted off and treated with an aqueous solution of alkali with concentrations of 4%(w/v) NaOH. The treatment was performed at 80°C for up to 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at forces of about 3500g. After alkaline treatment, the solid phase was treated with a 50% solution of acetic acid. After acidic treatment the solid phase was washed with distilled water for five times. Finally the solid phase was lifted off and homogenised in the product obtained according to example 6, but with the following difference in the second stage: The second stage. For obtaining thefinal product 3 liters of the modified polysaccharide were adjusted to a volume of 25 liters by adding sterile water for injection under stirring. Then, 500 ml of chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 30 liters. The concentration of particles was adjusted to 30-90 million per ml. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- Dermatophyte culture of the species Trichophyton verrucosum DSM - 28406 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte was lifted off and homogenised in an aqueous solution (for example 100-500 ml) of the product obtained according to example 6, but with the following difference in the second stage: The second stage. For obtaining the
final product 3 liters of the modified polysaccharide were adjusted to a volume of 10 liters by adding sterile water for injection under stirring. Then 500 ml of a chlorocresol solution containing 30 grams of the active ingredient were added to the mixture. The resultant suspension was adjusted to a volume of 15 liters. The resultant sterile product was added to the fungal suspension to obtain a concentration of 45-60 million microconidia per ml for each homogenate. The homogenates were inactivated by adding formaldehyde directly to the cell suspension so that the cell suspension contained 0.2% (v/v) formaldehyde in the end. The mixture was incubated for 5-7 days at 37°C. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of trichophytosis in cattle.
- A solution of biological material containing in its structure a linear polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine modified by 0.2% of paraaminobenzoic acid was added to the vaccine Polivac-TM against dermatophytosis of animals (manufacturer: "Vetbiochim" LLC, Moscow; Distributor: "Prostore" LLC, Moscow) to reach a final concentration of 0.3% (w/v). The pH of the solution was about 5.6. The concentration of microconidia was 40 million per ml.
- Vaccine preparable according to this method can be used for the prophylaxis and treatment of dermatophytosis in animals.
- Candida albians DSM - 9456 was cultivated on Agar plates as described in
EP 0564620 . One preferred medium was for example malt extract agar from Oxoid. The resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with a concentration of 3% (w/v). Alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g. 50% acetic acid at pH 4.0 for 2 hours at a temperature of 4° to 8°C, whereafter separation of the solid and liquid layers took place. Then, the supernatant from the separation step was subjected to a precipitation step. A ratio of one volume supernatant to 3 volumes of alcohol resulted in good precipitation of the antigenic material. Finally the ASMP preparation was lyophilised. - A solution of biological material containing in its structure a linear polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine modified by 0.5% of paraaminobenzoic acid was added to the vaccine Polivac-TM against dermatophytosis of animals (manufacturer: "Vetbiochim" LLC, Moscow; Distributor: "Prostore" LLC, Moscow) to reach a final concentration of 0.3% (w/v). The pH of the solution was about 5.8. The concentration of microconidia was 40 million per ml. Finally the solid phase of ASMP was mixed with modified vaccine Polivac-TM. The concentration of ASMP was adjusted to 400 µg per ml.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of dermatophytosis in animals.
- Keratinase Pure 70 produced by PROTEOS Biotech, 14 Almansa Street, 02006 Albacete, Spain was used to prepare a solution containing 2 U/ml. Candida albians DSM - 9456 was cultivated on Agar plates as described in
EP 0564620 . One preferred medium was for example malt extract agar from Oxoid. The resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with concentrations of 3% (w/v). Alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g. 50% acetic acid at pH 4.0 for 2 hours at temperatures of 4° to 8°C, whereafter separation of the solid and liquid layers took place. Then, the supernatant from the separation step was subjected to a precipitation step. A ratio of one volume supernatant to 3 volumes of alcohol resulted in good precipitation of the antigenic material. Finally the ASMP preparation was lyophilised. - The solution of Keratinase Pure 70 was mixed in an aqueous solution (for example 100-500 ml) of 0.3% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine modified of paraaminobenzoic acid prepared according to example 8 (First stage). The concentration of Keratinase Pure 70 was adjusted to 1-1.2 U per ml. Formalin was added to reach 0.2% (v/v) in end suspension. The mixture was incubated for 5-7 days at 37°C. Finally the solid phase of ASMP was lifted off and homogenised in an aqueous suspension of modified linear polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine. The concentration of ASMP was adjusted to 200 µg per ml.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of dermatophytosis in animals.
- Dermatophyte culture of the species Microsporum canis BINO 483 was cultivated on agar/wort, for example in 3-10 Roux flasks for 21 day at 26-28°C. Suspension of the microconidia was cultivated in media with keratin and dermatophytes exoantigens were obtained according to RF patent 2219945 as follows: The obtained suspension with concentration of microconidia of 40x106 to 50x106 was cultivated for 7 days under stirring at a temperature of 29°C. Subsequently, formalin was added to obtain an end concentration of 0.4%. The liquid phase was separated by three steps of filtration - through a metal grid with a cell of 200 µm - 300 µm, than through Whatman paper filter No.4 (
size 20 µm to 25 µm) and in end through nylon filter for sterilisation with size 0.22 µm, but in the process of formalin preservation surprisingly found increased antigenic activity of the fractions obtained (AEMP). The dermatophytes exoantigens AEMP were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine modified of paraaminobenzoic acid according to example 8. The concentration of AEMP was adjusted to 1-1.2 U per ml. Formalin was added to reach 0.2% (v/v) in the end suspension. The mixture was incubated for 5-7 days at 37°C. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of dermatophytosis in animals.
- Fungi culture of the species Chrisporium tropicum DSM-28405 was cultivated on agar/wort, for example in 3-10 Roux flasks for 21 days at 26-28°C. Subsequently, the obtained suspension of microconidia was cultivated in media with keratin and exoantigens were prepared according to RF patent 2219945 as follows: The obtained suspension with a concentration of microconidia of 50x106 to 60x106 was cultivated for 7 days under stirring at a temperature of 30°C. Then, formalin in end concentration of 0.4% was added. The liquid phase was separated by three steps of filtration - through a metal grid with a cell of 200 µm - 300 µm, than through Whatman paper filter No.4 (
size 20 µm to 25 µm) and in end through nylon filter for sterilisation with size 0.22 µm, but in the process of formalin preservation surprisingly found increased antigenic activity of the fractions of exoantigens (AEMP). The soluble exoantigens of fungi AEMP were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine modified of paraaminobenzoic acid according to example 8. The concentration of AEMP was adjusted to 1-1.2 U per ml. Formalin was added to reach 0,2% (v/v) in end suspension. The mixture was incubated for 5-7 days at 37°C. - Vaccine preparable according to this method can e.g. be used for the treatment of dermatophytosis and allergic diseases in animals.
- Dermatophyte culture of the species Trichophyton verrucosum DSM - 28406 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine modified by valeric acid chloride according to example 6. The concentration of microconidia was adjusted to 250-300 thousand per ml. The homogenates were inactivated by adding formaldehyde directly to the cell suspension to reach 0.2% (v/v) in end. The mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- Dermatophyte culture of the species Trichophyton mentagrophytes DSM -7279 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine modified of paraaminobenzoic acid according to example 8. The concentration of microconidia was adjusted to 250-300 thousand per ml. The homogenates were inactivated by adding formaldehyde to reach 0.2% (v/v) in end directly to the cell suspension. The mixture was incubated for 5-7 days at 37°C.Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- Dermatophyte culture of the species Trichophyton verrucosum DSM - 28406 was cultivated on agar/wort, for example in 3-10 Roux flasks. The culture was cultivated for 15-30 days at 26-28°C. The fungal masses of the dermatophyte were lifted off and homogenised in an aqueous solution (for example 100-500 ml) of 0.2% solution of biological material contained in its structure a linear polysaccharide of N-acetyl-1,4-β-D-glucopyranosamine modified by glucuronic acid according to example 9. The concentration of microconidia was adjusted to 250-300 thousand per ml. The homogenates were inactivated by adding formaldehyde directly to the cell suspension to reach 0.1% (v/v) in end. The mixture was incubated for 5-7 days at 37°C.
- Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of interdigital and /or digital dermatitis and/or interdigital phlegmon in animals.
- The first stage. Chitosan with a deacetylation of 67%-72%, a viscosity of 151 - 350 mPas and a molecular weight of 150-300 kDa was used as raw material. 40 grams of the polysaccharide was sterilized by autoclaving and 3.9 liters of 0.2 % paraaminobenzoic acid in water for injection were added under stirring. To obtain the gel suspension 4N hydrochloric acid solution was added under stirring until getting a pH of 5.6. The final volume was adjusted with water for injection to 4 liters. Suspended polysaccharide was stirred in a sterile container for 72 hours until a gel suspension was obtained. Unsolved particles were removed by filtration through a metal grid with a cell of 200 µm - 300 µm. Candida albians DSM - 9456 was cultivated on Agar plates as described in
EP 0564620 . One preferred medium was for example malt extract agar from Oxoid. The resulting fungal biomass was lifted off and treated with an aqueous solution of NaOH with a concentration of 3% (w/v). Alkaline treatment was performed at 80°C for 6h. Following the processing under aqueous alkaline conditions, the solid and liquid phases of the preparation were separated by centrifugation at 3500g. After the alkaline treatment, the resulting supernatant was treated under acidic aqueous conditions, e.g. 50% acetic acid at pH 4.0 for 2 hours at a temperature of 4° to 8°C, whereafter separation of the solid and liquid layers took place. Then, the supernatant from the separation step was subjected to a precipitation step. The precipitation was performed by adding ethanol. A ratio of one volume supernatant to 3 volumes of alcohol resulted in good precipitation of the antigenic material. Finally the ASMP preparation was lyophilised. The solid phase was lifted off and homogenised in the product obtained according to example 6, but with the following difference in the second stage: The second stage. For obtaining the final product 0.3 liters of the modified polysaccharide were adjusted to a volume of 2.5 liters by adding sterile water for injection under stirring. Then 500 ml of thiomersal solution containing 0.24 grams of the active ingredient were added to the mixture. The resulting suspension was adjusted to a volume of 6 liters. The concentration of ASMP was adjusted to 100 µg per ml. - Vaccine preparable according to this method can e.g. be used for the prophylaxis and treatment of allergies.
- An analysis for the presence of glucans was carried out.
- The 1,3-β-D-analyses (Cape Cod, USA). The test was performed as described in the manufacturer's Glucan content in antigen samples was determined using the CE-marked Fungitell® assay for serum Instructions. In brief, the test is a protease zymogen-based colorimetric assay and makes use of a modification of the Limulus Amebocyte Lysate (LAL) pathway. The Fungitell reagent is modified to eliminate Factor C and, thus, to only react with 1,3-β-D-Glucan. Unknown samples are mixed with the assay reagent and the mean rate of optical density change is calculated for all datapoints over an interval of 40 min. By comparison to an in parallel generated Standard curve, the amount of 1,3-β-D-Glucan in the samples can be calculated.
- Test Solutions of the antigens No.1-13 were prepared in sterile ddH20 and, subsequently, further dilutions were prepared in pyrogen-free LAL reagent grade water. Based on the results of the endotoxin testing, the highest dilution with detectable gel-clotting and one dilution above and below were measured in the Fungitell assay. Each sample was measured in duplicate in a 20 sec interval in a total of 40 min.
- For
Standard curve generation 1,3-β-D-Glucan Solutions of 100 pg/ml, 50 pg/ml, 25 pg/ml, 12.5 pg/ml and 6.25 pg/ml were prepared as recommended by the manufacturer (Fig. 1 ). The measured curve was linear over the entire range and meets the quality control acceptance criteria (R2 > 0.980). The standard curve is shown inFigure 1 .Table 1. On the basis of above shown curve the following 1,3-β-D-Glucan contents were detected in the test Solutions of analyzed samples: No. Example 1,3-β-D-Glucan content Analyzed dilutions based on the test Solution (bold indicates dilution for 1 1 115 ng/ml 1:100, 1:1000, 1:10,000 2 2 133 ng/ml 1:100, 1:1000, 1:10,000 3 3 123 ng/ml 1:100, 1:1000, 1:10,000 4 4 110 ng/ml 1:100, 1:1000, 1:10,000 5 7 45 pg/ml 1:10, 1:100, 1:1000 6 20 55 pg/ml 1:10, 1:100, 1:1000 7 18 25 pg/ml 1:10, 1:100, 1:1000 8 20 21 pg/ml 1:10, 1:100, 1:1000 9 26 50 pg/ml 1:10, 1:100, 1:1000 10 27 70 pg/ml 1:10, 1:100, 1:1000 11 28 110 pg/ml 1:10, 1:100, 1:1000 12 29 90 pg/ml 1:10, 1:100, 1:1000 13 30 120 pg/ml 1:10, 1:100, 1:1000 14 31 132 pg/ml 1:10, 1:100, 1:1000 mg > µg > ng > pg - An analysis for the presence of endotoxins was carried out.
- Endotoxin content in antigen samples was determined using the gel-clot method according to EP 2.6.14.
- Test Solutions of the antigens No.1-7 were prepared in sterile H20 and, subsequently, dilutions from 1:10 to 1:10,000,000 were prepared in pyrogen-free LAL reagent grade water. The dilutions were measured in duplicate and endotoxin concentration was calculated using the following formula:
tablle 4 -
Table 2 No. Example Endotoxin content [lU/ml] Highest dilution factor with gel- clot formation 1 1 60-600 1:1000 2 2 60-600 1:1000 3 3 60-600 1:1000 4 4 60-600 1:1000 5 7 0.06-6 < 1:100 6 20 60-600 1:1000 7 18 6-60 1:100 8 20 0.06-6 < 1:100 9 26 0.06-6 < 1:100 10 27 0.06-6 < 1:100 11 28 0.06-6 < 1:100 12 29 0.06-6 < 1:100 13 30 0.06-6 < 1:100 14 31 0.06-6 < 1:100 IU, International (endotoxin) units - An analysis for the antimicrobial activity was carried out.
- The antimicrobial activity of compounds was analyzed by the "Test for efficacy of antimicrobial preservation" according to the following procedure. To count the viable microorganisms in the inoculated products, the agar medium used for the initial cultivation of the respective microorganisms was used. A series of containers of the product to be examined was inoculated, each with a suspension of one of the test organisms to give an inoculum of 105 to 106 microorganisms per millilitre or per gram of the preparation. The volume of the suspension of inoculum did not exceed 1 per cent of the volume of the product. To ensure homogeneous distribution it was thoroughly mixed. The inoculated product was maintained at 20-25°C, protected from light. A suitable sample was removed from each container, typically 1 mL or 1 g, at zero hour and at appropriate intervals according to the type of the product and the number of viable microorganisms was determined by plate count or membrane filtration (2.6.12). It was ensured that any residual antimicrobial activity of the product was eliminated by dilution, by filtration or by the use of a specific inactivator. When dilution procedures was used, due allowance was made for the reduced sensitivity in the recovery of small numbers of viable microorganisms. When a specific inactivator was used, the ability of the system to support the growth of the test organisms was confirmed by the use of appropriate controls. The procedure was validated to verify its ability to demonstrate the required reduction in count of viable microorganisms.
- In brief, 4 x 10 ml of test Solution (prepared with ddH20) were inoculated each with 0.1 ml (1% v/v) of the test-microorganisms Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans and Aspergillus brasiliensis. 6 hpi (hours post inoculation), 24 hpi, 7 dpi (days post inoculation) and 14 dpi samples were drawn and numbers of viable microorganisms were determined by plating a dilution series on agar plates. The elimination of putative residual antimicrobial activity of the test Compounds by dilution was proofed prior to test Performance.
Table 3 Time Microorganism Compound according to Example 6 Compound according to Example 8 Compound according to Example 15 Recovered viable microorganisms and reduction factors in log10 [cfu/ml] 0 hpi P. a. 2.00 2.30 2.40 S. a. 3.97 4.30 4.50 C. a. 5.18 4.82 4.95 A.b. 5.79 5.72 5.79 6 hpi P. a. 0.00 (2.00) 0.00 (2.30) 0.00 (2.30) S. a. 0.00 (3.97) 2.74(1.56) 0.00(2.30) C. a. 3.04(2.14) 0.00 (4.82) 0.00 (4.82) A.b. 5.70 (0.09) 5.61 (0.11) 5.61 (0.11) 24 hpi P. a. 0.00 (2.00) 0.00 (2.30) 0.00 (2.30) S. a. 1.20(2.77) 1.82(2.48) 1.82(2.48) C. a. 0.00(5.18) 0.00 (4.82) 0.00 (4.82) A.b. 5.70 (0.09) 5.75 (-0.03) 5.75 (-0.03) 7 dpi P. a. 0.00 (2.00) 0.00 (2.30) 0.00 (2.30) S. a. 0.00 (3.97) 0.00 (4.30) 0.00 (4.30) C. a. 0.00(5.18) 0.00 (4.82) 0.00 (4.82) A.b. 5.82 (-0.03) 5.83 (-0.11) 5.83 (-0.11) 14 dpi P. a. 0.00 (2.00) 0.00 (2.30) 0.00 (2.30) S. a. 0.00 (3.97) 0.00 (4.30) 0.00 (4.30) C. a. 0.00(5.18) 0.00 (4.82) 0.00 (4.82) A.b. 5.89 (-0.10) 5.72 (0.00) 5.72 (0.00) P. a., Pseudomonas aeruginosa; S. a., Staphylococcus aureus; C. a., Candida albicans; A. b., Aspergillus brasiliensis; reduction factors in relation to 0 hpi are indicated in brackets. - Cows with latent (subclinical) mastitis were treated. The diagnosis was made by a usual procedure with 2% solution of mastidin. The animals were divided into 13 groups with 6 animals in each group. All groups of cows were treated by 10 ml of the preparation intracisternally twice with an interval of 24 hours. All the animals were re-tested with a 2% solution of mastidin by the standard procedure on
day 7 and day 14. - The results are shown in Table 4.
of group of example of animals Frequency of drug administration Amount of healthy animals on day 7 after the last administrationin day 14 after the last administration 1 1 6 2 3 4 2 2 6 2 4 4 3 3 6 2 3 3 4 4 6 2 3 3 5 5 6 2 3 3 6 6 6 2 4 3 7 7 6 2 4 4 8 8 6 2 4 4 9 9 6 2 4 4 10 10 6 2 4 4 11 11 6 2 4 4 12 12 6 2 4 4 13 16 6 2 4 4 - Cows with latent (subclinical) mastitis were treated. The diagnosis was made by a usual procedure with 2% solution of mastidin. The animals were divided into 14 groups with 10 animals in each group. All groups of cows were treated by 10 ml of the preparation intracisternally thrice with an interval of 24 hours. All the animals were re-tested with a 2% solution of mastidin by the standard procedure on
day 5. - The results are shown in Table 5.
of group of example of animals Frequency of drug administration Amount of healthy animals on day 5 after thelast administration 1 8 10 3 6 2 13 10 3 6 3 14 10 3 5 4 16 10 3 8 5 17 10 3 5 6 18 10 3 6 7 19 10 3 5 8 20 10 3 6 9 25 10 3 8 10 26 10 3 6 11 27 10 3 6 12 32 10 3 10 13 33 10 3 10 14 34 10 3 10 - Cows with latent (subclinical), clinical mastitis and purulent-catarrhal endometritis were treated. The diagnosis was made by a usual procedure with 5% solution of dimastin for mastitis and clinical symptoms for endometritis. All cows were administered by 10 ml of the preparation manufactured according to example 13 intracisternally or intrauterine twice or trice with the interval of 24 hours. All the animals were re-tested with a 5% solution of dimastin by the standard procedure and clinical observation on
day 7. - The results are shown in Table 6.
No. Identification (Id) no. of animal Disease Frequency of drug administration on day 7 after thelast administration 1 2273 Clinical mastitis 3 Recovery 2 2547 Clinical mastitis 2 Recovery 3 2234 Clinical mastitis 3 Recovery 4 2451 Latent mastitis 3 Recovery 5 2664 Latent mastitis 3 Recovery and relapse on day 56 2510 Latent mastitis 3 Recovery 7 2523 Purulent- catarrhal endometritis 3 Recovery 8 2653 Latent mastitis 3 Recovery 9 2463 Latent mastitis 3 Recovery - Cows with latent (subclinical) mastitis were treated. The diagnosis was made by a usual procedure with 5% solution of dimastin for mastitis and clinical symptoms for endometritis. All cows were administered by 10 ml of the preparation manufactured according to example 26 intracisternally or intrauterine twice or trice with the interval of 24 hours. All the animals were re-tested with a 5% solution of dimastin by the standard procedure and clinical observation on
day 7. - The results are shown in Table 7.
No. Id no. of animal Disease Frequency of drug administration on day 1 after the last administration1201 Latent mastitis 3 Latent mastitis 9262 Latent mastitis 3 Recovery 1180 Latent mastitis 3 Recovery 5324 Latent mastitis 3 Latent mastitis 1101 Latent mastitis 3 Recovery 1363 Latent mastitis 3 Latent mastitis 9249 Latent mastitis 3 Recovery 9210 Latent mastitis 3 Recovery 7250 Latent mastitis 3 Latent mastitis 0 0127 Latent mastitis 3 Recovery - Thus, the obtained immunobiological preparation makes possible treatment of mastitis of cows, which can be widely used in controlling of this widespread disease.
- Cows with latent (subclinical) mastitis were treated. The diagnosis was made by a usual procedure with 5% solution of dimastin for mastitis and clinical symptoms for endometritis. All cows were administered by 10 ml of the preparation manufactured according to example 26 intracisternally or intrauterine twice or trice with the interval of 24 hours. All the animals were re-tested with a 5% solution of dimastin by the standard procedure and clinical observation on day 7.59% of animals were recovered after treatment.
-
- Cows with clinical evidence of lameness, lesions of the interdigital space, which are typical for DD, ID and IP, were treated with various drugs. Therapeutic application of vaccine: 3 times with an interval of 7 days with a dose of 5 ml. Vaccine was prepared according to examples 45, 40 and 6.
- Clinical manifestation of disease:
- + Recovering, or gray, no pain
- ++ in healing, <2 cm, yellow, light pain
- +++lesions > 2 cm, yellow, moderate pain
- ++++ acute disease> 2 cm, red, significant pain
- The results are shown in Table 9.
of group of example of animals/ clinical manifestation Frequency of drug administration Amount of healthy animals In 30-35 days after the first application In 53-55 days after the first application 1 45 10/ 3 10 10 6 ++ 4 +++ 2 40 10/ 3 10 10 5 ++ 4 +++ 1 ++++ 3 6 10/ 3 10 10 7 ++ 3 +++ - Cows with clinical evidence of lameness, lesions of the interdigital space, which are typical for DD, ID and IP, were treated with various drugs. Therapeutic application of vaccine: 3 times with an interval of 10 days of vaccine prepared according to example 45.
- Clinical manifestation of disease:
- + Recovering, or gray, no pain
- ++ in healing, <2 cm, yellow, light pain
- +++ lesions > 2 cm, yellow, moderate pain
- ++++ acute disease> 2 cm, red, significant pain
- The results are shown in Table 10.
of group Amount of animals of animals with clinical manifestation Frequency of drug administration/dose Amount of animals with clinical manifestation In 33 days after the first application In 60 days after the first application 1 17 5 ++ 3/ 5 ml 11/+ 17/+ 12 ++++ 7/++ 2 23 7 ++ 3/ 2,5 ml 9/+ 23/+ 8 +++ 5/++ 8 ++++ 9/+++ - Cows with clinical evidence of lameness, lesions of the interdigital space, which are typical for DD, ID and IP, were treated with various drugs. Therapeutic application of vaccine: 3 times with an interval of 10 days of vaccine prepared according to example 45.
- Clinical manifestation of disease:
- + Recovering, or gray, no pain
- ++ in healing, <2 cm, yellow, light pain
- +++ lesions > 2 cm, yellow, moderate pain
- ++++ acute disease> 2 cm, red, significant pain
- The results are shown in Table 11.
of group Amount of animals of animals with clinical manifestation Frequency of drug administration/dose Amount of animals with clinical manifestation In 51 days after the first application 1 19 19 ++++ 3/ 5 ml 5/+ 7/++ 5/+++ 2 -culled for slaughter 2 18 18 ++++ 3/ 3,0 ml 1/+ 4/++ 6/+++ 2/++++ 5 -culled for slaughter dose 5 ml. - Cows with clinical evidence of lameness, lesions of the interdigital space, which are typical for DD, ID and IP, were treated with various drugs. Therapeutic application of vaccine: 3 times with an interval of 7 days in a dose of 5 ml. Vaccine was prepared according to examples 38, 39, 40 and 44.
- Clinical manifestation of disease:
- + Recovering, or gray, no pain
- ++ in healing, <2 cm, yellow, light pain
- +++lesions > 2 cm, yellow, moderate pain
- ++++ acute disease> 2 cm, red, significant pain
- The results are shown in Table 12.
of group of example of animals/clinical manifestation Frequency of drug administration Amount of healthy animals In 30-35 days after the first application In 53-55 days after the first application 1 38 10/ 3 5/+ 7/+ 5 ++ 5/++ 3/++ 5 +++ 2 39 10/ 3 6/+ 6/+ 5 ++ 4/++ 4/++ 5 +++ 3 40 10/ 3 5/+ 7/+ 6 ++ 5/++ 3/++ 4 +++ 4 44 10/ 3 4/+ 6/+ 4 ++ 5/++ 4/++ 6 +++ 1/+++ - Cows with clinical evidence of lameness, lesions of the interdigital space, which are typical for DD, ID and IP, were treated with various drugs. Therapeutic application of vaccine: 3 times, 0.4 ml intracutaneous with an interval of 7 days. Vaccine was prepared according to examples 51 and 52.
- Clinical manifestation of disease:
- + Recovering, or gray, no pain
- ++ in healing, <2 cm, yellow, light pain
- +++lesions > 2 cm, yellow, moderate pain
- ++++ acute disease> 2 cm, red, significant pain
- The results are shown in Table 13.
of group of example of animals/clinical manifestation Frequency of drug administration Amount of healthy animals In 35-40 days after the first application In 55-60 days after the first application 1 51 100/ 3 50/+ 70/+ 50 ++ 50/++ 30/++ 50 +++ 2 52 100/ 3 60/+ 60/+ 50 ++ 40/++ 40/++ 50 +++ - Dose titration study. Vaccination of cows against DD, ID and IP was done. Prophylactic application of vaccine: 2 times with an interval of 10 days of vaccine prepared according to example 6.
- Clinical manifestation of disease were investigated:
- + Recovering, or gray, no pain
- ++ in healing, <2 cm, yellow, light pain
- +++ lesions > 2 cm, yellow, moderate pain
- ++++ acute disease> 2 cm, red, significant pain
- The results are shown in Table 14.
73 days after application Dose 1 ml Dose 2.5 ml Control 100 animals 100 animals 215 animals 7 animals + 7 animals + 21 animals + 18 animals ++ 6 animals +++ doses 1 ml and 2.5 ml in this time was about 93%. 45 animals (about 21%) from control group were with clinical symptoms of DD, ID and IP. - The results are shown in Table 15.
107 days after application of vaccine Dose 1 ml Dose 2.5 ml Control 100 animals 100 animals 215 animals 7 animals + 9 animals + 11 animals + 12 animals ++ 4 animals - culled for slaughter 4 animals - culled for slaughter 9 animals +++ 27 animals - culled for slaughter - The results are shown in Table 16.
170 days after application of vaccine Dose 1 ml Dose 2,5 ml Control 100 animals 100 animals 215 animals 25 animals + 41 animals + 112 animals + Additional 6 animals - culled for slaughter Additional 3 animals - culled for slaughter Additional 42 animals - culled for slaughter - This investigation demonstrate prophylactic vaccination of animals with dose 1.0 ml. Duration of immunity was about 5.5 month.
- Vaccination of cows against DD, ID and IP was done. Prophylactic application of vaccine: 3 times intracutaneous with a dose of 0.4 ml in an interval of 10 days of vaccine prepared according to example 51.
-
Observation before vaccination Amount of animals/clinical manifestations of DD, ID and IP 200/100 In 160 to 175 days after last vaccination Amount of animals/amount of limbs with lameness 200/20 Amount of healthy animals 180 Efficacy of vaccination 90% -
Observation before vaccination Amount of animals/clinical manifestations of DD, ID and IP 200/100 In 160 to 175 days after last application of placebo Amount of animals/amount of animals with manifestations of Clinical symptoms of DD, ID and IP 200/132 Amount of healthy animals 68 Amount of ill animals during of observation time 66% - All animals with clinical symptom of deseases were treated with local application of aseptic medicine or antibiotics. In case of IP intramuscular injection of antibiotics were used.
- Vaccination of cows against DD, ID and IP was done. Prophylactic application of vaccine: 3 times intracutaneous with dose 0.4 ml with an interval of 10 days of vaccine prepared according to example 52.
-
Observation before vaccination Amount of animals/clinical manifestations of DD, ID and IP 150/80 In 160 to 190 days after last vaccination Amount of animals/amount of limbs with lameness 150/15 Amount of healthy animals 135 Efficacy of vaccination 90% -
Observation before vaccination Amount of animals/clinical manifestations of DD, ID and IP 150/70 In 160 to 175 days after last application of placebo Amount of animals/amount of animals with manifestations of Clinical symptoms of DD, ID and IP 150/118 Amount of healthy animals 32 Amount of ill animals during of observation time 78.7 % - Efficacy of the vaccination after Trichophyton and Microsporum challenge in guinea pigs (this method was described in
WO 98/15284 - The challenge of Trichophyton mentagrophytes and Microsporum canis microconidiae consisted of 100-200 thousand microconidia per cm2 (300-600 thousand microconidia) applied topically to each animal. The challenge of Trichophyton verrucosum consisted of 500 thousand microconidia per cm2 (1.5 million microconidia) applied topically to each animal. A single dose of 1.0 ml of the vaccine was applied by intramuscular injection on the same day as the challenge and a second dose after 7 days. The observation was continued for 4 weeks after the initial injection of the vaccine. Vaccines prepared according examples 38, 39, 46, 47, 48, 49, 50 (see tables 17-30) were tested.
- A single dose of 1.0 ml of the vaccine was applied through intramuscular injection on the same day as the challenge and a second dose after 7 days. The observation was continued for 4 weeks after the initial injection of vaccine.
- For infection of the animals, Trichophyton verrucosum ( Tv ) Trichophyton mentagrophytes ( Tm ), and Microsporum canis ( Mc ) were used as fungal pathogens. Data about these strains are shown below:
1. Species: Trichophyton verrucosum Strain number: 1220 Volume: 0.5 ml Infection dose (1000 cells): 500-600/cm2 Area of skin for infection: 2-4 cm 2. Species: Trichophyton mentagrophytes Strain number: 1440 Volume: 0.5 ml Infection dose (1000 cells): 100-200/cm2 Area of skin for infection: 2-4 cm 23. Species: Microsporum canis Strain number: 724 Volume: 0.5 ml Infection dose (1000 cells): 100-200/cm2 Area of skin for infection: 2-4 cm2 - On the 7th, 15th, 22nd,29th and 36th day of the study, the animals were observed and clinical symptoms were evaluated on the basis of the following scoring system:
- 0 = no symptoms
- 1 = hyperaemia of the skin in the area of fungal infection
- 2 = single spots of scaling
- 3 = scaling of the skin in the area of fungal infection
- 4 = thin small crusts in the area of fungal infection
- 5 = scab-like crusts in the area of fungal infection
-
Table 31. The dynamics of the intensity of the clinical symptoms of allergic bronchitis in horses after application of the vaccine prepared according to example 41 (experimental group) and without vaccination (control group). The vaccine was injected intramuscular 3 times with an interval of 4 days with a dose of 1.0 ml. Group of animals No. Day 1Day 15Day 22Day 29Day 36Day 50Application of vaccine (n=10) 1 3 2 0 0 1 1 2 2 1 0 0 0 1 3 3 2 0 0 0 1 4 2 1 0 0 0 0 5 3 1 0 0 0 0 6 4 2 1 0 0 0 7 3 1 0 0 0 0 8 4 3 2 0 0 0 9 2 1 0 0 0 0 10 2 1 0 0 0 0 Mean 2.8 1.5 0.3 0 0.1 0.3 Deviation 0.79 0.71 0.67 0.0 0.32 0.48 Control (n=5) 11 3 2 2 2 2 3 12 4 2 1 1 1 2 13 4 2 1 1 2 2 14 2 1 1 0 1 1 15 2 1 1 0 0 0 Mean 3.0 1.6 1.2 0.8 1.2 1.6 Deviation 1.0 0.55 0.45 0.84 0.84 1.14 Score of clinical symptoms
0 = no symptoms
1 = weak wheeze, without coughing
2 = weak wheeze, with coughing
3 = expressed wheeze
4 = expressed wheeze with clinical symptoms of depression - The dynamics of the intensity of the clinical symptoms of allergic bronchitis in horses are shown in
Figure 2 .Table 32. The dynamics of the intensity of the clinical symptoms of chronic obstructive pulmonary disease in horses after application of the vaccine prepared according to example 41 (experimental group) and without vaccination (control group). The vaccine was injected 3 times intramuscular with an interval of 4 days in a dose of 1.0 ml. The results are also shown in Figure 3. Group of animals No. Day 1Day 15Day 22Day 29Day 36Day 50Application of vaccine (n=10) 1 3 1 0 1 1 1 2 2 1 0 0 0 1 3 3 2 1 0 0 0 4 2 1 1 0 0 0 5 3 1 0 0 0 0 6 4 2 1 0 1 1 7 3 1 0 0 0 0 8 4 1 2 0 0 0 9 2 1 0 0 0 0 10 2 1 0 0 0 0 Mean 2.8 1.2 0.5 0.1 0.2 0.3 Deviation 0.79 0.42 0.71 0.32 0.42 0.48 Control (n=5) 11 3 2 0 0 0 0 12 4 1 2 1 1 1 13 4 1 1 1 1 1 14 2 1 1 0 1 1 15 2 1 1 0 0 0 Mean 3.0 1.2 1.0 0.4 0.6 0.6 Deviation 1.0 0.45 0.71 0.55 0.55 0.55 Score of clinical symptoms
0 = no symptoms
1 = weak wheeze, without coughing
2 = weak wheeze, with coughing
3 = expressed wheeze
4 = expressed wheeze with clinical symptoms of depressionTable 33. Dynamics of clinical signs of skin diseases in dogs immunized with vaccine according to Example 42 in doses of 0.5 ml and 1.0 ml (Mean score of clinical symptoms in each group was shown; n=10). The vaccine was injected intramuscular 3 times with an interval of 7 days in a dose of 1.0 ml. The dynamics are also shown in Figure 4. Groups Dose in ml Day 1 (1) Day 7 (2) Day 15 (3) Day 21 (4) Day 30 (5) 1 0,5 3,6 2,6 1,2 0 0 2 1,0 3,9 2,0 1,2 0 0 3 Control 3,8 3,8 3,6 3,6 3,4 Score of clinical symptoms
0 = no symptoms
1 = hair growth, active rejection of crusts or excessive flaking
2 = alopecia, no hair growth, rejection of crusts
3 = desquamation, swelling or swelling with crust, crust not rejected
4 = desquamation or swelling, pain on palpation
5 = inflammatory response, necrotic crustTable 34. Dynamics of clinical signs of skin diseases in dogs immunized with vaccine according to Example 50 intramuscular in doses of 0.5 ml (Mean score of clinical symptoms in each group was shown; in vaccinators n=15 and in control group n=15). The vaccine was injected 3 times with an interval of 3 to 4 days. The results are also shown in Figure 5. Groups Day 1 Day 7Day 15Day 21Day 301 Vaccinators Mean 3.5 2.8 1.6 0.67 0 Deviation 0.83 1.01 0.99 0.72 0.0 2 Control Mean 3.8 3.8 3.6 3.6 3.4 Deviation 0.84 0.84 0.55 0.89 0.55 Score of clinical symptoms
0 = no symptoms
1 = hair growth, active rejection of crusts or excessive flaking
2 = alopecia, no hair growth, rejection of crusts
3 = desquamation, swelling or swelling with crust, crust not rejected
4 = desquamation or swelling, pain on palpation
5 = inflammatory response, necrotic crustTable 35. Ear swelling test of mice. The reaction to the provocation in mice vaccinated subcutaneously with product according to Example 41 compere to treated with Hostacortin® H (corticosteroid) Medicine Dose (ml) ∑ Ear thickness after 2 hours post challenge (µm) ∑ Ear thickness after 24 hours post challenge (µm) ∑ Ear thickness after 48 hours post challenge (µm) Left Right Left Right Left Right Example 41 0.1 322 330 315 335 315 325 Hostacortin® H 0.1 335 345 330 360 326 355 Control 0.1 320 375 320 405 325 387 Table 36. Antiallergic activity of vaccine prepared according to Example 41. Medicine Dose (ml) Antiallergic activity in Ear swelling test (%) after 2 hours post challenge after 24 hours post challenge after 48 hours post challenge Example 41 0.1 14.7 20.3 16.5 Hostacortin® H 0.1 14.2 17.5 10.7 - Ear erythema was determined by visual inspection and detection of presence (+) or absence (-) signs.
-
- In all stages of the experiment the positive dynamics of reducing inflammatory response after vaccination and use of prednisolone-21-acetyl in challenged mice was observed. The most expressed inhibition of inflammation reaction was 24 hours after the provocation. It should be noted that all of the control animals' erythema with injection of vessels on the right ear (allergen provocation site) were reacted. In the vaccinated animals the immediate type allergic reaction was not expressed. Intensive erythema on the ear after applying the allergen was not observed. The intensity of the ear oedema was significantly higher in the control animals than in the vaccinated mice and greater than threshold of 10%. Also, it should be noted that a stronger inhibition provocations was in vaccinated animals than in the treated with prednisolone-21-acetate. The amount of unreacted animals in control and test groups ranged from 56 to 80%, which is permitted by the method.
Table 37. Ear swelling test of mice. The reaction to the provocation in mice vaccinated subcutaneously with different doses product according to Example 41. Medicine Dose (ml) ∑ Ear thickness after 2 hours post challenge (µm) ∑ Ear thickness after 24 hours post challenge (µm) ∑ Ear thickness after 48 hours post challenge (µm) Left Right Left Right Left Right Example (diluted 5 times) 0.1 352 394 346 415 344 397 Example 0.1 346 375 349 367 345 358 Example 0.5 340 368 338 351 340 352 Example 1.0 332 375 329 389 325 386 Control 1.0 338 379 341 408 342 410 Table 38. Antiallergic activity of vaccine prepared according to Example 41. Medicine Dose (ml) Antiallergic activity in Ear swelling test (%) after 2 hours post challenge after 24 hours post challenge after 48 hours post challenge Example (diluted 5 times) 0.1 0.2 - 0.3 4.5 Example 0.1 3.7 14.4 17.0 Example 0.5 3.9 15.8 16.4 Example 1.0 - 0.9 1.4 1.1 - It should be noted that despite the small difference in thickness of the ear of the control and vaccinated mice at a dose of 0.1 ml and 0.5
ml 2 hours after challenge, but all control animals showed erythema with injection vessels on the right ear (the allergen provocation). In the vaccinated animals immediate type of allergic reaction was not expressed.
Allergic reaction 24 and 48 hours was observed as the results of provocation in the control and vaccinated at a dose of 0.1 ml of diluted vaccine and undiluted vaccine with dose of 1.0 ml. The reaction after provocation of allergic reaction in mice vaccinated with a dose of 0.1 ml and 0.5 ml absent or weakly expressed. The intensity of the ear oedema was significantly higher in the control animals and in groups vaccinated with diluted vaccine and vaccine in dose of 1.0 ml, than in other vaccinators. The amount of unreacted animals in control and test groups ranged from 65 to 81%, which is permitted by the method.Table 39. Dynamics of clinical signs of skin diseases in dogs immunized intramuscularly with vaccine according to Examples 41 and 43 in a dose of 0.5 ml (Mean score of clinical symptoms in each group was shown; n=10). The vaccine was injected 3 times with an interval of 7 days. Groups Example Day 1 (1) Day 7 (2) Day 15 (3) Day 21 (4) Day 30 (5) 1 4,0 2,2 1,4 0 0 2 4,0 2,6 1,6 0 0 3 Control 3,8 3,8 3,8 3,6 3,4 Score of clinical symptoms
0 = no symptoms
1 = hair growth, active rejection of crusts or excessive flaking
2 = alopecia, no hair growth, rejection of crusts
3 = desquamation, swelling or swelling with crust, crust not rejected
4 = desquamation or swelling, pain on palpation
5 = inflammatory response, necrotic crustTable 40. Dynamics of clinical signs of rhinitis in cats treated with vaccine prepared according to Example 42. The animals were treated by instillation of the nose the vaccine for five days at a dose of 1-2 drops into each nasal passage 1-2 times a day, other animals from control group were treated by the same way but with physiological sodium chloride solution (placebo). The animals were examined with a description of the clinical manifestations of the disease before treatment and on day No. Name Day 1 Day 5Day 10Day 20Day 301 Bars 4 0 1 0 0 2 Vens 4 0 3 0 0 3 Masha 4 2 0 0 0 4 Mica 3 0 2 0 0 5 Nica 4 0 0 0 0 6 Nels 4 2 0 0 0 7 Roma 4 0 2 0 0 8 Timosha 4 0 2 0 0 9 Tomka 4 2 0 0 0 10 Niusha 4 0 0 0 0 Mean 3,9 0.6 1.0 0 0 Deviation 0.28 1,8 1,0 0.0 0.0 11 Dusia 4 4 4 4 - 12 Max 4 3 4 3 - 13 Pushok 4 3 4 4 - 14 Filka 4 4 3 3 - 15 Rudy 4 4 4 4 - Mean 4.0 3,6 3.8 3.6 - Deviation 0,0 0,3 0.5 0.3 - 0 = no symptoms
1 = hyperemia and / or swelling of the mucous membranes of the nasal passages
2 = slight discharge from the nose
3 = hyperemia and / or swelling of the mucous membranes of the nasal passages discharge from the nose
4 = difficulty breathing, hyperemia and swelling of the mucous membranes of the nasal passages, heavy discharge from the nose
5 = death of animalsTable 41. Dynamics of clinical signs of rhinitis in dogs treated with vaccine prepared according to Example 43. The animals were treated by instillation of the nose the vaccine for five days at a dose of 1-2 drops into each nasal passage 1-2 times a day, other animals from control group were treated by the same way but with physiological sodium chloride solution (placebo). The animals were examined with a description of the clinical manifestations of the disease before treatment and on day No. Name Day 1 Day 5Day 10Day 20Day 301 Mara 4 1 0 0 0 2 Paramon 4 0 2 0 0 3 Zoran 3 0 0 0 0 4 Bred 3 0 2 0 0 5 Rembo 4 0 0 0 0 6 Tornado 3 0 1 0 0 7 Tropka 3 0 2 0 0 8 Ataman 3 2 0 0 0 9 Arkan 4 0 0 0 0 10 Barbos 4 0 0 0 0 Mean 3,5 0.3 0.7 0 0 Deviation 0.28 0,98 0,87 0.0 0.0 11 Seras 4 4 4 4 - 12 Bingo 3 3 3 3 - 13 Drujok 3 2 3 3 - 14 Racket 4 3 3 3 - 15 Bernt 4 4 4 4 - Mean 3.6 3.2 3.4 3.4 - Deviation 0,3 0,63 0.55 0.68 - Score of symptions:
0 = no symptoms
1 = hyperemia and / or swelling of the mucous membranes of the nasal passages
2 = slight discharge from the nose
3 = hyperemia and / or swelling of the mucous membranes of the nasal passages discharge from the nose
4 = difficulty breathing, hyperemia and swelling of the mucous membranes of the nasal passages, heavy discharge from the nose
5 = death of animalsTable 42. Dynamics of clinical signs of conjunctivitis in cats treated with vaccine prepared according to Example 54.Ten cats were treated by instillation of the vaccine for three - five days at a dose of 1-2 drops into each eye 2-3 times per day. In the absence of clinical signs of treatment was discontinued. The other 5 animals were treated with a physiological sodium chloride solution (placebo) as well as experimental animals of the experimental group. The animals were examined with a description of the clinical manifestations of the disease before treatment and every day during the treatment. Then the animals were examined on day 10. The results are also shown in Figure 9.No. Name Day 1 Day 2Day 3Day 4Day 5Day 101 Dark 4 2 1 1 0 0 2 Felix 4 1 0 0 0 2 3 Barsa 3 2 1 0 0 0 4 My 4 2 2 0 0 1 5 Rudy 4 0 0 0 0 0 6 Boris 4 2 1 0 0 0 7 Zanika 4 2 1 1 1 0 8 Plaksa 4 1 0 0 0 0 9 Gray 4 2 0 0 0 2 10 Markisa 4 2 1 0 0 0 Mean 3,9 1.6 0.7 0.2 0.1 0.3 Deviation 0.28 1,2 0,5 0.5 0.8 0.9 11 Zadira 4 4 4 4 - - 12 Visy 4 4 4 4 - - 13 Trindy 4 4 4 4 - - 14 Riny 4 4 4 4 - - 15 Fily 4 4 4 4 - - Mean 4.0 4,0 4.0 4.0 - - Deviation 0,0 0,0 0.0 0.0 - - Score of symptoms:
0 = no symptoms
1 = hyperemia and / or swelling of the conjunctiva
2 = slight lacrimation, discharge from the eyes
3 = hyperemia and / or swelling of the conjunctiva, discharge from the eyes
4 = hyperemia and swelling of the conjunctiva, intensive discharge from the eyes
5 = destruction of eyeball -
-
Case 1. The efficacy of a vaccine prepared as described in Example 38 was demonstrated by the vaccination of 16 year old girl with Common warts (Verucae vulgares and paronychial warts). The vaccine was applied 5 times at an interval of 24 hours topically with plaster and drops under affected nail, resulting in a significant reduction of the amount of warts after the last application and the warts disappeared about two weeks after the last treatment. No severe side effects were observed. -
Case 2. The efficacy of a vaccine prepared as described in Example 39 was demonstrated by the vaccination of 12 year old girl with Common warts (Verucae vulgares). The vaccine was applied 7 times at an interval of 24 hours topically with plaster, resulting in a significant reduction of the amount of warts after the last application and the warts disappeared about two weeks after the last treatment. No severe side effects were observed. -
Case 3. The efficacy of a vaccine prepared as described in Example 40 was demonstrated by the vaccination of 6 year old boy with Common warts (Verucae vulgares). The vaccine was applied 6 times at an interval of 24 hours topically with plaster, resulting in a significant reduction of the amount of warts after the last application and the warts disappeared about two weeks after the last treatment. No severe side effects were observed. -
-
Molecular weight: x∗(161)+y∗(203)+z∗(102)+z∗(36.5)+m∗(18) - Appearance: natural white to yellowish viscous liquid with typical odor
Solubility: soluble in: Water
Odor: typical, similar to Valeric acid
Density: 1.002
pH-value: 5.5
Storage: Keep protected from light; store in a container protected from air in a refrigerator at 4° - 8°C
Stability: 36 months under conditions described above -
-
Molecular weight: x∗(161)+y∗(203)+z∗(137.14)+m∗(18) Appearance: Yellowish to yellow viscous liquid -
-
Molecular weight: x∗(161)+y∗(203)+z∗(194.14)+m∗(18) - Purification of
Chitosan 80/ 100 and 80/200, AS-No.: 9012-76-4,
Amino-N-acetyl-D-glucosamine is sterilized in a separate vessel and is carried out to obtain Chitosan in pharmaceutical quality. - Sterile Amino-N-acetyl-D-glucosamine is resuspended under stirring for 15 minutes in this sterile water. 400 ml of Acetic acid is added to suspension under stirring (24 h) until a clear solution is obtained.
- To this solution the 4 N Sodium hydroxide solution is added drop by drop (carefully) to obtain a pH 8.0 to 8,5. The resulting solution precipitates to a white mass. The obtained suspension is stirred not less than 30 minutes. The residue is separated from the liquid phase by filtration.
- The precipitate is resuspended in an equal amount of purified (sterile) water (water for injection (Pharm. Eur.)) (401, initial amount). 80 ml of Pentanoyl chloride is measured. Under stirring conditions the Pentanoyl chloride is added drop by drop to the suspension. The obtained suspension is stirred until the solution is clear. 1.6g Thiomersal is added (40µg/mL). The clear solution is the active ingredient (Hydro-Colloid). The obtained polysaccharide colloid (CVHC) is stored under 4°C to 8°C. For an endproduct a aqueous solution is done with defined biological activity.
- Overview of the reaction steps of manufacturing
- 1.Chitosan + water →suspension
suspension + HAc (24h) → Chitosan-HAc-solution - 2.Purification step
- 2.1. Chitosan-HAc-solution + 4N NaOH →(pH 8-8.5)Chitosan + NaAc+ H2O
- 2.2. Chitosan + NaAc+ H2O →H2O + NaAc
→Chitosan (solid, purified)
- 3.Production
Chitosan (solid) + H2O + Pentanoylchlorid→
Chitosan + Valeric acid + H2O + HCl →CVHC (Chitosan-Valeric acid-Hydro-Colloid) - The production is a combination of a purification step of the basic material Chitosan and in process reaction with the second reagent Pentanoyl chloride.
This first critical step is the precipitation of Chitosan to obtain the total amount of the purified chitosan in pharmaceutical quality.
In process control: The reaction time and the pH-value are monitored to get a quantitative precipitation. - Test for the pharmaceutical quality of chitosan:
Test for the quality of the intermediate (Chitosan pharm quality) - Solubility in water: A sample of about 250 mg of the precipitate of Chitosan is resuspended in 1 ml of purified water
Target: No solubility can be obtained
Quality: is fulfilled if no reduction of the amount of the solid material can be detected. - Solubility in stronger acids: In parallel same amount of precipitate is suspended in 1 ml HCl (3N)
Target: Total solution
Quality: is fulfilled if a solution of the total amount of the solid material can be detected. - The second critical step is the dissolution process to the active ingredient. The control is done visually: The total amount of the precipitate should be solubilized.
- Test method according to EUROPEAN PHARMACOPOEIA 2.2.25 was used.
Apparatus: Spectrophotometer Jasco 7800
Conditions of measurement: -
Bandwidth 2 nm - Range 200 - 600 nm
- Blank correction with solvent
- Temperature: 25 °C
- UV-Cell: 12.5 x 45 mm semi-micro, 10 mm path length UV-grade silica
- Test solution: An adequate sample of Chitosan HCl, Chitosan-HAc, Chitosan, Chitosan-Valeric acid-Hydro Colloid and valeric acid, respectively was dissolved in the solvent above. This mixture was shacked and afterwards sonified in an ultrasonic bath for 5 min.
- The absorption maxima according to the general fundamentals of spectroscopy and the chemical structure with specific chromophore groups and substituents can be expected at:200 nm for Chitosan HCl, Chitosan-HAc, Chitosan-Valeric acid-Hydro Colloid and valeric acid, respectively
UV-Maximum Chitosan HCl Chitosan HAc Chitosan CVHC Valeric acid nm 200 200 - 200 211 - The absorption maxima of Chitosan could not be analysed since Chitosan is a water insoluble solid, which can also not be solubilized in typical organic solvents.
- The comparison of all spectra show no significance or structural modification like aromatic bonds etc. Based on the measured spectra and literature data of the raw materials the measured spectrum corresponds to prospected spectra. Thus, the measured data above confirm the identity of the prospected structure.
- Test method according to EUROPEAN PHARMACOPOEIA 2.2.24 was used.
For identification of the active priciple Chitosan-Valeric acid-Hydro-Colloid a series of IR-spectra of different Chitosan-Derivates are compared with the spectrum of the product and of Valeric acid. - Apparatus Infrared-Spectrometer FT/IR 410 Jasco
Range: 4000 cm-1 to 600 cm-1
Test sample: A mixture of 4.8 mg of Chitosan, or a mixture of 4 mg of Chitosan-HCl or a mixture of 3.8 mg of Chitosan Acetate and 100 mg KBr is carefully grinded and pressed to a suitable potassium bromide disk, or a film of Chitosan-Valeric acid-Hydro Colloid or NaCl plate for valeric acid - Background correction: actual
Temperature 20 °C - The measured spectrum corresponds directly to the literature spectra from database. Result: The measured data above confirms the identity of the tested substances.
-
Chitosan-Base Chitosan-HCl Chitosan-HAc Dried Chitosan-valeric acid Colloid Valeric acid 3398 3365 3424 3426 2919/2875 2887 2926/ 2960-2872 2960-2875 2673 2018 2092 2130 1708 1717 1665 1596 1606 1562 1561 1569 1509 1467/1456 1421 1410 1408 1424 1413 1377 1380 1381 1320 1320 1336 1315 1279 1256 1246 1254 1236 1215 1154 1155 1155 1154 1079/1032 1084 1089 1076-1013 1109 897 896 890 926 940
Comparison to literature data: Based on the measured spectra and literature data of the raw materials, the measured spectrum of CVHC corresponds to prospected spectrum.
Result: The measured data above confirm the identity of the proposed structure. - Test method according to EUROPEAN PHARMACOPOEIA 2.2.33 was used.
- Apparatus Bruker AMX 500 AVANCE
-
- Scan frequency: 125 MHz for Chitosan, Chitosan HCl, Chitosan HAc, Glucosamin HCl, N-Acetylglucosamin, Chitosan-Valeric acid-Hydro-Colloid, Valeric acid
- Temperature:
- 300 K for Chitosan, Chitosan HCl, Chitosan HAc, Chitosan-Valeric acid-Hydro-Colloid, Valeric acid;
- 301 K for Glucosamin HCl and N-Acetylglucosamin
- Solvent:
- D2O for Chitosan, Chitosan HCl, Chitosan HAc, Glucosamin HCl, N-Acetylglucosamin;
- DMSO-D6 for Chitosan-Valeric acid-Hydro-Colloid
- CDCl3 for Valeric acid
- Concentration: - for Chitosan, Chitosan HCl, Chitosan HAc, Chitosan-Valeric acid-Hydro-Colloid;
approx. 15 mg/0.5 ml for Glucosamin HCl, N-Acetylglucosamin and Valeric acid - Calibration: - for Chitosan, Chitosan HCl, Chitosan HAc, Glucosamin HCl, N-Acetylglucosamin
DMSO-D6 for Chitosan-Valeric acid-Hydro-Colloid
CDCl3 for Valeric acid - Measurement in solution: According to the missing solubility in neutral solvents a
measurement in solution is not possible.
Measurement in solid state: A measurement in solid state was not possible. Also after long measurement conditions (time) no acceptable signals appeared.
Result: NMR-Identification of Chitosan is not possible. -
Results [d] Classification (Carbon number) 97.67 C1 76.41 / 74.80 C5 70.28 C3 64.41 C4 60.11 C6 56.06 C2 Target The following characteristic chemical shifts according to the general fundamentals of spectroscopy and the chemical skeleton with substituents can be expected at: [ppm] 100 70 56 General Literature: Hesse, Meier, Zeeh Spektr. Methoden Thieme Verlag 5.Auflage 1995 - Result: The measured data above confirms the identity of the tested substance.
-
Results [d] Classification (Carbon number) Glucosamine skeleton 98.39 C1 74.79 C5 - C3 - C4 - C6 - C2 Acetic Acid 23.82 CH3 180.31 >C=O Target The following characteristic chemical shifts according to the general fundamentals of spe [ppm] 98.39 spectroscopy and the chemical skeleton with substituents can be expected at: 23.82 180.31 General Literature: Hesse, Meier, Zeeh Spektr. Methoden Thieme Verlag 5.Auflage 1995 - Result: The measured data above confirms the identity of the tested substance.
-
Results [d] Classification (Carbon number) 92.94 / 89.34 C1 76.25 C5 72.28 / 71.69 C3 69.85 / 69.77 C4 60.66 / 60.51 C6 54.62/57.08 C2 Target The following characteristic chemical shifts according to the general fundamentals of spectroscopy and the chemical skeleton with substituents can be expected at: [ppm] 92.94/89.34 60.66/60.51 54.62/57.08 General Literature: Hesse, Meier, Zeeh Spektr. Methoden Thieme Verlag 5.Auflage 1995 - Comparison to literature data: The measured spectrum corresponds directly to the literature spectra from database.
- Result: The measured data above confirms the identity of the tested substance.
-
Results [d] Classification 95.06 / 90.95 C1 76.01 / 74.08 C5 71.64 / 70.86 C3 70.22 / 69.99 C4 60.89 / 60.74 C6 56.90 / 54.26 C2 22.29 / 22.03 CH3 174.85 / 174.59 C=O Target The following characteristic chemical shifts according to the general fundamentals of spectroscopy and the chemical skeleton with substituents can be expected at: 95.06/90.95 22.29/22.03 174.85/174.59 General Literature: Hesse, Meier, Zeeh Spektr. Methoden Thieme Verlag 5.Auflage 1995 - Result: The measured data above confirms the identity of the tested substance.
-
Results [d] Classification Glucosamine skeleton 100.95 C1 78.57 C5 76.10 C3 73.10 C4 61.40 C6 57.57 C2 Valeric acid 180.66 C5' 29.23 C4' 24.85 C3' 23.37 C2' 14.87 C1' Target The following characteristic chemical shifts according to the general fundamentals of spectroscopy and the chemical skeleton with substituents can be expected at: [ppm] 100.95 61.40 57.57 180.66 14.87 General Literature: Hesse, Meier, Zeeh Spektr. Methoden Thieme Verlag 5.Auflage 1995 - Result: The measured data above confirms the identity of the proposed structure.
-
Results [d] Classification (Carbon number) 180.5 C5 33.8 C4 26.7 C3 22.2 C2 10.6 C1 Target The following characteristic chemical shifts according to the general fundamentals of spectroscopy and the chemical skeleton with substituents can be expected at: [ppm] 180 10.6 General Literature: Hesse, Meier, Zeeh Spektr. Methoden Thieme Verlag 5.Auflage 1995 - Comparison to literature data: The measured spectrum corresponds directly to the literature spectra from database.
- Result: The measured data above confirms the identity of the tested substance.
-
Chitosan HCl Chitosan HAc Glucosamin HCl N-Acetylglucosamin Chitosan-Valeric acid-Hydro- Valeric acid Classification (Carbon number) 97.7 98.4 92.9/89.3 95.0/91.0 101.0 C1 56.1 54.6/57.1 54.3 /56.9 57.6 C2 70.3 71.7 / 72.3 71.6 / 70.9 76.1 C3 64.4 69.9/69.8 70.2 / 70.0 73.1 C4 76.4 / 74.8 74.8 7 76.0/74.1 78.6 C5 60.1 60.5 / 60.7 60.9/60.7 61.4 C6 22.7 23.8 180.3 174.9 / 174.6 14.9 13.06 23.4 22.02 24.9 26.07 29.2 33.8 108.7 180.5 Literature - - X - - X - Comparison to literature data: Not available or Based on the measured spectra and literature data of the raw materials, the measured spectrum corresponds directly to prospected spectra.
Result: The measured data above confirm the identity of the proposed structure. - Test method according to EUROPEAN PHARMACOPOEIA 2.2.27 was used.
- This part presents the procedures and data of thin layer chromatography for the identification of CVHC along with the Rf values in the used solvent mixtures and spot colors when detected under UV-light (365 nm and 254 nm), visible light and with typical visualisation reagents.
- The original based raw material for any kind of glucosamines is the natural material Chitin from insects or crabs. The monomeric structure of these biopolymers is N-Acetyl-Glucosamine.
For pharmaceutical and other use in most cases deacetylated Chitin is typical. This resulting biopolymer is the so called Chitosan, which can be modified into water soluble ionic compounds. The monomeric structure of this Chitosan should be theoretically Glucosamine. Because the deacetylation step does not run totally, Chitosan has a mixed structure of N-Acetyglucosamine (acetylated) and Glucosamine (deacetylated) units. Chitosan-Valeric acid-Hydro-Colloid is a new Polyaminosugar-valeric acid hydro-complex. Therefore no positive analytical test results for N-Acetyl-Glucosamine and Glucosamine should be possible. If monomeric fragments are embedded as residual impurities, it should be possible to identify Chitosan in form of its water soluble ionic compounds Chitosan HCl and Chitosan HAc. -
Apparatus Camag Chromatographic Tank System TLC-plate Merck Si 60 F 254 precoated plates Conditions Protected from sunlight and with chamber saturation Temperature 20 - 25 °C Development: Vertical development Chromatographic conditions Sample-solution See the single analvtes Application 30µl Drying Min. 2 minutes in an air-stream Motion range 80 mm Mobile phase Solvents Acetone Water 25% aq. Ammonia - Mixture 20 10 5 - -
- 1) Apparatus: reflux condensor
Conditions: heating for about 30 minutes under reflux (145°C) - 2) Apparatus: Ultra sonic bath
Conditions: Sonification for about 30 minutes at 45°C - 3) Apparatus: reflux condensor
Conditions: heating for about 30 minutes under reflux (145°C) - 4) Filtration: 0.45 µm filter
The clear filtrate was used for analysis. - 5mg Chitosan HCl/ml H2O was used for analysis.
Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent 1Group specific reagent 2Anisaldehyde-Sulfuric acid reagent Iodine Compound signal No No Grey spot Brown spot Impurities No No No No Group specific reagent 1: Naturstoff-Reagent / DT / 366 nm Group specific reagent 2: 5% Ninhvdrine / EtOH Rf-value Chitosan HCl 0.0 Non specified impurities: Not detected Target Compound purity One main spot Anisaldehyd-Sulfuric acid-reagent respectively Iodine as non-selective reagents for detection of non-specified impurities should show no greater impurities A relative retardation factor (Rf) of this compound according to the chemical skeleton under this described chromato- graphic conditions for such an polymer can be expected at: 0.0 - - Result: Compound purity; One main spot. - 5mg Chitosan HAc/ml H2O was used for analysis.
Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent 1Group specific reagent 2Anisaldehyde-Sulfuric acid reagent Iodine Compound signal No No Grey spot Brown spot Impurities No No No No Group specific reagent 1: Naturstoff-Reagent / DT / 366 nm Group specific reagent 2: 5% Ninhvdrine / EtOH Rf-value Chitosan HAc 0.0 Non specified impurities: Not detected Literature Value Not available data from - Target Compound purity One main spot Anisaldehyd-Sulfuric acid-reagent respectively Iodine as non-selective reagents for detection of non-specified impurities should show no greater impurities A relative retardation factor (Rf) of this compound according to the chemical skeleton under this described chromato- graphic conditions for such an polymer can be expected at: 0.0 - - Result: Compound purity; One main spot. - 5 mg Glucosamine HCl/ml H2O was used for analysis.
Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent 1Group specific reagent 2Anisaldehyde-Sulfuric acid reagent Iodine Compound signal Blue spot Red spot Grey spot Brown spot Impurities No No No No Group specific reagent 1: Naturstoff-Reagent / DT / 366 nm Group specific reagent 1: Naturstoff-Reagent /DT/ 366 nm Group specific reagent 2: 5% Ninhydrine / EtOH Rf-value Glucosamine HCl 0.67 Non specified impurities: Not detected Literature Value Not available data from - Target Compound purity One main spot Anisaldehyd-Sulfuric acid-reagent respectively Iodine as non-selective reagents for detection of non-specified impurities should show no greater impurities A relative retardation factor (Rf) of this compound according to the chemical skeleton under this described chromato- graphic conditions can be expected between 0.6 and 0.8 Result: Compound purity; One main spot. - 5 mg N-Acetylglucosamine/ml H2O was used for analysis
Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent 1Group specific reagent 2Anisaldehyde-Sulfuric acid reagent Iodine Compound signal Blue spot No Grey spot Brown spot Impurities No No No No Group specific reagent 1: Naturstoff-Reagent / DT / 366 nm Group specific reagent 2: 5% Ninhydrine / EtOH Rf-value N-Acetylglucosamine 0.72 Non specified impurities: Not detected Target Compound purity One main spot Anisaldehyd-Sulfuric acid-reagent respectively Iodine as non-selective reagents for detection of non-specified impurities should show no greater impurities A relative retardation factor (Rf) of this compound according to the chemical skeleton under this described chromato- graphic conditions can be expected between 0.6 and 0.8 Result: Compound purity; One main spot. - CVHC is a high viscous waterish gel. Two drops of CVHC was used for analysis.
Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent 1Group specific reagent 2Anisaldehyde-Sulfuric acid reagent Iodine Compound signal No No Grey spot Brown spot Impurities No No No No Group specific reagent 1: Naturstoff-Reagent / DT / 366 nm Group specific reagent 2: 5% Ninhvdrine / EtOH Rf-value Chitosan-Valeric acid-Hydro-Colloid 0.0 Non specified impurities: Not detected Literature Value Not available data from - Target Compound purity One main spot Anisaldehyd-Sulfuric acid-reagent respectively Iodine as non-selective reagents for detection of non-specified impurities should show no greater impurities A relative retardation factor (Rf) of this compound according to the chemical skeleton under this described chromato- graphic conditions for such an polymer can be expected at: 0.0 - - Result: Compound purity; One main spot. - 1 µl Valeric acid (pure) was used for analysis.
Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent 1Group specific reagent 2Anisaldehyde-Sulfuric acid reagent Iodine Compound signal No No No Yellow spot Impurities No No No No Group specific reagent 1: Naturstoff-Reagent / DT / 366 nm Group specific reagent 2: 5% Ninhvdrine / EtOH Rf-value Valeric acid 0.0 Non specified impurities: Not detected Literature Value Not available data from - Target Compound purity One main spot Anisaldehyd-Sulfuric acid-reagent respectively Iodine as non-selective reagents for detection of non-specified impurities should show no greater impurities A relative retardation factor (Rf) of this compound according to the chemical skeleton under this described chromato- graphic conditions can be expected between 0.0 - - Result: Compound purity; One main spot. -
Chitosan Chitosan HCl Chitosan HAc Glucosamine HCl N-Acetyl-glucoamine HCl Chitosan-Valeric colloid Valeric acid Rf-value Not possible 0 0 0.67 0.72 0 0 Detection Compound signal UV 254nm - - - - - - - UV 365nm - - - - - - - Visible light - - - - - - - Naturstoff-Reagent - - - Blue spot Blue spot - - Ninhydrine Reagent - - - Red spot - - - Anisaldehyde-Sulfuric acid reagent - Grey spot Grey spot Grey spot Grey spot Grey spot - Iodine Reagent - Brown spot Brown spot Brown spot Brown spot Brown spot Yellow Spot - The results above from TLC show that there is no evidence of monomeric or dimeric structure which could be detected with the specific derivation reagents tested above. The detection and the Rf value of "0" show the similarity of Chitosan-Valeric acid-Hydro-Colloid to the related compounds Chitosan HCl and Chitosan HAc. A specific identification of Valeric acid with this TLC-System failed. Chitosan-Valeric acid-Hydro-Colloid can only be a Poly-Amino-sugar-colloid, but not a solution of Chitosan or a Chitosan derivate with Valeric acid in water.
- A new TLC system was established for an identification and purity testing of the constituent Valeric acid.
Apparatus Camag Chromatographic Tank System TLC-plate Merck Si 60 F 254 precoated plates Conditions Protected from sunlight and with chamber saturation Temperature 20 - 25 °C Development: Vertical development Chromatographic conditions Drying Min. 2 minutes in an air-stream Motion range 80 mm Mobile phase Solvents Ethyl Acetate - - - Mixture 100 - - - - 2 µl of Valeric acid (pure) was used for analysis.
-
Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent Anisaldehyde-Sulfuric acid reagent Iodine Compound signal Yellow spot/ blue background Pink spot Yellowish spot Impurities No No No Group specific reagent: Bromcresol Green / Bromphenol Blue / Potassium Permanganate Reagent [Jork et al.] Rf-value Valeric acid 0.56 Non specified impurities: Not detected Literature Value Not available data from - - 45µl Chitosan-Valeric acid-Hydro-Colloid, pure (this is an about 850 times higher amount of valeric acid, compared with the tests before) was used for analysis.
Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent Anisaldehyde-Sulfuric acid reagent Iodine Compound signal Blue spot/ blue background Grey spot Brown spot Impurities No No No Group specific reagent: Bromcresol Green / Bromphenol Blue / Potassium Permanganate Reagent [Jork et al.] Target Compound purity One main spot Anisaldehyd-Sulfuric acid-reagent respectively Iodine as non-selective reagents for detection of non-specified impurities should show no greater impurities The Group specific reagent Bromcresol Green / Bromphenol Blue / Potassium Permanganate Reagent should show typical results for the compounds A relative retardation factor (Rf) of this compound according to the chemical skeleton under this described chromatographic conditions can be expected at 0.0 for Chitosan-derivatives appr. 0.6 for valeric acid if available Rf-value Chitosan-Valeric acid-Hydro-Colloid 0.0 Non specified impurities: Not detected Rf-value Valeric acid Not detected Non specified impurities: Not detected Literature Value Not available data from - - Pure Valeric acid can be identified with this TLC-System. Colloidal integrated Valeric acid can not be detected in the pure compound Chitosan-Valeric acid-Hydro-Colloid. The detection and the Rf value of "0" show the similarity of Chitosan-Valeric acid-Hydro-Colloid to other related Chitosan compounds. Chitosan-Valeric acid-Hydro-Colloid can only be a Poly-Amino-sugar colloid, but not a solution of Chitosan or a Chitosan derivate with Valeric acid in water. The results above confirm the identity of the proposed structure.
- Method: Estimation of the loss on drying (special method)
Apparatus: Speed circulating vacuum concentrator
Conditions: 5 mbar
Temperature: 60°C
Time: 1 week
End point: Constant mass
Appearance: Glassy mass - Result Odor: No typical odor from valeric acid
- Appearance: High viscous gel
- Apparatus: Camag Chromatographic Tank System
TLC-plate: Merck Si 60 F 254 precoated plates
Conditions: Protected from sunlight and with chamber saturation
Temperature: 20 - 25 °C
Development: Vertical development
Chromatographic conditions - Application: 5µl
Drying: Min. 2 minutes in an air-stream
Motion range: 80 mmMobile phase Solvents Ethyl Acetate - - - Mixture 100 - - - Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent Anisaldehyde-Sulfuric acid reagent Iodine Compound signal Blue spot/ blue background grey spot brown spot Impurities No No No Group specific reagent: Bromcresol Green / Bromphenol Blue / Potassium Permanganate Reagent [Jork et al.] Rf value spot 0 - Detection limit: of Valeric acid with this visualization reagent after TLC- chromatography: 0.03µg
Result: With high vacuum and higher temperature a disproportion of Chitosan-Valeric acid-Hydro-Colloid takes place. The elimination of Valeric acid can be shown by absolutely no typical odor from Valeric acid. The elimination of Valeric acid can be shown by TLC analysis: no typical spot of free valeric acid at Rf-value 0.56. Chitosan or Chitosan compounds can be identified at Rf-value 0. Chitosan-Valeric acid-Hydro-Colloid can only be a Poly-Amino-sugar-colloid, but not a solution of Chitosan or a Chitosan derivate with valeric acid in water. - The structure of Chitosan-Valeric acid-Hydro-Colloid is decomposed in Ethyl acetate to Valeric acid and a Chitosan compound.
- Apparatus: separating funnel, evaporator
Liquid-liquiddistribution: 20ml Chitosan-Valeric acid-Hydro-Colloid and 10ml Ethyl acetate Conditions: Shaking for about 5 minutes and wait for phase separation
Separation of phases: The ethyl acetate phase was collected
Concentration step: The about 10 ml were concentrated to liquid residue (waterish) with an evaporator
Resolubilization: in 1 ml Methanol
Homogenization: Centrifugation step about 5 min 12.000 rpm
Phase separation: Upper phase: clear methanolic solution
Lower phase: high viscous gel - Apparatus: Camag Chromatographic Tank System
TLC-plate: Merck Si 60 F 254 precoated plates
Conditions: Protected from sunlight and with chamber saturation
Temperature: 20 - 25 °C
Development: Vertical development - Sample-solution: clear methanolic solution
Application: 5µl
Drying: Min. 2 minutes in an air-stream
Motion range: 80 mmMobile phase Solvents Ethyl Acetate - - - Mixture 100 - - - Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent Anisaldehyde-Sulfuric acid reagent Iodine Compound signal Yellow spot/ blue background No Light yellowish spot Impurities No No No Group specific reagent: Bromcresol Green / Bromphenol Blue / Potassium Permanganate Reagent [Jork et al.] Rf-value Valeric acid 0.57 Non specified impurities: - - Detection limit with visualisation reagent: 0.03µg
Result: The upper phase is a clear methanolic solution. Valeric acid can be identified after decomposition of the Hydro-Colloid in this solution with TLC. No Chitosan or Chitosan compound can be detected with TLC. - Apparatus: Camag Chromatographic Tank System
TLC-plate: Merck Si 60 F 254 precoated plates
Conditions: Protected from sunlight and with chamber
Temperature: 20 - 25 °C
Development: Vertical development - Sample-solution: high viscous gel, totally redissolved in water Application: 30µl
Drying: Min. 2 minutes in an air-stream
Motion range: 80 mmMobile phase Solvents Ethyl Acetate - - - Mixture 100 - - - Detection with UV-fluorescence and VIS Fluorescence wavelength 254 nm 365 nm VIS Compound signal No No No Impurities No No No Detection with visualisation reagents Visible light Group specific reagent Anisaldehyde-Sulfuric acid reagent Iodine Compound signal Blue spot/ blue background Grey spot Brown spot Impurities No No No Group specific reagent: Bromcresol Green / Bromphenol Blue / Potassium Permanganate Reagent [Jork et al.] Rf-value Spot 0 Non specified impurities: - - Results: The lower phase is a high viscous gel, soluble in water. No Valeric acid can be detected in this phase by TLC. Chitosan or a Chitosan compound can be identified in the lower phase (gel) by TLC.
Results from TLC analysis A disproportion of Chitosan-Valeric acid-Hydro-Colloid is possible with typical solvents like Ethyl acetate and afterwards with Methanol A re-solubilization of from disproportioned Chitosan-Valeric acid-Hydro-Colloid can be realized with Methanol The decomposition of Chitosan-Valeric acid-Hydro-Colloid in Ethyl acetate shows two phases Upper phase Lower phase Ethyl acetate phase Aqueous Colloid residue After concentration the Ethyl acetate phase was redissolved in Methanol and results also two phases Upper phase Lower phase clear methanolic solution high viscous gel This gel can be re-dissolved totally in water can be identified No can be identified No Chitosan or Chitosan compound can be detected Chitosan or a Chitosan compound can be detected Summary of the results Valeric acid pure Chitosan-Valeric acid-Hydro-Colloid (pure CVHC) Elimination of from CVHC with high vacuum Chitosan-Valeric acid-Hydro-Colloid (decomposed with Ethyl acetate) Upper phase (Methanol) Lower phase (Water) Rf-value 0.56 + - - + - Rf-value 0 - + + - + Detection Compound signal UV 254 nm - - - - - UV 365 nm - - - - - Visible light - - - - - Anisaldehyde-Sulfuric acid reagent Pink spot Grey spot Grey spot - Grey spot Iodine reagent Yellowish spot Brown spot Brown spot Light yellowish spot Brown spot Bromcresol Green Bromphenol Blue reagent Yellow spot Blue spot Blue spot Yellow spot Blue spot - Result: Chitosan-Valeric acid-Hydro-Colloid can only be a Poly-Amino- sugar-colloid, but not a solution of Chitosan or a Chitosan derivate with valeric acid in water. The results above confirm the identity of the proposed structure.
- Because of the high viscosity of Chitosan-Valeric acid-Hydro-Colloid the estimation of the density is not possible with a density bottle/pycnometer according to Test method according to EUROPEAN PHARMACOPOEIA 2.2.5.
- Apparatus: 250ml volumetric flask
Balance:Sartorius MC 1 LC 2200S
Thermometer: Thermometer with graduation (min 0.5 °C) and a range not more than 60°C Results 1.001 [d20 20] - The active principle is a hydrogel, so the theoretical density should be higher than 1.0. The measured data confirms the identity of the proposed substance.
- Test method according to EUROPEAN PHARMACOPOEIA 2.2.5 was used.
Apparatus: 250ml volumetric flask
Hydrometer: Widder 1573°, 20°C-M100-DIN 12791 Klasse H
Thermometer Thermometer with graduation (min 0.5 °C) and a range not more than 60°C Conditions of measurement:Temperature 20 +/- 0.5°C with electronic thermostate - The active principle is a hydrogel, so the theoretical density should be higher than 1.0. The measured data confirms the identiy of the proposed substance.
- The Test method according to EUROPEAN PHARMACOPOEIA 2.4.14 was used.
Testing Apparatus Suitable crucible (porcelain or platinum) were ignited at 600+/- 50°C for 30min in a "Muffel"-oven allow to cool in a desiccator over silica gel or other suitable desiccant Estimation of crucible weight Weight Weight of crucible 1: 52.0120 [g] Weight of crucible 2: 57.6055 [g] Method 2 (acid insoluble ash) Additional for this Hydrogel a concentration step to dryness was done by drying at 105 °C in an normal oven Sample: 25ml of Hydrogel CVHC Usually 1-2 g Sample weight: usually 1-2g or sufficient amount to obtain a residue of minimum 1g. Moisten the sample with a small amount of sulfuric acid R [95-97 % m/m] (usuallyl ml_) and heat at as low temperature as practicable until the residue is charred. After cooling, moisten the residue with a small amount of sulfuric acid R [95-97 % m/m] (usuallyl ml_ ) Heat until white fumes are no longer evolved Ignite at 600+/- 50°C for 30min until the residue is completely incinerated. Flames are not allowed to be produced at any time during the procedure allow to cool in a desiccator over silica gel or other suitable desiccant Weigh and calculate the percentage of residue Weighting of total weight Total Weight of crucible 1: 52.0668 g Total Weight of crucible 2: 57.6612 g Sulphated ash content Value 1: 0.0548 g Value 2: 0.0557 g Average: 0.05525 g / 25 ml Calculation of content of sulphated ash 0.05525 g / 25.05 g = 0.0022055g/g = 2.2055 mg/g 0.22 % - Based on this Phytochem® established appropriate methods for the determination of loss on drying.
- Pretreatment of container: The substance is placed in a suitable weighing bottle, previously dried under the conditions used afterwords
Filling: the material is filled not higher than 5 millimeter
Transport: The weighing bottle is closed with a suitable cover
PC-method: A "under higher vaccum"
modified Pharmacopoeia-method 2.2.32 (EP)"in vacuum in a desiccator "
Apparatus: desiccator
Drying time: to constant weight
Drying temperature: 25°C ± 2°C
Vacuum: permanent 4-8 mbar with specific pumps
Drying reagent: Diphosporuspentoxide (freshly) - The content of Chitosan in Chitosan-Valeric acid-Hydro-Colloid is estimated with a gravimetric measurement.
Apparatus: Speed circulating vacuum concentrator
Method: Estimation of the loss on drying (special method) - Pressure: 5 mbar
Temperature: 60°C
Time: 1 week
End point: Constant mass
Appearance: Glassy mass
Measurement: Test solution 4ml Chitosan-Valeric acid-Hydro-Colloid
Repetition: 10 times
Result Odor: No typical odor from valeric acidWeighing 1 40,20mg 6 40, 10mg 2 39, 80mg 7 39, 90mg 3 40,20mg 8 39, 60mg 4 39,90mg 9 40, 20mg 5 40, 10mg 10 40,40mg
Standard deviation 0,236643191
Relative standard deviation 0,591016961
Variance 0,056
Results: The weighing of the dried substance shows good similarity. Based on this measurements the content of Chitosan in Chitosan-Valeric acid-Hydro-Colloid is 1%.Comparison of the results Chitsoan solid Chitsoan HCI solid Chitsoan HAc solid Chitosan-Valeric acid-Hydro-Colloid Loss on drying 7.2% 7.9% 20.3% - Residue from drying - - - 1% Target EP - <10% - - - The active principle should be a Hydro Colloid gel. The measured data confirm the structure of compound.
- The estimation of the Osmolarity can be done was an indirect measurement of the decrease of the melting point of a solution.
Apparatus: Halbmicro Osmometer Knauer
Conditions of measurement: External cooling system
Range: 0-1600 mOsmol
Method: Freezing - Calibration with Standard solution 400 mOsmol/Kg: 12,687 g NaCl in 11 Wasser at 20°C
Repetition: 2 times
Vessel: Specific glass vial
Sample: Chitosan-Valeric acid-Hydro-Colloid
Test solution: - 1 without dilution
- 2 Dilution of 1:5
- Results: The measurement of the Osmorarity of Chitosan-Valeric acid-Hydro-Colloid show a relatively low content. The measured content of osmolar reacting components can only be so low, if there is no solution or suspension of chitosans and valeric acid. The high viscous gelling compound can only be a Hydro-Colloid.
Result:The measured data above confirms the identity of the proposed substance.
Group | Day 1 | Day 15 | Day 22 | Day 29 | Day 36 |
Vaccination Challenge | Vaccination 1st observation | 2nd observation | 3rd observation | 4th observation | |
Example 38 | 1st injection of vaccine: intramuscular, 1 ml | 2nd injection of vaccine: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Trichophyton verrucosum infection | ||||
Example 39 | 1st injection of vaccine: intramuscular, 1 ml | 2nd injection of vaccine: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Trichophyton verrucosum infection | ||||
Example 50 | 1st injection of vaccine: intramuscular, 1 ml | 2nd injection of vaccine: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Trichophyton verrucosum infection | ||||
Control | 1st injection of solvent: intramuscular, 1 ml | 2nd injection of solvent: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Trichophyton verrucosum infection |
Group | Day 1 | Day 15 | Day 22 | Day 29 | Day 36 |
Vaccination Challenge | Vaccination 1st observation | 2nd observation | 3rd observation | 4th observation | |
Example 46 | 1 st injection of vaccine: intramuscular, 1 ml | 2nd injection of vaccine: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Trichophyton mentagrophytes infection | ||||
Example 47 | 1st injection of vaccine: intramuscular, 1 ml | 2nd injection of vaccine: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Trichophyton mentagrophytes infection | ||||
Example 50 | 1st injection of vaccine: intramuscular, 1 ml | 2nd injection of vaccine: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Trichophyton mentagrophytes infection | ||||
Control | 1st injection of solvent: intramuscular, 1 ml | 2nd injection of solvent: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Trichophyton mentagrophytes infection |
Group | Day 1 | Day 15 | Day 22 | Day 29 | Day 36 |
Vaccination Challenge | Vaccination 1st observation | 2nd observation | 3rd observation | 4th observation | |
Example 48 | 1st injection of vaccine: intramuscular, 1 ml | 2nd injection of vaccine: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Trichophyton Microsporum canis infection | ||||
Example 49 | 1st injection of vaccine: intramuscular, 1 ml | 2nd injection of vaccine: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Microsporum canis infection | ||||
Example 50 | 1st injection of vaccine: intramuscular, 1 ml | 2nd injection of vaccine: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Microsporum canis infection | ||||
Control | 1st injection of solvent: intramuscular, 1 ml | 2nd injection of solvent: intramuscular, 1 ml | |||
Challenge: application of fungus cell suspension on skin | Assessment of clinical symptoms of Microsporum canis infection |
Date of observation | |||||
Vaccine prepared according to | | | | | |
Example 38 | mean | 2.2 | 3.4 | 1.4 | 0 |
Example 39 | mean | 3.0 | 3.2 | 1.0 | 0 |
Untreated control | mean | 2.4 | 4.0 | 4.0 | 2.2 |
Date of observation | ||||||
Group | Complex / | Day | 15 | | | |
1 | Example 38 | 3/5 | 5/5 | 3/5 | 0/5 | |
2 | Example 39 | 3/5 | 5/5 | 1/5 | 0/5 | |
3 | | 4/5 | 5/5 | 5/5 | 4/5 |
(Note: number of animals with clinical symptoms / number of challenged) |
Date of observation | |||||
Vaccine prepared according to | | | | | |
Example 46 | mean | 3.0 | 3.2 | 1.6 | 0 |
Example 47 | mean | 3.0 | 3.6 | 1.2 | 0 |
Untreated control | mean | 4.0 | 4.8 | 3.8 | 2.0 |
Date of observation | ||||||
Group | Complex / | Day | 15 | | | |
1 | Example 46 | 5/5 | 5/5 | 5/5 | 0/5 | |
2 | Example 47 | 5/5 | 5/5 | 3/5 | 0/5 | |
3 | | 5/5 | 5/5 | 5/5 | 4/4 |
(Note: number of animals with clinical symptoms / number of challenged) |
Date of observation | |||||
Vaccine prepared according to | | | | | |
Example 46 | mean | 3.2 | 3.8 | 2.0 | 0.2 |
Example 47 | mean | 3.2 | 3.4 | 1.8 | 0 |
Untreated control | mean | 3.4 | 4.2 | 2.2 | 2.0 |
Date of observation | ||||||
Group | Complex / | Day | 15 | | | |
1 | Example 46 | 5/5 | 5/5 | 4/5 | 1/5 | |
2 | Example 47 | 5/5 | 5/5 | 4/5 | 0/5 | |
3 | | 5/5 | 5/5 | 4/5 | 4/5 |
(Note: number of animals with clinical symptoms / number of challenged) |
Date of observation | |||||
Vaccine prepared according to | | | | | |
Example 48 | mean | 3.4 | 3.6 | 1.0 | 0 |
Example 49 | mean | 3.0 | 3.2 | 1.6 | 0 |
Untreated control | mean | 3.6 | 4.2 | 2.2 | 2.2 |
Date of observation | ||||||
Group | Complex / | Day | 15 | | | |
1 | Example 48 | 4/5 | 5/5 | 3/5 | 0/5 | |
2 | Example 49 | 4/5 | 5/5 | 4/5 | 0/5 | |
3 | | 5/5 | 5/5 | 4/5 | 4/5 |
(Note: number of animals with clinical symptoms / number of challenged) |
Date of observation | |||||
Vaccine prepared according to | | | | | |
Example 50 | mean | 2.2 | 3.6 | 1.6 | 0 |
Untreated control | mean | 2.2 | 4.2 | 4.0 | 2.0 |
Date of observation | ||||||
Group | Complex / | Day | 15 | | | |
1 | Example 50 | 3/5 | 5/5 | 2/5 | 0/5 | |
2 | | 4/5 | 5/5 | 5/5 | 3/5 |
(Note: number of animals with clinical symptoms / number of challenged) |
Date of observation | |||||
Vaccine prepared according to | | | | | |
Example 50 | mean | 3.0 | 3.4 | 2.0 | 0 |
Untreated control | mean | 4.0 | 4.8 | 4.0 | 2.0 |
Date of observation | ||||||
Group | Complex / | Day | 15 | | | |
1 | Example 50 | 3/5 | 5/5 | 5/5 | 0/5 | |
2 | | 4/5 | 5/5 | 5/5 | 4/5 |
(Note: number of animals with clinical symptoms / number of challenged) |
Date of observation | |||||
Vaccine prepared according to | | | | | |
Example 50 | mean | 3.2 | 3.4 | 1.0 | 0 |
Untreated control | mean | 3.8 | 4.0 | 2.4 | 2.0 |
Date of observation | ||||||
Group | Complex / | Day | 15 | | | |
1 | Example 50 | 4/5 | 5/5 | 3/5 | 0/5 | |
2 | | 4/5 | 5/5 | 4/5 | 4/5 |
(Note: number of animals with clinical symptoms / number of challenged) |
Fluorescence wavelength | 254 nm | 365 nm | VIS |
Compound signal | No | No | No |
Impurities | No | No | No |
Visible light | Group | Group | Anisaldehyde-Sulfuric acid reagent | Iodine |
Compound signal | No | No | No | No |
Impurities | No | No | No | No |
Group specific reagent 1: Naturstoff-Reagent / DT / 366 nm | ||||
Group specific reagent 2: 5% Ninhydrine / EtOH |
Rf-value | No signal for chitosan can be identified | - |
Non specified impurities: | Not detected |
Result: An acceptable solution of Chitosan in waterish or organic solvents like Methanol etc. is not possible. A suitable solubilization of Chitosan is only possible in stronger acids like HCl or HAc under production of Chitosan HCl or Chitosan HAc.
Sample | Spezification | Setpoint | Measured |
Calibration | |||
1 | Bidest. water | 0 mOsmol | 0 |
Calibration | |||
2 | 400m Osmol/kg | 400 mOsmol | 400 mOsmol |
Number | Sample | Measured value |
1a | Chitosan-Valeric acid-Hydro-Colloid | 100 mOsmol |
1b | Chitosan-Valeric acid-Hydro-Colloid | 110 mOsmol |
2a | Chitosan-Valeric acid-Hydro-Colloid | 1:5 20 mOsmol |
2b | Chitosan-Valeric acid-Hydro-Colloid | 1:5 20 mOsmol |
Claims (13)
- A method for preparing a modified chitosan, chitosan variant or chitosan derivative, the method comprises the step of:(a) incubating chitosan in an aqueous solution of an organic carboxylic acid or a salt thereof, wherein the organic carboxylic acid is selected form the group consisting of valeric acid, para-aminobenzoic acid, glucuronic acid or a salt of any of said acids, in particular a valeric acid chloride,wherein the chitosan has a degree of deacetylation of 62% to 98%.
- The method of claim 1, wherein the chitosan has a degree of deacetylation of 80% to 95 % and/or wherein the chitosan has a molecular weight or average molecular weight of 80 kDa to 700 kDa.
- The method according to claim 1 or 2, wherein the method comprises the following steps prior to step (a):(i) dissolving chitosan in an aqueous solution of an acid, in particular in an aqueous solution of an acetic acid,(ii) increasing the pH value, in particular to a pH value of 8.0 to 8.5, until chitosan is precipitated, and(iii) recovering the precipitated chitosan,wherein the recovered chitosan of step (iii) is used in step (a).
- The method according to any one of claims 1 to 3, wherein step (a) additionally comprises the addition or the presence of a mineral acid, in particular HCl or H2SO4, or an organic acid, in particular lactic acid, para-aminobenzoic acid or glucuronic acid.
- A hydro colloid comprising:(i) 0.1% to 5% (w/v) chitosan and 0.001 to 5% (w/v) valeric acid, or a salt thereof, preferably chloride of valeric acid or(ii) 0.1% to 5% (w/w) chitosan and 0.001 to 5% (w/w) glucuronic acid or p-aminobenzoic acid or a salt thereof.
- A compound of formula [X]n, in which n represents an integer of 1 to 5000, in particular an integer of 300 to 4000, and X has the following formula (1):
- A composition comprising the hydro colloid according to claim 5 or the compound of claim 6, in particular wherein the composition is a pharmaceutical composition and comprises a pharmaceutical acceptable diluent, excipient and/or carrier.
- The composition according to claim 7, wherein the composition comprises additionally antigenic material from microorganisms and/or enzymes, in particular antigenic material of keratinophilic fungi and/or keratinophilic yeasts, preservatives and/or antibiotics.
- The composition of claim 8, wherein the antigenic material is derived from one or more of Candida, in particular Candida albicans, Trichophyton, in particular Trichophyton verrucosum, Trichophyton mentagrophytes, Trichophyton equinum, Trichophyton sarkisovii, Trichophyton rubrum and/or Trichophyton mentagrophytes, Microsporum, in particular Microsporum canis such as Microsporum canis var. obesum and/or Microsporum canis var. distortum, and/or Microsporum gypseum, and/or Chrisporium, in particular Chrisporium tropicum.
- The composition of claim 9, wherein the antigenic material is derived from one or more of the following strains: Trichophyton mentagrophytes DSM - 7279, Trichophyton verrucosum DSM - 28406, Trichophyton rubrum DSM - 9469, Trichophyton rubrum DSM - 9470, Trichophyton rubrum DSM - 9471, Trichophyton rubrum DSM - 9472, Candida albicans DSM - 9456, Candida albicans DSM - 9457, Candida albicans DSM - 9458, Candida albicans DSM - 9459, Chrisporium tropicum DSM-28405, and Microsporum canis DSM-32271.
- The composition according to any one of claims 7 to 10, wherein the modified chitosan, chitosan variant, chitosan derivative or compound is present in a concentration of 0.1 to 2.0% (w/v), in particular of 0.1 to 1.4% (w/v), more particularly of 0.1% to 0.3% (w/v).
- The hydro colloid according to claim 5, the compound according to claim 6, or the composition according to any one of claims 7 to 11 for use in human and/or veterinary medicine, in particular as a vaccine.
- The compound according to claim 6 or 12, the hydro colloid according to claim 5 or 12, or the composition according to any one of claims 7 to 12 for use in a method of treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis, interdigital phlegmon, trichophytosis, microsporosis, mycosis of skin, allergies, as well as diseases complicated by allergies, in particular allergic obstructive pulmonary disease, allergic skin diseases, allergic ear erythema, allergic rhinitis, allergic conjunctivitis, acute allergic contact dermatitis, chronic allergic contact eczema or atopic eczema, obstructive pulmonary disease, in particular chronic obstructive pulmonary disease, skin diseases, in particular dermatitis, ear erythema, rhinitis, conjunctivitis, dermatophytosis or warts, in particular Common warts, in a subject and for modulating the immune response in a subject and/or for enhancing reproduction efficiency, preferably reproduction efficiency in animal breeding.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL17711627T PL3429600T3 (en) | 2016-03-15 | 2017-03-15 | New immunobiological products |
SI201730754T SI3429600T1 (en) | 2016-03-15 | 2017-03-15 | New immunobiological products |
RS20210639A RS61885B1 (en) | 2016-03-15 | 2017-03-15 | New immunobiological products |
HRP20210801TT HRP20210801T1 (en) | 2016-03-15 | 2021-05-18 | New immunobiological products |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16160534 | 2016-03-15 | ||
PCT/EP2017/056146 WO2017158040A1 (en) | 2016-03-15 | 2017-03-15 | New immunobiological products |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3429600A1 EP3429600A1 (en) | 2019-01-23 |
EP3429600B1 true EP3429600B1 (en) | 2021-03-03 |
Family
ID=55588088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17711627.4A Active EP3429600B1 (en) | 2016-03-15 | 2017-03-15 | New immunobiological products |
Country Status (19)
Country | Link |
---|---|
US (1) | US11173193B2 (en) |
EP (1) | EP3429600B1 (en) |
CN (1) | CN109152793B (en) |
AU (1) | AU2017234986C1 (en) |
CA (1) | CA3017673C (en) |
CY (1) | CY1124290T1 (en) |
DK (1) | DK3429600T3 (en) |
EA (1) | EA037516B1 (en) |
ES (1) | ES2878071T3 (en) |
HR (1) | HRP20210801T1 (en) |
HU (1) | HUE054207T2 (en) |
IL (1) | IL261780B (en) |
LT (1) | LT3429600T (en) |
MX (1) | MX2018010495A (en) |
PL (1) | PL3429600T3 (en) |
PT (1) | PT3429600T (en) |
RS (1) | RS61885B1 (en) |
SI (1) | SI3429600T1 (en) |
WO (1) | WO2017158040A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109152793B (en) | 2016-03-15 | 2022-05-17 | 伊戈尔.波利亚科夫 | Immunological products |
MX2018010710A (en) | 2016-03-15 | 2019-01-14 | Polyakov Igor | Compositions for the treatment and prevention of hoof and claw diseases. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2304347A (en) | 1995-08-11 | 1997-03-19 | Boeringer Ingelheim Vetmedica | Antigenic preparations |
EP0834322A3 (en) | 1996-10-04 | 1998-04-22 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Mycosis vaccine |
WO2013033400A2 (en) * | 2011-08-31 | 2013-03-07 | Perosphere Inc. | Methods for effectively and rapidly desensitizing allergic patients |
CN102727887B (en) | 2012-07-12 | 2014-04-02 | 中国人民解放军第三军医大学第二附属医院 | Application of chitosan serving as immuno-adjuvant in preparing mouse allergic asthma model |
CN109152793B (en) | 2016-03-15 | 2022-05-17 | 伊戈尔.波利亚科夫 | Immunological products |
-
2017
- 2017-03-15 CN CN201780017269.2A patent/CN109152793B/en active Active
- 2017-03-15 SI SI201730754T patent/SI3429600T1/en unknown
- 2017-03-15 LT LTEP17711627.4T patent/LT3429600T/en unknown
- 2017-03-15 DK DK17711627.4T patent/DK3429600T3/en active
- 2017-03-15 HU HUE17711627A patent/HUE054207T2/en unknown
- 2017-03-15 CA CA3017673A patent/CA3017673C/en active Active
- 2017-03-15 EA EA201891934A patent/EA037516B1/en unknown
- 2017-03-15 WO PCT/EP2017/056146 patent/WO2017158040A1/en active Application Filing
- 2017-03-15 ES ES17711627T patent/ES2878071T3/en active Active
- 2017-03-15 EP EP17711627.4A patent/EP3429600B1/en active Active
- 2017-03-15 US US16/085,033 patent/US11173193B2/en active Active
- 2017-03-15 PL PL17711627T patent/PL3429600T3/en unknown
- 2017-03-15 AU AU2017234986A patent/AU2017234986C1/en active Active
- 2017-03-15 MX MX2018010495A patent/MX2018010495A/en unknown
- 2017-03-15 RS RS20210639A patent/RS61885B1/en unknown
- 2017-03-15 PT PT177116274T patent/PT3429600T/en unknown
-
2018
- 2018-09-13 IL IL261780A patent/IL261780B/en unknown
-
2021
- 2021-05-18 HR HRP20210801TT patent/HRP20210801T1/en unknown
- 2021-05-27 CY CY20211100458T patent/CY1124290T1/en unknown
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
CA3017673C (en) | 2023-03-07 |
AU2017234986B2 (en) | 2022-04-07 |
EA037516B1 (en) | 2021-04-07 |
AU2017234986A1 (en) | 2018-08-16 |
CN109152793B (en) | 2022-05-17 |
HUE054207T2 (en) | 2021-08-30 |
CA3017673A1 (en) | 2017-09-21 |
HRP20210801T1 (en) | 2021-06-25 |
WO2017158040A1 (en) | 2017-09-21 |
EA201891934A1 (en) | 2019-03-29 |
PT3429600T (en) | 2021-05-17 |
AU2017234986C1 (en) | 2022-08-18 |
EP3429600A1 (en) | 2019-01-23 |
IL261780A (en) | 2018-10-31 |
SI3429600T1 (en) | 2021-08-31 |
US11173193B2 (en) | 2021-11-16 |
RS61885B1 (en) | 2021-06-30 |
DK3429600T3 (en) | 2021-05-25 |
US20190125846A1 (en) | 2019-05-02 |
CY1124290T1 (en) | 2022-07-22 |
ES2878071T3 (en) | 2021-11-18 |
CN109152793A (en) | 2019-01-04 |
PL3429600T3 (en) | 2021-09-13 |
MX2018010495A (en) | 2019-03-28 |
LT3429600T (en) | 2021-06-10 |
IL261780B (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020147475A1 (en) | Use of rhodococcus ruber product in treatment of recurrent aphthous ulcer | |
EP3212166B1 (en) | Heat-sterilized formulation comprising chitosan and process of preparation thereof | |
EP3429600B1 (en) | New immunobiological products | |
EP3429616B1 (en) | Compositions for the treatment and prevention of hoof and claw diseases | |
US11384160B1 (en) | Method of making a beta glucan compound | |
EP1452545B1 (en) | Novel chitosans | |
EA040511B1 (en) | COMPOSITIONS FOR TREATMENT AND PREVENTION OF DISEASES OF HOOVES AND CLAWS | |
US11912795B2 (en) | Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof | |
US20110065911A1 (en) | Method for producing a bioactive glucan product substantially free of endotoxin contamination | |
CN113924107B (en) | Yeast-containing composition for preventing simple and/or recurrent cystitis | |
CN112022800B (en) | Composition, vaginal gel prepared from composition and application of vaginal gel in resisting human papilloma virus | |
US20240238352A1 (en) | Bacterial cell wall bound to a mucopolysaccharide, uses thereof and process for its production | |
EP0666271B1 (en) | Type 1 and type P fimbriae-adhesins isolated from novel E. coli strains, process for their preparation and uses thereof | |
CN116875507A (en) | Wessella-J4-1 fusion and application of extracellular polysaccharide thereof in prevention and treatment of colon cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181002 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190711 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20201201 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1366467 Country of ref document: AT Kind code of ref document: T Effective date: 20210315 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017033764 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ALDO ROEMPLER PATENTANWALT, CH |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3429600 Country of ref document: PT Date of ref document: 20210517 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20210510 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20210801 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210521 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: FGE |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 37162 Country of ref document: SK |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20210801 Country of ref document: HR Ref country code: HR Ref legal event code: ODRP Ref document number: P20210801 Country of ref document: HR Payment date: 20210531 Year of fee payment: 5 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20210401176 Country of ref document: GR Effective date: 20210614 |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20210303 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E020809 Country of ref document: EE Effective date: 20210519 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E054207 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2878071 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211118 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017033764 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20211206 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20210801 Country of ref document: HR Payment date: 20220309 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MK Payment date: 20220303 Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1366467 Country of ref document: AT Kind code of ref document: T Effective date: 20210303 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20210801 Country of ref document: HR Payment date: 20230313 Year of fee payment: 7 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230525 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AL Payment date: 20230321 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20210801 Country of ref document: HR Payment date: 20240308 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20240319 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IS Payment date: 20240321 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LT Payment date: 20240305 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240320 Year of fee payment: 8 Ref country code: IE Payment date: 20240319 Year of fee payment: 8 Ref country code: LU Payment date: 20240321 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20240318 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20240320 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SM Payment date: 20240320 Year of fee payment: 8 Ref country code: RO Payment date: 20240306 Year of fee payment: 8 Ref country code: HU Payment date: 20240318 Year of fee payment: 8 Ref country code: FI Payment date: 20240319 Year of fee payment: 8 Ref country code: EE Payment date: 20240315 Year of fee payment: 8 Ref country code: DE Payment date: 20240321 Year of fee payment: 8 Ref country code: CZ Payment date: 20240301 Year of fee payment: 8 Ref country code: BG Payment date: 20240315 Year of fee payment: 8 Ref country code: PT Payment date: 20240305 Year of fee payment: 8 Ref country code: GB Payment date: 20240322 Year of fee payment: 8 Ref country code: SK Payment date: 20240308 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SI Payment date: 20240306 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20240304 Year of fee payment: 8 Ref country code: SE Payment date: 20240321 Year of fee payment: 8 Ref country code: RS Payment date: 20240313 Year of fee payment: 8 Ref country code: PL Payment date: 20240306 Year of fee payment: 8 Ref country code: NO Payment date: 20240321 Year of fee payment: 8 Ref country code: MT Payment date: 20240325 Year of fee payment: 8 Ref country code: LV Payment date: 20240318 Year of fee payment: 8 Ref country code: IT Payment date: 20240329 Year of fee payment: 8 Ref country code: HR Payment date: 20240308 Year of fee payment: 8 Ref country code: FR Payment date: 20240320 Year of fee payment: 8 Ref country code: DK Payment date: 20240321 Year of fee payment: 8 Ref country code: BE Payment date: 20240320 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240401 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240417 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20240311 Year of fee payment: 8 |